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Thesis Abstract
Estrogen withdrawal due to either menopause or ovariectomy has previously been
1
shown to promote bone loss and to be associated with the apoptotic death of osteocytes
A
in vivo. The presence of viable osteocytes in bone has been hypothesized to be an
important parameter in maintaining bone quality while osteocyte death by apoptosis
► during estrogen deficiency has been associated with loss of bone strength. Estrogen
■> (l7p-estradiol) administration, as part of hormone replacement therapy (HRT), has
previously been shown to exert positive effects on the maintenance of osteocytes
through the inhibition of their apoptotic cell death. Although the beneficial role of other
anti-resorptive agents such as the Selective Estrogen Receptor Modulators (SERMs) in
preventing bone loss in postmenopausal osteoporosis are well established, the effects of
SERMs on the maintenance of the osteocytic population in vivo are less clear. Work in
this thesis has investigated whether the SERM LY 117018, which is a Raloxifene
analogue, can mimic the osteocyte-sparing effect of l7p-estradiol in a rat model of
ovariectomy.
Abrupt estrogen withdrawal was shown to increase osteocyte apoptosis in rat bone,
while the ovariectomy-induced stimulation of osteocyte apoptosis in rats was shown to
be reversed following administration of the LY 117018 SERM in a similar way to the
known effect of 17P-estradiol replacement. These data point to the potential benefits of
SERMs on bone viability in estrogen-depleted rats. However, the molecular mechanism
by which 17P-estradiol and the LY 117018 SERM maintain the osteocytic population
has to date not been well characterised.
In vitro studies in this thesis indicated that 17P-estradiol, raloxifene and LY 117018
suppressed the pro-apoptotic stimuli induced in response to H2C>2 in osteocyte cultures
possibly by exerting direct anti-oxidant properties related to their chemical structure.
These data introduced a novel mechanism of action for 17p-estradiol, raloxifene and LY
117018, as antioxidants, in the protection of the osteocytic population increasing the
knowledge available on their activity in bone. In addition, these data suggested that the
effects of SERMS on preventing osteocyte apoptosis will in future help to determine
their effectiveness and interest for the clinical development of estrogen replacement
compounds with activities consistent with the maintenance of both bone mass and bone
quality.
Finally, the effect ofmechanical loading on the maintenance of the osteocytic population
was investigated in human cancellous bone explants ex vivo in the presence or absence
of 17P-estradiol. Results suggested that mechanical stimulation or 17p-estradiol alone
increased the Bone Formation Rate (BFR/BS) compared to the unloaded conditions after
27 days in culture. Furthermore, application of mechanical loading at physiological
levels improved osteocyte viability and significantly reduced osteocyte apoptosis
relative to that seen under disuse conditions.
In this study identification of anti-apoptotic effects of SERMs on osteocytes in vivo and
in vitro highlighted an important bioactivity that may explain part of the action of
SERMS in vivo. Further characterization of the anti-apoptotic effects of 17P-estradiol
and SERMs in vitro indicated direct antioxidant capabilities pointing to the possibility
that SERMs mimic not only the bone-sparing activity of 17p-estradiol but its anti¬
oxidant nature as well.
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The effects of 17f5-estradiol and Selective Estrogen
Receptor Modulators (SERMs) on bone.
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1.1 Introduction
Bone is a rigid form of connective tissue that supports locomotion as a site of muscle
attachment, provides protection for vital organs, nurtures the bone marrow and stores
ions such as calcium and phosphate that participate in serum homeostasis (Felsenfeld et
al. 1999, Rasmussen et al. 1971, Baron 1996). Bone is a highly diverse and dynamic
tissue that goes through continuous modelling and remodelling cycles during life in
order to sense structural and mechanical requirements, adapt its architecture, accordingly
and repair any damage occurring as a result of everyday use (Wolf 1892, Turner 1992,
Parfitt 1994).
The processes of bone modelling and remodelling are controlled by a number of
hormones, growth factors and cytokines (Rodan 1992). Steroid hormones, such as
estrogens, have been shown to influence bone cells in order to maintain a balance
between bone resorption and bone formation. Estrogen deficiency has been shown to
result in bone loss due to increased bone resorption and impaired bone formation (Raisz
2005). Imbalances between bone resorption and formation may lead to abnormal
turnover cycles, characterised by increased resorptive activity, that often lead to bone
diseases such as osteoporosis. Osteocytes, which have been proposed to target the
remodelling process by undergoing apoptosis (Noble et al. 1997, Verborgt et al. 2000),
have been shown to be negatively affected by estrogen deficiency (Tomkinson et al.,
1997; 1998, Kousteni et al. 2001). The aim of this thesis was to investigate the effects of
estrogen and SERMs on osteocyte viability and apoptosis induced by estrogen
deficiency in vivo and by oxidative stress in vitro.
This chapter outlines the organisation of bone, describes osteocytes and the apoptotic
bone cell death and summarises the effects of estrogen and SERMs on bone.
1.2 Bone organisation
Bone consists of hydroxyapatite crystals, non-collagenous proteins and collagen fibres
which are organised in parallel or concentric layers giving bone its lamellar structure
(Baron 1996). Bones can be categorised into flat bones such as bones in the skull and the
ilium and long bones, such as the tibia and the femur.
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Long bones (Figure 1.1) consist of cortical (Figure 1.2A) and trabecular bone (Figure
1.2B) (Carter and Orr 1992, Parfitt 1994, Baron 1996) both of which contribute to their
ability to function as the load-bearing parts of the skeleton. Cortical bone is a dense
structure that forms the outer shell of the long bones and encloses the medullary cavity.
The construction of the medullary cavity in long bones achieves stiffness and increases
resistance to bending (Ruff 1988) and deformation, characteristics necessary for
enabling weight bearing and mobility. Cortical bone consists of osteons (Figure 1.2A)
oriented in the direction of maximal stress (Eihorn 1996). Each osteon, which is
composed of a blood vessel enclosed in a Harvesian canal, is surrounded by concentric
lamellae of collagen fibres (Figure 1.2A) and interstitial bone (areas of cortical bone
surrounded by cement lines that do not contain an osteon). The surface of the cortical
bone which faces the bone marrow is called the endosteum while the outer surface
facing the soft tissue is called the periosteum (Figure 1.1).
Trabecular or cancellous bone is a highly porous structure located mainly in the
vertebrae and the metaphyses of the long bones. It has a spongy appearance (Figure
1.2B) and consists of an inner network of interconnecting trabecular plates oriented in
such a way in order to resist mechanical loading (Einhorn 1996, Weiner 1999, Sikavitsas
et al. 2001). Due to its spongy appearance, trabecular bone contributes to more than 61%
of the total bone surface area. The role of the trabecular bone is to be flexible (Turner
2002) in order to absorb more energy imparted during mechanical loading. Trabecular
bone is capable of tolerating deformation; returning to its initial conformation before
structural damage and distributing mechanical loads from the articular cartilage to the




















Figure 1.1. Schematic diagram of a long bone. Either end of a long bone
consists of the epiphysis, characterised by internal cancellous structure, while the central
region known as the diaphysis consists mainly of cortical bone. Diaphysis and epiphyses
are separated by the metaphysis which includes both trabecular and cortical bone and is













During growth, skeletal architecture is established and controlled by the process of bone
modelling. Modelling can be distinguished into; the intramembranous ossification
process responsible for the formation of flat bones and the thickening of the long bones,
and the endochondral ossification which forms the long bones. During intramembranous
ossification, mesenchymal cells differentiate into osteoblasts (primary ossification
centre) which synthesize and secrete the woven bone. Woven bone, which is
characterised by irregular calcification and orientation of the collagen fibres and by high
osteocyte cell density, is eventually replaced by the more structurally organised lamellar
bone (Turner 1992, Weiner and Wagner 1998, Sikavitsas 2001).
Endochondral ossification (Figure 1.3) is a more complicated process that involves the
differentiation of mesenchymal stem cells initially into chondroblasts, which form a
cartilaginous template of the future bone and then differentiate into chondrocytes that
eventually form the growth plate (secondary ossification centre) and bring about
longitudinal (interstitial) growth (Parfitt 1976, Carter et al 1996). As chondroblasts
continue to proliferate and secrete the cartilaginous matrix (interstitial growth),
chondrocytes move further away from the proliferative zone and become hypertrophic.
Hypertrophic chondrocytes initiate the mineralization process of the cartilaginous matrix
(primary ossification centre) and eventually undergo apoptosis. This process is regulated
by factors such as parathyroid hormone-related protein (PTHrP), Indian hedgehog (Ihh),
and bone morphogenetic proteins (BMPs) (Strewler 2001). Osteoclasts then begin to
resorb the calcified matrix, while osteoblasts, recruited to the primary ossification centre
by blood vessels, use the calcified matrix as a template to form the woven bone on top of
the resorbed areas, known as the primary spongiosum. The woven bone, located lower in
the growth plate, will be further remodelled to form the lamellar bone, known as the




















Figure 1.3. Endochondral ossification. During endochondral ossification
mesenchymal stem cells differentiate into chondrocytes which produce a cartilaginous




The bone remodelling or bone turnover process is a complex process occurring in both
trabecular and cortical bone by which old or damaged bone is replaced by new bone
(Mundy 1995). Bone remodelling is essential to bone in order to maintain skeletal
architecture during the adult life, to repair microdamage in response to the mechanical
requirements (Turner 1992, Parfitt 1994, Burr et al. 1985) and to regulate mineral
homeostasis through the interaction of hormones, growth factors and cytokines with
osteoblasts and osteoclasts.
In endochondral and trabecular bone remodelling the source of osteoblasts and
osteoclasts is the stromal and haematopoietic precursors in the marrow, respectively,
whereas in the periosteal remodelling osteoblasts are derived from the periosteal
mesenchymal cells and the osteoclasts from peripheral blood haematopoietic precursors
(Rodan 1992, Prockop 1997, Teitelbaum 2000). Bone turnover was proposed to occur in
discrete basic multicellular units (BMUs) (Frost 1969) and to follow a cycle of tightly-
regulated events initiated by the retraction of osteoblasts from a particular site in
response to appropriate-yet uncharacterised-stimuli. This event is followed by the
activation and recruitment of osteoclasts to the particular site through signals produced
by osteoblasts and stromal cells in order to carry out bone resorption; osteoblasts replace
the resorbed bone by secreting the collagenous and the non-collagenous matrix (osteoid)
that eventually becomes calcified returning that site to quiescent state. The fate of
osteoblasts is to either line the surface of the new bone, to undergo apoptosis or to
differentiate into osteocytes as they become encased in their own matrix production
(Parfitt 1994, Parfitt 2003).
1.5 Mechanical loading and bone
Mechanical loading controls both the modelling and the remodelling processes, playing
an important role in the development of bone structure and shape during growth and the
maintenance of this shape in adult life, respectively (Rubin 1984, Rubin and Lanyon
1987, Carter 1996, Mosley et al. 1997).
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The ability of bone to respond to mechanical loading is best summarised by the
mechanostat theory proposed by Frost (Frost 1988) which describes the ability of bone
to adapt its structure to suit its function. Bone continuously adjusts to mechanical
loading by changing its mass, shape, or microarchitecture and responds differently
depending on the magnitude of the strain. For example, reduction in mechanical strain
due to disuse situations such as prolonged bed-rest, space flight and reduced physical
activity in old age results in increased bone resorption and bone loss (Inman et al.,
1999), whereas under physiological strains bone mass is maintained. High strains are
associated with increased bone formation and increased bone mass, while excessive
mechanical loading could result in bone loss.
Evidence has suggested that bone has the ability to repair microdamage accumulating as
a result of everyday use (Parfitt 2001) by sensing changes in the distribution of strain
within the bone microenvironment and targeting bone for removal by the osteoclasts
(Burr and Martin 1993, Parfitt 2002). In addition, several studies have demonstrated that
microdamage induced by loading on canine (Burr and Martin 1993) or rat bone
(Verborgt et al. 2000, Noble et al. 2003) was targeted for removal by osteoclastic cells
more frequently than would have been expected by chance alone (Burr et al. 1985, Mon
and Burr 1993, Burr and Martin 1993, Burr et al. 2001, Parfitt et al. 2001) followed by
increased remodelling activity. The mechanism directing the targeted activity of bone
forming and bone resorbing cells to specific sites is still not known. However, the
osteocyte has been proposed by many studies to participate in this mechanism (Kakizaki
et al. 1971, Kenzora et al. 1978, Kamijou 1994, Mori et al. 1997, Marrotti et al. 1998).
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1.6 Bone forming and resorbing cells
Osteoblasts are derived from bone marrow stromal cells or pluripotent mesenchymal
stem cells, and carry out bone formation. (Ducy et al. 2000, Prockop 1997). Central in
the regulation of osteoblast differention and formation is the Indian hedgehog and sonic
hedgehog, the transcription factor core-binding 1 (Cbfal) and the bone morphogenetic
proteins (Yamagushi et al. 2000). Osteoblast formation and proliferation are also
regulated by the action of hormones such as PTH, estrogen, vitamin D and
glucocorticoids (Beresford et al. 1992; 1994, Manolagas et al. 2000, Kousteni et al.
2001, Strewler et al. 2001); as well as by the expression of genes such as TGF-(3, FGF
and IGF. These factors influence matrix production, secretion of matrix proteins and
mineralization of bone by regulating the expression of genes such as collagen type I and
fibronectin, alkaline phosphatase (ALP), osteopontin and osteocalcin (Puzas et al. 1996).
Osteoblast activity is also regulated by members of the Wnt signalling pathways, since
gain or loss of function mutations in the receptor LRP5 induce high bone mass or
osteoporosis-pseudoglioma syndrome, respectively (Boyden et al. 2002). High bone
mass phenotypes also arise from mutations in the SOST gene that leads to sclerosteosis,
which is also implicated in the Wnt signalling pathway. Following the deposition of
matrix, active osteoblasts differentiate into lining cells, apoptose or become encased in
their own matrix production and differentiate into osteocytes (Jilka et al. 1998, Karsdal
et al. 2002).
Osteoclasts are polynuclear cells formed by the fusion of monocytes of the, colony
forming unit of the granulocyte-macrophage (CFU-GM) series and are derived from
haematopoietic stem cells in the bone marrow or peripheral blood. In order to carry out
bone resorption, osteoclasts which have a half-life of about two weeks, migrate to a
particular site; form a ruffled border and polarise onto the bone tissue; degrade the bone
matrix and the hydroxyapatite crystals; remove the resorption products and finally
undergo apoptosis (Hughes and Boyce 1989, Xing and Boyce 2005).
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Osteoblast activity is also regulated by members of the Wnt signalling pathways, since
gain or loss of function mutations in the receptor LRP5 induce high bone mass or
osteoporosis-pseudoglioma syndrome, respectively (Boyden et al. 2002). High bone
mass phenotypes also arise from mutations in the SOST gene that leads to sclerosteosis,
which is also implicated in the Wnt signalling pathway. Following the deposition of
matrix, active osteoblasts, differentiate into lining cells, apoptose or become encased in
their own matrix production and differentiate into osteocytes (Jilka et al. 1998, Karsdal
et al. 2002).
1.7 Osteocytes
Osteocytes are terminally differentiated osteoblastic cells that reside in lacunae within
the bone matrix (Aarden et al. 1994) and are the most abundant type of cell in bone,
while their density has been observed to be inversely related to the size of the species
(Mullender 1996) (Table 1.1). It has been suggested that 10-20% of osteoblasts
differentiate into osteocytes (Aubin et al. 1996); however the signals that regulate this
process are not fully understood yet. Osteocytes communicate with other osteocytes and
other cells on the bone surface through dendritic processes that radiate in all directions
and pass through small canals, the canaliculi, in bone (Palumbo et al. 1990, Aarden et al.
1994).
Due to their location within the mineralised bone matrix and the lack of antibodies
directed against specific osteocytic markers, very few studies describing the
characteristics of osteocytes in culture are available to date. Avian postmitotic
osteocytic-like cells (Van der Plaas et al. 1994) have been isolated and purified based on
the use of an antibody termed mAb OB7.3 (Nijweide and Mulder 1986, 1992) which is
thought to be specific for the chicken PHEX endoprotease (Phosphate-regulating gene
with homology to endopeptidases on X chromosome) (Westbroek et al. 2002), possibly
forming part of the OF45 signalling pathway (MacDougall et al. 2001, Gowen et al.
2003). Studies have localised the OF45 mRNA on mature osteoblasts and osteocytes
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throughout ossification in the skeleton of rats and mice (Petersen et al. 2000, Igarashi et
al. 2002) suggesting that OF45 might be involved in the mineralization process and the
differentiation of osteoblasts to an osteocytic phenotype. Another possible marker of the
osteocytic phenotype is the El 1 antigen, which has been proposed to regulate formation
and maintenance of the osteocytic cellular processes (Wetterwald et al. 1996, Schulze et
al. 1999).
Most of the osteocytic characteristics in vitro have been based on the use of the murine
osteocytic-like cell line called MLO-Y4 (Kato et al. 1997). MLO-Y4 osteocyte-like cells
were isolated from the long bones of transgenic mice in which expression of the SV40
large T-antigen oncogene was targeted to osteocytes under the control of the osteocalcin
promoter (Kato et al. 1997). These cells were able to proliferate and secrete high
amounts of osteocalcin. In addition, MLO-Y4 are also characterised by long dendritic
processes, osteopontin and connexin 43 expression, low collagen type I, low alkaline
phosphatase expression (Kato et al. 1997) and Ell expression (Bonewald et al. 2000)
suggesting that these cells display osteocyte-like properties. Other cell lines include the
MLO-D1, -D6, -A5 and -C2 osteocyte-like cells, which are proposed to represent
various stages in the differentiation of osteoblasts to osteocytes (Kato et al. 2001), and
are not very well characterised yet.
Several functions have been proposed for the osteocytes, including their involvement in
the mineralization process due to their high osteocalcin expression (Ikeda et al. 1996)
and also bone resorption known as osteocytic osteolysis, as suggested by the lacunar size
in diseases and collagenase production (Shimizu et al. 1990, Fuller and Chambers 1995),
although this property remains controversial (Boyde 1980, Marotti et al. 1990, Van der
Plaas et al. 1994). Other studies have suggested that osteocytes provide an inhibitory
signal to neighbouring osteoblasts that negatively regulates bone formation (Marotti et
al. 1996). Recently, several groups have proposed this inhibitory signal to be the protein
sclerostin (van Bezooijen et al. 2004; 2005, Poole et al. 2005), the product of the SOST
gene responsible for sclerosteosis (Brunkow et al. 2001), which is localised on mature
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osteocytes. Studies have suggested that sclerostin exerts pro-apoptotic effects on human
osteoblastic cells possibly by binding to BMPs reducing their availability and therefore
decreasing BMP signalling (Sutherland et al. 2004). However, research on this field is
still ongoing and further studies are required to conclude that osteocytes negatively
regulate bone formation.
In contrast to this theory come studies in which examination of the lacunar occupancy at
different stages of the remodelling cycle revealed that forming as well as resorbing
osteons contained higher osteocyte density and lacunar occupancy, compared to
quiescent osteons (Power et al. 2002). In addition, there is evidence accumulating that
the controlled death of osteocytes through apoptosis might be providing the signals that
direct turnover, since apoptotic osteocytes have been observed in close association with
resorbing areas (Noble et al. 1997, Verborgt et al. 2000) and most importantly prior to
initiation of bone resorption (Noble et al. 2003). However, in order for the osteocytes to
target remodelling to specific areas, they should be able to sense such a requirement.
The communicating network that osteocytes form as well as their location within the
bone matrix have suggested that osteocytes might sense the amount of strain applied in
the local environment (Lanyon 1993, Klein Nulend et al. 1995, Zhang et al. 1997, Noble
et al. 2003) and communicate a metabolic signal to bone effector cells (Duncan and
Turner 1995, Lean et al. 1996, Aarden et al. 1996, Klein Nulend et al. 1995, Yellowley
et al. 2000). Examples of such load-induced responses in osteocytes, would be the
production of prostaglandin E2 (PGE2) which has been shown to induce osteoclast
maturation and osteoblast proliferation and differentiation (Suda et al. 1995, Samoto et
al. 2003); release of NO from ecNOs, the expression of which has been suggested to
regulate the direction of resorption and pit size formation (Loveridge et al. 2002, Burger
et al. 2003); osteopontin production which was associated with increased resorption pit
formation (Terai et al. 1999); increased IGF-1 mRNA expression associated with
increased osteogenic effects (Lean et al. 1995) and downregulation of glutamate and
aspartate transporter (GLAST) mRNA expression, pointing to a paracrine role of
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glutamate in the communication between osteocytes and osteoblasts (Mason et al. 1997).
Although the exact mechanism by which the mechanical force is recognized by cells in
bone and transduced into a biochemical signal is unknown, membrane spanning proteins
that anchor the cells to its extracellular environment such as integrins have been
suggested to play a role in the mechanotransduction process. Mechanical stimulation
affects the integrins, which act as mechanoreceptors, activating signalling pathways and
affecting gene expression (Rubin J et al. 2006).
Several hormones that are known to regulate the bone turnover process have been
demonstrated to also affect osteocyte survival and function following binding to their
receptors expressed on the osteocyte (Table 1.2). Osteocytes have been shown to
undergo apoptosis in response to glucocorticoids both in vivo (Weinstein et al. 1998)
and in vitro (Kogianni et al. 2004); respond to PTHrP and PTH binding (Rao et al.
1983, Fermor et al. 1995), which were shown to alter cx43 expression and induce
osteocyte apoptosis possibly regulating osteocyte communication and survival (Divieti
et al. 2001). Osteocytes were also shown to respond to intermittent PTH administration
by downregulating expression of sclerostin, which is normally thought to maintain bone
lining cells in a quiescent state on the bone surface, therefore allowing the lining cells to
return to an active bone forming state (Keller et al. 2005, Poole et al. 2005). In addition,
osteocytes have been shown to express receptors for 1, 25(OH)2D3 (Boivin et al. 1987)
and the androgens testosterone and DHEA (Notelovitz et al. 2002).
Furthermore, osteocytes have been shown to undergo apoptosis in response to estrogen
loss induced by either gonadotrophin-releasing hormone analogs or ovariectomy
(Tomkinson et al. 1997) which could be reversed following the administration of
estrogen (Tomkinson et al. 1998). The effect of estrogen on osteocytes is reviewed in















93,200 ± 5400 Mullender et al.
1996
rabbit 679.2 ± 68.5 Mullender et al.
1996
61,500 ±6800 Mullender et al.
1996
monkey 400.1 +47.9 Mullender et al.
1996
37,300 ± 4800 Mullender et al.
1996
pig 399.5 ±65.4 Mullender et al.
1996
43100 ±7600 Mullender et al.
1996
cow 294.8 ± 24.4 Mullender et al.
1996






Qiu et al. 2003





























mouse 8wks: 402.5 ±47.1
16wks: 587.4±41.6
Garris et al. 2006 90000±10000 Erlebacher et al.
1998
Table 1.1. Osteocyte density in different species.
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Osteocyte Receptors Function References
PTH receptor
Femor and Skerry 1995






Divieti et al. 2001
Bringhurst et al.
2002
Bellido et al. 2005
Glucocorticoid receptor (GR)















Ehrilch et al. 2002
Riggs et al. 2002
FAS receptor
In vivo (Hatakeyama 2000)
In vitro (Kogianni 2004)
• Mediates apoptosis in
vitro (MLOY-4)
Kogianni et al. 2004
CD 40 receptor • Regulates production of
matrix metalloproteases
Ahuja et ai. 2003
Neurokinin-1 receptor • Possibly regulates
osteoclastic resorption
Goto et al. 1998
Glutamate receptor • Mechanotransduction Mason et al. 1997
Serotonin receptor (5-HT2b) • Mechanotransduction Westbroek et al.
2001






Lohmann et al. 2000
Androgen receptors Abu et al.1997,
Notelovitz et al.2002
Braidman et al. 2000
Prostaglandin receptors • Mechanotransduction Cherian et al. 2003
Table 1.2. Receptors identified in osteocytes and their proposed functions.
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1.8 Cell death
Cell death can be distinguished into necrotic cell death, which refers to the morphology
seen when cells or tissues die from severe physical, chemical or toxic damage
accompanied by inflammation and changes in tissue architecture and apoptotic cell
death, a form of programmed cell death, which is the result of the induction of an
internal suicide program.
Apoptosis is a physiological and essential homeostatic mechanism for the healthy
development and maintenance of tissues (Kerr et al. 1972, Levine et al. 1994, Cotman
and Anderson 1995) by regulating the size and the functions of organs through the
removal of harmful, excess or damaged cells (Hall et al. 1994, Pradhan et al. 1997).
Apoptosis, as defined in literature, is characterised by membrane blebbing, chromatin
condensation, DNA cleavage and fragmentation of the cell into apoptotic bodies. The
contents of dying cells are eliminated by phagocytosis in order to avoid the generation of
an inflammatory response within the body (Kerr et al. 1972, Savill et al. 1997).
Apoptosis usually involves an initiating phase, decision, execution and clearing phase
(Guchelaar et al. 1997) although the exact sequence of events in the apoptotic cycle is
now thought to be less clearly defined and to involve some complex interactions
(decision events) between the cell destined to be apoptotic and nearby phagocytes
(Reddien et al. 2001). Apoptosis is stimulated by a number of stimuli including lack of
extracellular survival factors, administration of steroid hormones, viral infections,
oxidative stress, ionising radiation and DNA damage and is regulated by the function of
several proteins such as the bcl-2 proteins, death receptors, the p53 protein and the
caspases (Dragovich et al. 1998).
Caspases (Cysteine Aspartate ProteASES), are cysteine proteases that cleave their target
molecules at very specific sites, following aspartate residues (asp-x). (Allen, et al. 1998,
Thornberry et al. 1998). Caspases play a central role in the apoptotic machinery as they
mediate the apoptotic process in cells from the initial stages (initiator caspases) to their
package in apoptotic bodies for elimination by phagocytosis (effector caspases). Initiator
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caspases (caspases 1, 2, 8, 9 and 10) are activated mainly by death receptors and by
functional changes occurring in the mitochondria (Dragovich et al. 1998, Chen et al.
2002). For example, caspase 8 is recruited during initial phases of the apoptotic cascade
following the binding of FAS ligand to FAS death receptor enabling the activation of
effector caspases further down the apoptotic cascade. The latter include caspases 3, 6
and 7 which mediate the execution phase of apoptosis (Dragovich et al. 1998, Allen et
al. 1998, Decaudin et al. 1998). For example, activated caspase-3 causes proteolytic
cleavage of the DFF45 enzyme (DNA fragmentation factor 45) in humans, or ICAD
(inhibitor of caspase activated Dnase) in mice, which are inhibitors of DFF40 and CAD
respectively, allowing CAD and DFF40 to enter the nucleus and degrade DNA into
oligomers of 180bp (Guchellar et al. 1997) by activating endogenous Ca++/Mg+
dependent endonucleases that cleave DNA into nucleosomes) (Guchelaar et al. 1997). In
addition, caspases carry out the cleavage of proteins such as PAK-2 and gelsolin and
actin fdaments and result in the disassembly of the cytoskeleton (Thomberry et al. 1998,
Allen et al. 1998). Caspases are also thought to be responsible for cleavage of proteins
involved in the repair and replication of DNA, such as PARP and replication factor C,
resulting in DNA damage and degradation by endonucleases (Thornberry et al. 1998,
Allen et al. 1998). In general, caspases disassemble the cell's structure, terminate DNA
replication, attack the nucleus, prevent repair mechanisms and prepare the cell for
phagocytosis.
1.9 Apoptosis and bone
In bone there is evidence of both necrotic and apoptotic cell death. For example,
necrosis has been observed in response to exposure to radiation (Sugimoto et al. 1993),
steroid use (Watanabe et al. 1989), ischemia (Rosingh and James 1968) and leads to the
formation of dead bone patches separated from healthy bone (Wong et al. 1987).
Furthermore, there is evidence indicating that chondrocytes and bone cells such as
osteoclasts, osteoblasts and osteocytes undergo apoptosis during development, bone
remodelling as well as in disease situations indicating that apoptotic cell death is
important for the skeletal development and maintenance throughout life, as described in
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the following paragraphs. Hypertrophic chondrocytes present during endochondral
ossification and fracture healing undergo apoptosis during the replacement of
cartilaginous tissue by woven bone (Lee et al. 1998) possibly in order to signal to
osteoclasts for their removal from the area. However, the mechanism is not clear yet
(Bronckers et al. 2000). Osteoclasts have been shown to undergo apoptosis following the
completion of the resorption process (Hughes and Boyce 1997, Xing and Boyce 2005)
as well as in response to anti-resorptive agents such as estrogen and bisphosphonates
(Kameda et al. 1997, Hughes et al. 1996, 1995; Papapoulos et al. 1997, Rodan 1998,
Rogers et al. 1999).
Furthermore, osteoblasts have also been observed to undergo apoptosis at the end of
bone formation in order to regulate the number of osteoblasts present during bone
remodelling (Jilka et al. 1998, Landry et al. 1997) or in response to glucocorticoids in
mouse (Weinstein et al., 1998, Plotkin et al., 1999) and human (Weinstein et al. 1998),
but not in rat (Silvestrini 2000) and to various cytokines in vitro such as TNF-a, IL-1,
IFN-y (Ozeki et al. 2002) and FasL (Kawakami et al. 1997, Jilka et al. 1998).
1.10 Apoptosis and osteocytes
It has been demonstrated that apoptotic death of osteocytes, characterised by DNA
fragmentation, chromatin condensation and cell shrinkage in both pathological and
healthy bone (Noble et al. 1997), is associated with regions of damaged bones or regions
characterised by increased bone modelling and remodelling activity. For example,
increased incidence of apoptotic osteocytes has been observed in growing bone
characterised by increased bone resorption (Noble et al. 1997) as well as in response to
estrogen deficiency induced by either gonadotrophin-releasing hormone analogues
(GnRHa) or ovariectomy (Tomkinson et al. 1997, 1998) indicating that the increase in
bone turnover following estrogen loss is associated with high prevalence of apoptotic
osteocytes. These indices of apoptosis were reversed following estrogen administration
in both humans and rats (Tomkinson et al. 1997, 1998). More recent studies have also
shown that estrogen deficiency induces osteocyte apoptosis in ovariectomised mice
(Kousteni et al. 2001).
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Intermittent administration of PTH has been suggested to reduce osteocyte apoptosis in
mouse vertebra in vivo and in MLO-Y4 osteocytes in vitro (Jilka et al. 1999). However,
other studies have suggested that PTH induces a transient increase in osteocyte apoptosis
in the distal femur (Stanislaus et al. 2000) indicating that further work is required in
order to identify the exact role of PTH in osteocyte apoptosis.
In addition, in vivo evidence of increased osteocyte apoptosis has been demonstrated in
response to prolonged use of glucocorticoid treatment in humans and mice and could be
associated with the pathogenesis of osteonecrosis (Weinstein et al. 2000) and
osteoporosis (Weinstein et al. 1998). In vitro, apoptosis of osteocytes has been observed
in response to dexamethasone (Plotkin et al. 1999, Kogianni et al. 2004, Kousteni et al.
2001), etoposide and TNF-a treatment (Plotkin et al. 1999; Kousteni et al. 2001) and to
be reversed following treatment with bisphosphonates (Plotkin et al. 1999, Kogianni et
al. 2004) or estrogen (Kousteni et al. 2001, Gu et al. 2005). In addition, Kogianni et al
has suggested that the dexamethasone-induced apoptosis was characterised by
upregulated Fas and ERK protein expression as well as the involvement of caspases 8
and 3/7 in osteocytes (Kogianni et al. 2004). Furthermore, it has been suggested that
hydrogen peroxide induces apoptosis with the involvement of caspase 3 activation in
osteocytes (Kikuyama et al. 2002).
Large numbers of apoptotic osteocytes have also been identified surrounding resorption
areas induced by fatigue microdamage (Verborgt et al. 2000) or during orthodontic tooth
movement (Hamaya et al., 2002). Furthermore, unloading has also been linked to an
increase in osteocyte apoptosis in murine (Aguirre et al. 2006) and rat bone (Basso et al.
2006) in vivo and in vitro (Bakker et al. 2004), shown in rat bone to be reversed upon
reloading (Basso et al. 2006). Furthermore, Noble et al have shown that there is a U-
shape relationship between osteocyte survival and the strains they experience, with
normal physiological strains reducing apoptosis, whereas damagingly high levels of
loading induced apoptosis. In the latter case, the transient increase in the proportion of
apoptotic osteocytes in response to high levels of mechanical loading was immediately
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normal physiological strains reducing apoptosis, whereas damagingly high levels of
loading induced apoptosis. In the latter case, the transient increase in the proportion of
apoptotic osteocytes in response to high levels of mechanical loading was immediately
followed by subsequent intracortical remodelling providing the first evidence that the
presence of apoptotic osteocytes within bone might regulate specific site-directed
remodelling (Noble et al. 2003). In addition, studies have demonstrated that bones
containing low osteocyte numbers such as the ear ossicle (Marotti et al. 1998) and the
labyrinthe capsule (Kakizaki et al. 1971) have been characterised by reduced
remodelling (Marotti et al. 1998) and increased accumulation of microdamage (Mori et
al. 1997). These findings indicate that osteocyte apoptosis is a process observed both in
normal and pathological bone conditions and it might be essential in influencing the
remodelling process towards specific sites.
1.11 Estrogen
1.11.1 General background
Estrogens are a group of steroid hormones that include the 17/3-estradiol (E2) and the
estrone (Ei) mainly produced by the ovaries during puberty and by the adipose tissue
during menopause respectively, and estriol (E3) produced by the fetoplacental unit
during pregnancy (Dotsch et al. 2001).
The production of 17/3-estradiol, the main endogenous estrogen in the human body,
varies throughout the phases of the menstrual cycle, so that it is produced at low levels
during the early follicular phase (110-1100 pmol/1), reaches a peak at the mid-cycle
(1100-1450 pmol/1) and decreases to intermediate levels (740pmol/l) in the luteal phase
(Dotsch et al. 2001). At menopause, the serum concentration of 17/3-estradiol falls
dramatically to levels below the early follicular phase levels (commonly below 110
pmol/1). During this time, the major estrogen in the body is estrone (Ei) produced by the
aromatisation of androgen precursors in the adipose tissue (Dotsch et al. 2001).
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Estrogen (E2) exerts multiple effects on a variety of tissues in the body. For example, it
has been shown to influence the growth, differentiation and function of the reproductive
system and the female mammary gland (Dotsch et al. 2001), promote sexual
differentiation in the mammalian brain and modulate mood, behaviour (Genazzani et al.
1998) and memory performance (Luine et al. 1985). In addition, estrogen has been
shown to prevent oxidation of low density lipoproteins (LDL) in the cardiovascular
system (Miller et al. 1996, Perrela et al. 2003), to induce relaxation of the vascular
smooth muscle, and to promote and maintain body fat distribution, an effect lost during
postmenopause (Ley et al. 1992). The effects of estrogen on the skeletal system are
reviewed in more detail in §1.11.4.
1.11.2 Estrogen Receptors (ERs) and bone
Most of the skeletal effects of estrogen are known to be mediated following binding to
estrogen receptors (Couse and Korach 1999). In bone, both ERo; and ER/3 have been
localised on osteoclasts, osteoblasts and osteocytes (Braidman et al. 1995; Hoyland et al.
1997, Vidal et al. 1999, Westbroek et al. 2000) but also on chondrocytes possibly
mediating the effects of estrogen on the fusion of the epiphyseal growth plate (Sims et
al. 2002, Bord et al. 2001). However, differences have been reported in the expression
levels of the two ER subtypes in these cells. For example, in primary neonatal rat
osteoblasts, the level of ER(3 mRNA was found to be higher than the ERamRNA levels
which in turn were gradually increased following the differentiation of osteoblasts to
mature osteoblasts (Onoe et al. 1997). These findings suggested that the levels of ER
expression could change during the differentiation process of the same cells. In addition,
it has been observed that cells at different sites within the same tissue might respond
differently to estrogen due to alternative expression of distinct patterns of ER subtypes;
For example, ER/3 was found to be predominantly expressed in osteoblasts and to a
minor extend in osteoclasts and osteocytes in cancellous bone, whereas ERa was
predominantly expressed in osteoblasts and osteocytes in cortical bone (Bord et al. 2001)
possibly suggesting that the two types of ERs might mediate different functions.
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whereas, ERP knockout male mice (PERKO) exerted no phenotypical differences
(changes in BMD) compared to the wild type mice (Windhal et al. 1999, Vidal et al.
2000). In contrast to male ERP KO mice, adult female ERP KO mice showed a slightly
elevated BMD (Windhahl et al. 1999) and an increase in cortical bone (Widhal et al.
2001), while aged pERKO mice were also protected against the age-related bone loss
observed in the wild type mice (Ke et al. 2002). These studies indicated a possible
inhibitory role of ERP in bone growth and bone formation during adolescence and the
prevention of bone loss associated with ageing in female mice.
There are various experimental models for investigating postmenopausal bone loss, such
as the rat, mouse, dog and primates. The use of dogs is controversial and primates are
not practical to most research groups. The most frequently practiced in vivo model is the
rat model of OVX (Frost and Jee 1992), since it is characterised by changes that mimic
the response of the human skeleton to estrogen deficiency. Most studies have
demonstrated that, in a similar way to humans, estrogen loss in mature rats results to
bone loss due to abnormal turnover (Wronski et al. 1988). In contrast to the rat model,
the responses of the mouse and human skeleton to estrogen are different. For example,
estrogen loss does not affect bone growth in mice possibly indicating that the murine
periosteal osteoblasts are less responsive to estrogen than in humans (Turner 1999).
1.11.3 Estrogen receptors and osteocytes
Even though both ERs have been identified in osteocytes (Braidman et al. 1995,
Hoyland et al. 1997, Vidal et al. 1999), it has been demonstrated that both primary
(Westbroek et al. 2000) and MLO-Y4 osteocytes (Matikainen and Vaananen 1999)
preferentially express ERa. Expression of ERa has been shown to be reduced following
estrogen withdrawal (Hoyland et al. 1999) and idiopathic osteoporosis in humans
(Braidman et al. 2000) and ovariectomy in rats (Lim et al. 1999) possibly indicating that
the concentration of estrogen in the serum might be regulating the expression of ERa. In
addition, in vivo studies have also shown that the expression of ERa in osteocytes is
enhanced in response to mechanical loading (Ehrlich et al. 2002) indicating that this
receptor might be involved in the osteocytic response to mechanical strain.
Figure 1.4. Sites of estrogen action. Estrogen affects the growth and function of
a number of organs in the body including the heart, brain, liver, thymus and bone (for
review see Dotsch et al. 2001).
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1.11.4 Effects of estrogen on bone tissue
Estrogen has been shown to exert multiple effects on the skeletal system such as
modulating the size and shape of the skeleton and maintaining skeletal microarchitecture
during the adult life (Turner et al. 1994; Couse and Korach, 1999).
Bone mass increases throughout childhood and adolescence (Compston et al. 2001) and
reaches a peak in the third decade of life, indicating that the accrual of bone mass during
puberty and growth is tightly regulated by the presence of estrogen. Peak bone mass,
which is also affected by diet, exercise and genetic background (Ralston et al. 1997), is
maintained until the fifth decade of life when age-related as well as menopausal bone
loss commence. Even though bone loss continues throughout life for both sexes (0.3%-
0.5% of their bone mass every year), the rate of bone loss is accelerated in females at the
time of the menopause and decreases after 5 to 10 years (Schneider et al. 1997).
1.11.5 Estrogen deficiency and bone
Estrogen deficiency that occurs during late menarche, amenorrhea caused by anorexia
nervosa and excessive exercise, disease or drug treatment, and natural or induced
menopause has been shown to be harmful to the attainment of peak bone mass during
adulthood and to result in osteoporosis characterised by low bone mass and increased
fracture risk (Aitken et al. 1973, Riggs et al. 2002, Cummings et al. 1998). These
findings indicate that the development of osteoporosis depends both on the estrogen-
regulated peak bone mass attained during growth and the subsequent rate of bone loss
(Riggs 1991).
At the tissue level, estrogen deficiency has been associated with changes in the
equilibrium between formation and resorption leading to increased bone resorption and
turnover activity and impaired bone formation within each remodelling cycle (Wronski
et al. 1988; 1989, Raisz 2005). The consequences of E2 deficiency involve a biphasic
pattern of bone loss characterised by an initial transient increase in bone loss followed
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by a gradual chronic phase of bone loss in postmenopausal women (Riggs et al. 1991)
and in ovariectomised rats (Wronski et al. 1989, Kalu et al. 1991).
Recent findings also suggest that estrogen deficiency could upregulate the immune
system by activating and expanding TNF-a-producing T cells, which is a key step in
estrogen deficiency-driven bone loss regulated by transforming growth factor-|3 (TGF-
P), interleukin-7, and interferon-y (Weitzmann and Pacifici 2005). In addition, there is
increasing evidence suggesting that estrogen deficiency could be controlling the
generation of reactive oxygen species (ROS) since upregulated production of ROS
during estrogen deficiency is implicated in estrogen deficiency-induced bone loss,
further analysed in Chapter 2.
1.11.6 Hormone Replacement Therapy (HRT)
HRT is generally used for the management of osteoporosis in women with acute
menopausal symptoms (hot flushes, night sweats) and in postmenopausal women who
prefer HRT over other treatments such as bisphosphonates, raloxifene, strontium
ranelate.
Long-term hormone replacement therapy has been shown to prevent postmenopausal
bone loss (Lindsay et al. 1976, Christiansen et al. 1980, Grady et al. 1992) by reducing
bone turnover (Compston J et al. 2001, Grady et al. 1992), the activation frequency and
the size of the resorption cavities in postmenopausal women (Vedi and Compston 1996).
Although long-term estrogen administration (26-42 months) resulted in reduced bone
resorption followed by reduced bone formation, short-term studies of HRT (2.5-4
months) to postmenopausal women demonstrated a significant reduction only in bone
resorption and not in bone formation observed. These findings indicate that, in contrast
to bone resorption which is rapid and could be observed only in shorter period of time,
bone formation requires a longer period in order to be completed (Riggs et al. 1972). In
a similar way to postmenopausal women, estrogen administration to ovariectomised
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(OVX) rats not only managed to provide complete protection against bone loss, but to
significantly reduce all of indices of bone turnover as well (Wronski et al. 1988).
HRT has also been shown to reduce clinical vertebral (Lindsay et al. 1980, Lufkin et al.
1992) and non-vertebral fractures (Weiss et al. 1980, Michaelsson et al. 1998) in HRT
users. Evidence from the WHI study has shown that HRT is important for fracture
protection in healthy postmenopausal women (Writing Group of the Women's Health
Initiative Investigators 2002, The Women's Health Initiatiave Steering Committee 2004)
within the first decade following menopause when administered alone or combined with
progestogens (Naessen et al. 1990).
1.11.7 Estrogen and bone cells
The presence of estrogen prevents bone loss by reducing osteoclastogenesis or by
inducing osteoclast apoptosis either by downregulating the production of the
osteoclastogenic factors IL-1, IL-6 (Girasole et al. 1992, Passeri et al. 1993, Manolagas
et al. 1995, 2000), RANKL (Hofbauer et al. 1999), MCSF (Srivastava et al. 1998) and
TNF-a (Srivastava et al. 1999) and upregulating TGF-J3 production by the
stromal/osteoblastic cells (Hughes et al. 1996) or by directly binding to ERs (Kameda
et al. 1997, Sunyer et al. 1999). In addition, the inhibitory effect of estrogen on
osteoclastogenesis could be associated with the upregulation of osteoprotegerin (OPG)
production by the stomal/osteoblastic cells that blocks the binding of the RANKL to
RANK on osteoclasts (Bord et al. 2003, Michael et al. 2005).
Estrogen has also been shown to upregulate the expression of collagen type I (Ernst et
al. 1988), alkaline phosphatase (ALP) (Chen et al. 2002), OPG, IGFI (Ernst et al. 1989,
Gray et al. 1989) and TGF-(3 gene in osteoblasts (Tau et al. 1998). Even though there is
no evidence that estrogen administration at bone sparing doses increases bone formation,
studies have suggested that administration of high estrogen doses have anabolic skeletal
effects in postmenopausal women (Vedi et al, 1999, Tobias and Compston 1999) as well
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effects in postmenopausal women (Vedi et al, 1999, Tobias and Compston 1999) as well
as in animal models (Edwards et al. 1992) by increasing the proliferation, differentiation
and function of osteoblasts (Manolagas 2000). In vitro studies have also shown that
estrogen induces the proliferation of rat (Ernst et al. 1988, Cheng et al. 2002) and human
osteoblasts (Ikegami et al. 1994, Chen et al. 2002). Furthermore, both in vitro and in
vivo studies have shown that estrogen prevents glucocorticoid-induced apoptosis of
osteoblasts following the end of the formation period (Kousteni et al. 2001) possibly
through the increased production of TGF-/3 (Karsdal et al. 2002).
1.11.8 Estrogen and osteocytes
Estrogen deficiency due to gonadotrophin-releasing hormone analogs (GnRH) in
postmenopausal women or ovariectomy in rats has been shown to induce an increase in
osteocyte apoptosis (Tomkinson et al. 1997, 1998) which was reversed following
estrogen administration (Tomkinson et al. 1998). These studies along with other in vivo
studies on OVX mice (Kousteni et al. 2001) supporting the negative effects of estrogen
deficiency on osteocyte apoptosis, have indicated that the presence of estrogen is
important in the control of osteocyte apoptosis as well as in the maintenance of
osteocyte viability.
In addition, estrogen has been shown to protect osteocytes against glucocorticoid-
induced apoptosis (Kousteni et al. 2001, Gu et al. 2005), etoposide and TNF-a induced
apoptosis in vitro (Kousteni et al. 2001) indicating that estrogen is associated with pro-
survival effects against a number of death-inducing stimuli in osteocytes. In vitro studies
have demonstrated that the release of TGF-/3 by the osteocytes was enhanced in response
to estrogen in order to suppress osteoclastic bone resorption (Heino et al. 2002) possibly
indicating that osteocytes could be mediating the inhibitory effect of estrogen on bone
resorption.
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1.12 Selective Estrogen Receptor Modulators (SERMs)
1.12.1 General background
The use of HRT exerts beneficial effects on bone as discussed in §1.11.6. However, the
chronic use of estrogen as a part of HRT has also been associated with an increased risk
of endometrial (Grady et al. 1995) and breast cancer (Colditz et al. 1995). Furthermore,
agents that exert bone-specific effects like calcitonin or bisphosphonates have been
widely used to prevent postmenopausal bone loss in established osteoporosis (Gennari et
al. 1998, Whiteman et al. 1999) without however exerting any positive extraskeletal
effects on postmenopausal women. These findings point to the need of the design of new
molecules that would demonstrate tissue selective activities (McDonnell et al. 2000,
Sandberg et al. 2002) and be efficiently used for the treatment of postmenopausal
osteoporosis. During the last decades, Selective Estrogen Receptor Modulators (SERMs)
have played an important role in the current therapeutic approach against menopause-
associated conditions.
SERMs are synthetic non-steroidal compounds that produce estrogen-like effects and
can act as estrogen agonists in some target tissues such as bone, nervous and
cardiovascular system, while they may also exhibit estrogen antagonism and/or minimal
agonism in reproductive tissues such as the breast or uterus (Kauffman et al. 1995,
Dodge et al. 1997, McDonnell et al. 2000, Sandberg et al. 2002). SERMs are categorised
according to their structure into the triphenylethylenes such as clomiphene, tamoxifen,
droloxifene and idoxifene, the benzothiophenes such as raloxifene and the LY 117018
SERM (analysed in more detail in Chapters 3 and 5), the benzopyrans such as
levormeloxifene and the dehydronapthalenes such as nadoxifene (Agnusdei and Iori
2000).
MER-25, an anticholesterol agent, was the first SERM introduced into the market in the
1950s (Lerner and Jordan 1990) and was shown to inhibit the stimulatory effects of
estrogen without itself inducing any stimulatory effects on the breast tissue. However,
MER-25 was soon removed from the market due to increased toxicity and low potency
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(Lerner 1981) while derivatives of MER-25, such as clomiphene citrate and tamoxifen,
were introduced clinically in the 1970s. Tamoxifen has been extensively used for the
treatment of breast cancer in postmenopausal women (Cole et al. 1971) but its long-term
use has been associated with increased risk of endometrial cancer (Friedl et al. 1994) and
uterine stimulation (Fisher et al. 1994) indicating that the tissue selective effects exerted
by tamoxifen are not free of adverse effects on other reproductive tissues.
Interestingly, SERMs such as raloxifene were demonstrated to be effective against
advanced breast cancer (Hoi et al. 1997) and to block the uterotrophic effect of estrogen
(Black et al. 1993, 1994) or tamoxifen (Jordan and Gosden 1983, Black and Goode,
1980, 1981). These findings suggest that the use of SERMs, such as raloxifene, could be
ideal in order to study their beneficial effects on non-reproductive tissues such as bone,
as reviewed in § 1.13.2.
1.12.2 SERMs and bone
The beneficial effects of raloxifene on bone have been extensively described in
estrogen-deficient rats (Sato et al. 1994, 1995, 1996; Evans et al. 1994, 1996) and were
demonstrated to be comparable to the effects induced by estrogens such as 17a ethinyl
estradiol (Evans et al. 1994, 1996; Sato et al. 1995, 1996a, 1996b) or 17|3-estradiol (Sato
et al. 1994) used in the same studies. For example, raloxifene treatment was shown to
prevent the OVX-induced loss of BMD in the femur and tibia (Black et al. 1994) and to
increase bone strength and BMD in the lumbar vertebrae (Turner et al. 1994) to a similar
extend to estrogen administration without however exerting any negative effects on the
uterus (Black et al. 1994, Turner et al. 1994). Comparative studies between the effects of
estrogen, raloxifene, tamoxifene and the bisphosphonate alendronate demonstrated that
all these antiresorptive agents effectively inhibited bone loss to the same extent by
reducing bone resorption and bone turnover. However, raloxifene, in contrast to
estrogen, had no effect on the uterus while it also appeared to lower the cholesterol
levels in the serum (Frolik et al. 1996, Sato et al. 1996b). These studies on OVX rat
models have provided a strong parallel between the anti-osteopenic effects of raloxifene
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and estrogen and have indicated that raloxifene acts as an estrogen agonist in bone
without negatively affecting the reproductive system (Black LJ et al. 1994, Kauffman et
al. 1995, Frolik et al. 1996, Draper et al. 1996).
Treatment of postmenopausal women, with or without established osteoporosis, with
raloxifene has been shown to decrease biochemical markers of turnover such as alkaline
phosphatase and serum osteocalcin (Draper et al. 1996, Lufkin et al. 1998), and to
increase the BMD in the lumbar spine and hip (Delmas et al. 1997, Lufkin et al. 1998). In
addition, in early postmenopausal women treatment with raloxifene reduced bone
resorption to levels comparative to estrogen treatment (Heaney et al. 1997) indicating
that raloxifene preserves bone mass possibly by affecting mechanisms similar to those
operative in postmenopausal women receiving HRT (Weinstein et al. 2003).
Furthermore, raloxifene treatment has been shown to also exert positive effects in late
postmenopausal osteoporotic women up to 80 years of age by reducing the risk of
fracture and increasing the BMD in the spine and femoral neck (Ettinger et al. 1999).
LY 117018, an analogue of raloxifene, has also been shown to act as an antiestrogen in
order to prevent estrogenic activity on the uterus of ovariectomised (OVX) rodents
(Black and Goode 1981, Jordan and Gosden 1983) and to completely prevent high
turnover osteopenia caused by oophorectomy (Bowman et al. 1996). The effects of LY
117018 on bone are the subject of study in Chapter 3 in this thesis.
Other SERMs have also been shown to prevent bone loss and reduce serum cholesterol
levels, while the SERM CP336156 has been shown to increase BMD in combination
with the anabolic agents CP424391 and PTH in ovariectomised rats (Ke et al. 1998).
Tamoxifen has also been shown to preserve bone mass in ovariectomised rats (Turner et
al. 1987, Kalu et al. 1991, Grey et al. 1995) and to reduce bone resorption (Steward and
Stern 1986; Jordan et al. 1987) and to stimulate cancellous bone formation in intact
female mice (Perry et al. 2005). Tamoxifen administration in healthy postmenopausal
women reduced serum cholesterol and increased bone mineral density (Chang et al.
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1.13 Summary
Bone undergoes continuous remodelling cycles in order to sense structural and
mechanical requirements, adapt its structure to suit its function and to repair damage
(Wolf 1892, Turner 1992, Parfitt 1994). Osteocytes are thought to play an important role
in the bone remodelling process since high osteocyte density has been associated with
regions characterised by resorption and formation activity (Power et al. 2002) while
absence of osteocytes is associated with low occurrence or absence of remodelling
surfaces (Marotti et al. 1998). In addition, there is evidence accumulating that the
apoptotic death of osteocytes might be providing the signals that direct turnover since
high incidence of osteocyte apoptosis has been associated with increased resorptive
activity in response to unloading or excessive loading (Verborgt et al. 2002; Noble et al.
2003), glucocorticoid treatment (Weinstein et al. 1998, 2000) or estrogen deficiency
(Tomkinson et al. 1997, 1998). Estrogen deficiency has been shown to lead to
osteoporosis characterised by low bone mass and increased fracture risk (Aitken et al.
1973, Riggs et al. 2002, Cummings et al. 1998). These observations suggest that it might
be beneficial to prevent excess osteocyte apoptosis that might lead to pathological
conditions.
This thesis investigates compounds, such as the SERMs, that might lead to osteocyte
survival in a similar manner to the known protective effects of 17/3-estradiol. In addition,
the possible mechanism of action of these compounds, as antioxidants, on osteocytes is
discussed in Chapter 2 and is investigated in Chapters 4 and 5.
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CHAPTER 2
Antioxidant molecules and bone
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2.1 Mechanism of estrogen action
As described in the previous chapter, estrogen (E2) has been shown to elicit diverse
effects on a variety of tissues in the body, which are believed to be mediated through
genomic or non-genomic mechanisms depending on whether gene transcription takes
place following the interaction of the ligand with intracellular, nuclear estrogen
receptors (ERs) (Figure 2.1).
The most well characterised genomic mechanism of estrogen action, also known as the
classical mode of estrogen action, involves the diffusion of estrogen across the plasma
membrane and its interaction with intracellular nuclear ERs (Figure 2.1) of the subtypes
a and P present in an inactive form either in the cytosol or the nucleus. Following
binding of E2, the receptor complex undergoes dimerization and conformational changes
in order to act as a transcription factor and bind to cognate Estrogen Response Elements
(EREs) in the promoter region of the target genes enhancing gene transcription (Tsai et
al. 1998, Razandi et al. 1999). However, not all estrogen receptors are involved in the
classical mechanism of estrogen action since three of the five recently identified ERp
isoforms (ERp 3-5) have not been demonstrated to interact with estrogen or to drive
ERE-dependent gene transcription (Moore et al. 1998). Paradoxically, ERE-dependent
gene transcription could also occur following the activation of the estrogen receptor by
growth factor signalling (Figure 2.1). For example, it has been demonstrated that EGF
could activate the estrogen receptor through the MAP-Kinase pathway (Bunone et al.
1996) indicating that the ER could demonstrate activity independently of estrogen
binding (Hall et al. 2001).
In addition, the estrogen-ER complex could also induce the expression of genes lacking
EREs in their promoter region by indirect binding of the complex to cognate DNA
binding sites by interacting with transcription factors such as the fos/jun transcription
complex on AP-1 sites, NF-kB and Sp-1 (ERE-independent pathway) (Webb et al. 1995,
Saville et al. 2000). These ERE- and ligand-independent mechanisms of estrogen action
along with the non-genomic pathway (Pietras & Szego 1975; 1977, Wehling et al. 1997,
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Collins & Webb 1999, Levin et al. 1999, Falkenstein et al. 2000) constitute the non-
classical mode of estrogen action.
The non-genomic actions of estrogen can be distinguished into the ER-mediated and the
non ER-mediated mechanisms (Wehling et al. 1997). In the former mechanism, estrogen
is thought to interact with a cell surface form of estrogen receptor (Figure 2.1) (Pietras
and Szego 1977), the precise nature of which is still not well characterised. Studies have
suggested that the membrane ER might be a variant form of ERa that has translocated to
the plasma membrane, where it is thought to activate survival pathways such as the
MAPK (Kousteni et al. 2001) or PI3-Kinase signalling pathways (Levin et al. 2002).
However, further studies are required in order to characterise the exact nature and
function of this membrane receptor as well as the significance of E2 binding to an ER
without entering the cytoplasm.
The non ER-mediated mechanisms involve the interaction of E2 with membrane
receptors such as the insulin like growth factor-1 receptor (IGF-1R) and the epidermal
growth factor receptor (EGFR) (Kahlert et al. 2000, Filardo et al. 2002) leading to
activation of PI3K, Akt and MAP Kinase pathways enhancing gene transcription (Levin
2002), while E2 is also thought to interact with the G-protein coupled receptor GRP30
(Filardo et al. 2002, Revankar et al. 2005, Manavathi et al. 2006) activating MAP Kinase
pathways (Filardo et al. 2002, Manavathi et al. 2006), (Figure 2.1), Furthermore,
steroids could also interact with lipids on the plasma membrane affecting membrane
fluidity and therefore enzyme activity (Whiting et al. 2000); and with proteins on the
membrane known as estrogen binding proteins (EBPs) that trigger changes in
intracellular signalling stimulating transcription (Deroo and Koorach 2006).
Furthermore, evidence is accumulating on the action of estrogen as an antioxidant
molecule (Behl et al. 1995; 1997, Green et al. 1997, Miranda et al. 2000) and the
significance of this mechanism of estrogen action to bone will be discussed in detail in
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Figure 2.1. Summary of ER-dependent and independent mechanisms of
estrogen action.
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2.2 Reactive Oxygen Species (ROS)
2.2.1 Free radicals, ROS and oxidative stress
Free radicals are short-lived, highly reactive molecules that contain one or more
unpaired electrons in their outer orbit (Halliwell 1991). They interact with other
molecules in order to acquire the necessary electron, inducing changes on the chemical
structure of these molecules and converting them into free radicals. Free radicals along
with molecules that exhibit free radical-like behaviour, such as hydrogen peroxide and
the singlet oxygen, are known as oxidants or reactive oxygen species (ROS) and are
outlined in Table 2.1.
ROS, which sense changes in oxygen concentration, are constantly produced inside the
cells under normal metabolic pathways (Flarman 1981, Halliwell et al. 1992, Finkel and
Holbrook 2000, Balaban et al. 2005), such as during the cellular respiration process that
takes place in the mitochondria during which a small percentage of oxygen is converted
to the superoxide radical (Richter et al. 1995, Finkel 2000). ROS are also produced in
the peroxisomes, which are the site of hydrogen peroxide (H2O2) production or also
through the action of enzymes with peroxidase activity such as the cytochrome P450
enzymes or enzymes associated with the plasma membrane such as the NADPH oxidase.
ROS generation could be enhanced during the process of ageing (Harman et al. 1956),
by factors such as radiation (Stief et al. 2003), pollutants, smoking, dmgs, chemicals
(Halliwell 1997), inflammation (Cumutte et al. 1987), bone fractures (Symons et al.
1996), by the binding of growth factors such as EGF to their receptors (Bae et al. 1997,
Cha et al. 2000, Droge et al. 2002) and by the presence of cytokines such as for example
TNF-a (Chang-Hoon et al. 2000).
When the generation of endogenous ROS is tightly regulated, ROS exert positive
biological roles. For example, they are essential for the defence against anti-microbial
insults (Babior et al. 1773, Cumutte et al. 1987), in sensing oxygen tension in the control
of ventilation and erythropoietic production (Droge et al. 2002), in regulating functions
controlled by O2 concentration (Chandel et al. 2000), in the maintenance of redox
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homeostasis (Droge et al. 2002) and also in signal transduction pathways mediating
proliferation, differentiation (Allen and Tresini 2000, Finkel 2003), survival or
programmed cell death (Finkel 2003).
Disturbance in the balance between pro-oxidant -antioxidant balance leads to oxidative
stress (Sies H. 1991, Behl et al. 2002) which results in cell injury by inducing energy
depletion, lipid peroxidation, protein and DNA oxidation and possibly cell death through
either apoptosis or necrosis (Finkel 2000). Oxidative stress has been linked to a number
of pathological conditions including carcinogenesis (Klaunig and Kamendulis 2004),
diseases of the eye such as age-related macular degeneration (AMD) (Beatty et al.
2001) and maturity onset cataract formation (Spector et al. 1984, Taylor and Nowell
1997) and diabetes mellitus (Gorogawa et al. 2002). Oxidative stress is also associated
with the pathogenesis of diseases related to inflammation such as rheumatoid arthritis
(Jaswal et al. 2003), in atherosclerosis (Parthasarathy et al. 1992, Babior et al. 2000,
Finkel 2000, Perrella et al. 2003) as well as in neurodegenerative disorders such as





• Weakly reactive radical
• Generates hydroxyl radical (OH ) by reaction with H202
• Produced by activated phagocytic cells to kill bacteria
(Curnutte et al. 1987)
Hydroxyl radical
(OH)
• Most reactive radical, very short half life (10"9 sec)
(Jacob 1995)
• Produced by superoxide and by H202 (Fenton reaction)
• Stimulates lipid peroxidation by attacking the fatty acids
of the phospholipids. Fatty acid chains are then converted
to peroxyl radicals, H202 and lipid hydroperoxides
• DNA damage, ATP depletion and gene mutations
(Breimer et al. 1991).
Peroxyl radicals
(R02)
• Produced during lipid degradation
Hydrogen peroxide
(H2O2)
• More stable ROS than radicals, weak oxidant
• Diffuses freely across membranes (Halliwell and
Gutteridge 1981)
• Generates OH" by reacting with transition metals (Fenton
reaction) in cytoplasm and mitochondria (Halliwell and
Gutteridge 1992)
• Produced by NADPH oxidase in phagocytes and
following dismutation of superoxide
• Triggers intracellular events (Halliwell and Gutteridge
1981): oxidation ofNF-kB (Schreck et al. 1991) and
transcription of inflammatory cytokines such as IL-2, IL-
6, IL-8 , TNF-a (Baeurele et al. 1988)
Singlet oxygen (102) • Oxygen with antiparallel spin direction
• Highly reactive with lipids; forms peroxide radicals
• Limited knowledge on its role
Table 2.1. Important ROS and some of their characteristics.
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2.2.2 Oxidants and bone
Both in vivo and in vitro studies have shown that the production of ROS, such as O2 ~
and H2O2, in response to exogenous stimuli is involved in the formation and activation
ofmurine (Garrett et al. 1990, Suda et al. 1993, Fraser J et al.1996, Steinbeck et al. 1998)
and rat osteoclasts, respectively (Bax et al. 1992). Under physiological conditions in
bone, ROS are produced by osteoclasts through the action of the enzymes NADPH
oxidase (Steinbeck et al. 1994) and tartrate resistant acid phosphatase (TRAP)
(Vaaraniemi et al. 2004) in order to degrade the calcified tissue (Garett et al. 1990,
Sontakke et al. 2002). ROS are also generated during the production of RANKL by the
osteoblasts possibly in order to mediate the RANKL-induced cellular events in
osteoclasts (Ha et al. 2004).
Some studies have shown that the oxidant status is increased during the inflammatory
process associated with bone fractures (Turgut et al. 1999). As the collagen strands
break, their ends become exposed to oxygen, which finally form peroxyl radicals
affecting and disrupting the cells in the vicinity of the fracture (Symons et al. 1996,
Sontakke et al. 2002), while the inflammatory cells recruited to the fracture site
contribute to the increase in the oxidant status observed during callus formation (Turgut
et al. 1999, Prasada et al. 2003, Yeler et al. 2005) by producing large amounts of
superoxide (Finkel 2000). Besides the inflammatory stage of the fracture healing
process, ROS generation is also associated with progressive diseases such as rheumatoid
arthritis and periodontitis (Madsen et al. 2004) indicating that ROS could be involved in
pathological cartilage and bone degradation. In addition, reduced bone mineral density
(BMD) observed in pathological conditions such as osteoporosis has also been
associated with accumulation of ROS, as evidenced by the use of biochemical markers
of oxidative stress (urinary excretion of isoprostanes) (Basu et al. 2001). Furthermore,
accumulation of ROS and in particular of hydrogen peroxide observed in ovariectomised
mice (Lean et al. 2003) has been proposed to mediate the bone loss associated with
estrogen deficiency (Lean et al. 2005). The implication of ROS accumulation in the E2-
deficiency induced bone loss is further discussed in §2.4.2.
47
Furthermore, ROS have also been observed to reduce bone nodule formation, inhibit the
proliferation and differentiation of osteoblasts (Suzuki et al. 1997, Mody et al. 2001, Bai
et al. 2004) and bone marrow stromal cells (BMSC) (Bai et al. 2004) and possibly to
induce apoptosis in osteoblastic cells in vitro. However, very little is known about the
effects of oxidative stress in osteocytes, a subject that will be analysed in Chapter 4 and
5.
2.3 Antioxidant defence system
All organisms have developed defence mechanisms against oxidative stress in order to
maintain a balance between the production and clearance rate of free radicals and
therefore to maintain cellular integrity (Noguchi et al. 2000, Floyd et al. 1999). These
mechanisms include the enzymatic and the non-enzymatic antioxidants (outlined in
Table 2.2). Enzymatic antioxidants form the body's first line of defence against
oxidative stress by preventing the formation of ROS and include primarily the
glutathione-dependent enzymes (Chaudiere et al. 1999) such as the glutathione reductase
and the glutathione peroxidase (GPx), enzymes responsible for maintaining the balance
between the oxidised and reduced forms of glutathione, respectively. Other antioxidant
enzymes include the superoxide dismutases (SOD1 and SOD2) which are responsible
for the dismutation of the superoxide anion (CV) to H2O2 which is then further
detoxified by glutathione peroxidase (GPx) or catalase (CAT), (Figure 2.2).
Non-enzymatic antioxidants, also known as free radical scavengers or chain-breaking
antioxidants such as vitamin E and C, terminate the propagation of free radical
generation in the electron transport chain (Noguchi et a. 2000) by donating a proton
atom (H+) to the free radical in order to saturate the unpaired electron present in their
outer orbit (Halliwell 1991, Green et al. 1997, Behl et al. 1995, 1997).
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2.3.1 Estrogen as an antioxidant
Estrogen is thought to exert antioxidant properties either directly by acting as a free
radical scavenger due to the presence of the hydroxyl group at the C3 position of the
phenolic A ring as has been demonstrated in neuronal cells (Behl et al. 1995, 1997;
Green et al. 1997, Miranda et al. 2000) or indirectly by modulating the expression of
antioxidant enzymes such as glutathione peroxidase (GPx4) in the oviducts (Lapointe et
al. 2005).
Furthermore, estrogen-deficient animals have been characterised by the presence of
intense oxidative stress associated with the lack of estrogen in different tissues (Montilla
et al. 2000, Persky et al. 2000, Hernandez et al. 2000) such as liver (Ha et al. 2004),
heart and brain (Ozgonul et al. 2003) indicating that the presence of estrogen might be
related to the maintenance of the redox balance in those tissues.
These studies indicate that estrogen exerts direct or indirect antioxidant properties
further increasing the repertoire of estrogen's beneficial actions in the body. The
importance of these properties in bone is supported by studies investigating the impact











Figure 2.2. Schematic diagram of the function of the main antioxidant
enzymes necessary for the cellular protection against oxidative stress.
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2.3.2 Estrogen deficiency induces oxidative stress in bone
In bone tissue, estrogen deficiency and the subsequent bone loss (Allbright 1947) has
been associated with accumulation of ROS resulting in a decrease in the levels of the
antioxidant enzymes GPx, SOD and thioredoxin in elderly osteoporotic women (Maggio
et al. 2003, Sontakke and Tare 2002), in ovariectomised rats (Isomura. et al 2004,
Muthusami et al. 2005) and in ovariectomised mice (Lean et al. 2003, 2005, Jagger et al.
2005).
More direct evidence on the impact of estrogen deficiency on the accumulation of ROS
such as H2O2 has been obtained following treatment of ovariectomised mice with
catalase, which prevented ovariectomy-induced osteopenia (Lean et al. 2005). These
findings indicated that the presence of ROS such as H2O2 is possibly engaged in
mechanisms responsible for the induction of bone loss in response to estrogen
deficiency. This evidence was further supported by in vitro studies that demonstrated
that administration of 17|3-estradiol to murine bone marrow cultures upregulated the
expression of GPx in osteoclasts (Lean et al. 2005), while overexpression of GPx in the
pre-osteoclastic cell line RAW cells was found to suppress osteoclast formation and
differentiation (Lean et al. 2005). These findings suggest that oxidative stress might play
a role in the etiology of estrogen-deficiency bone loss by creating an oxidised bone
environment and point to the possible implication of estrogen in the maintenance of the
redox balance in bone.
2.3.3 SERMs as antioxidants
In view of the vast amount of studies investigating the effects of estrogen as an
antioxidant molecule, the action of SERMs as potent antioxidants has also been tested in
several studies. For example, in neuronal cultures tamoxifen and its metabolites have
been shown to decrease the propagation rate of lipid peroxidation (Wiseman et al. 1990,
Moreira et al. 2004). However, tamoxifen itself has also been associated with ROS
production as past of tamoxifen's mechanism to induce pro-apoptotic effects on breast
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cancer cells (Mandlecar et al. 2000) and leukemic cells (Hayon et al. 1999) indicating
controversial evidence for the ability of tamoxifen to act as an antioxidant in bone.
Studies have suggested that treatment with raloxifene exerts beneficial effects on
endothelial dysfunction; a prerequisite of atherosclerosis characterised by enhanced
release of ROS and reduced bioavailability of nitric oxide (NO). In addition, raloxifene
has been shown to reduce the release of free radicals from the vascular cells by exerting
antioxidant properties that improve bioavailability of NO (Wassmann et al. 2002) and
possibly reduce the incidence of atherosclerosis (Wassmann et al. 2002).
2.4 Summary
Bone loss due to estrogen deficiency has been associated with increased accumulation of
ROS (Lean et al. 2003, 2005). This stresses the requirement of further studies on the
antioxidant properties exerted by the drugs administered to prevent and treat
postmenopausal osteoporosis such as estrogen and SERMs both on the cellular and
molecular level. Despite evidence suggesting the induction of osteocyte apoptosis during
estrogen loss, no evidence exists so far to characterise the impact of ROS on osteocyte
apoptosis. In chapters 4 and 5 of this thesis an attempt is made to study the mechanism
of estrogen and SERM action against H202-induced oxidative stress in osteocytic
cultures.
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Enzymatic antioxidants Cellular localization and properties
Superoxide dismutase (SOD)
(SOD1. SOD2)
• Present in mitochondria, cytosol (McCord et al. 1969)
• Degrades superoxide into H202 and 02
Glutathione peroxidase (GPx)
• Present in mitochondria, cytosol, nucleus, peroxisomes
(Godeas et al. 1994)
• Reduces H202 and lipid peroxides
Catalase (CAT) • Present in peroxisomes and cytosol
• Decomposes H202to H20
Major non-enzymatic
antioxidants Source and function
Glutathione (GSH) • Present in plasma, saliva (McCord et al. 1969)
• Chain breaking antioxidant or plays a role in GSH peroxidase
and GSH catalase enzymatic reactions (see §2.4.1)
Vitamin E (a-tocopherol) • Diet-derived; found in plasma, saliva (McCord et al. 1969)
• Lipophilic, in all cell membranes (Leibovitz & Siegel 1980)
• Chain-breaking antioxidant (Halliwell 1991)
Vitamin C • Diet-derived
• Hydrophilic
• Chain breaking antioxidant (Wefers et al. 1988)
• Recycles vitamin E (Halliwell 1991, Jacob 1995) and
glutathione (Jacob 1995)
Selenium • Diet-derived
• Activates glutathione peroxidase (GPx)
• (Leibovitz &Siegel 1980)
a-Lipoic acid • Found in the body, diet-derived (Packer et al. 1997)
• Scavenges most radicals and reduces lipid peroxidation
• Recycles vitamin C
Ubiquinone • Present in mitochondria (Emster & Dallner 1995)
• Ubiquinol (reduced form) inhibits lipid peroxidation in
membranes (Stocker et al. 1991)
• Prevents protein and DNA oxidation
Carotenoids (Vitamin A) • Lipid-soluble, found in plasma (McCord et al. 1969)
• Free radical scavenger
Melatonin • Gland hormone, readily absorbed
• Scavenges hydroxyl, superoxide and lipid peroxide radicals
(Reiter et al. 1996)
• Protects against lipid peroxidation, radiation and protein
damage
Estrogen • Systemic steroid hormone
• Lipophilic
® Functions are summarised in Chapter 1




Selective Estrogen Receptor Modulator (SERM) Inhibits
Osteocyte Apoptosis During Abrupt Estrogen
Withdrawal. Implications for Bone Quality Maintenance.
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Abstract
Estrogens have previously been shown to exert positive effects on the quantity and
quality of bone including the maintenance of osteocytes through the inhibition of
their apoptotic cell death. Selective Estrogen Receptor Modulators (SERMs) have
been designed to confer all of the positive bone-associated effects of estrogens
without any of their negative soft tissue side effects. This study has investigated
whether the osteocyte-sparing effect of E2 (17(3-estradiol) can be mimicked by the
SERM LY 117018, a Raloxifene analogue, in a rat model of ovariectomy (OVX).
Twenty-four juvenile female rats were divided into four treatment groups; sham
operated (SHAM) (n=3), ovariectomy OVX (n=3), ovariectomy + 17p-estradiol
(OVX +E2) (0.125 mg/kg/day) (n=3) and ovariectomy + SERM (OVX + SERM)
(3 mg/kg/day) (n=3) at two time points (n=24). Radius and ulna were removed; snap
frozen and examined histologically at 7 or 14 days following the start of treatment.
In the region of secondary spongiosa with cortical medullary distinction, osteocytes
were examined for viability using the lactate dehydrogenase enzyme activity assay
(LDH assay) and for apoptosis using an in situ nick-translation (NT) technique. The
percentage of apoptotic osteocytes was significantly increased (2.5 fold at 7 days and
6 fold at 14 days) in the OVX group compared to the SHAM operated group in both
the radii and the ulnae. Treatment of OVX animals with either 17P-estradiol
(OVX+E2) or LY 117018 (OVX+SERM) for 7 or 14 days following surgery
prevented the increase in osteocyte apoptosis induced by OVX in both the radius and
ulna.
These observations demonstrated that the LY 117018 SERM can exert a powerful
inhibitory effect upon osteocyte apoptosis following estrogen loss in a similar way to
the known effect of 17|3-estradiol pointing to the potential benefits of SERMs on
both the quantity and quality of bone in E2 depleted rats.
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3.1 Introduction
Estrogen withdrawal either due to menopause or ovariectomy has been characterized
by bone loss (Allbright et al. 1941, Wronski et al. 1989, Kalu et al. 1991) and a high
prevalence of osteocyte death (Tomkinson et al. 1997; 1998, Kousteni et al. 2001).
The presence of osteocytes within bone has been associated with its ability to
respond to mechanical stimuli (Lanyon et al. 1993), remodel efficiently and repair
accumulated microdamage (Burr et al. 1985, Parfitt 2001, Noble et al. 2003)
indicating that bone quality is closely associated with the presence of osteocytes and
the communicating network they form through their cytoplasmic processes within
the bone matrix (Dunstan et al. 1993).
Previous studies have identified an increase in the proportion of osteocytes
undergoing apoptosis in ovariectomised rats (Tomkinson et al. 1998) and in women
undergoing estrogen suppression when treated for endometriosis with
gonadotrophin-releasing hormone (GnRH) analogs (Tomkinson et al. 1997). In these
studies, estrogen administration, as part of HRT, was shown to inhibit the apoptotic
death of osteocytes, hence potentially maintaining a viable osteocytic network and
positively affecting bone health (Tomkinson et al. 1997, 1998). However, besides the
beneficial effects of HRT on bone (§1.11.6), the chronic administration of estrogen
has also been associated with an increased risk of endometrial (Grady et al 1995) and
breast cancer (Colditz et al 1995). These findings have pointed to the need for the
design of new molecules that would both be efficiently used for the treatment of
postmenopausal osteoporosis and demonstrate tissue selective activities (McDonnell
et al. 2000, Sandberg et al. 2002).
Selective Estrogen Receptor Modulators (SERMs) are currently the focus of much
research effort since they have been shown to mimic the positive effects of estrogen
on bone and cholesterol metabolism, without being associated with its negative
effects on the reproductive tissues (Kauffman et al. 1995). Therefore, during the last
decade raloxifene has effectively replaced estrogen as a first-line treatment against
postmenopausal osteoporosis (Delmas et al. 1997). The LY 117018 SERM,
employed in this study, is a structural analogue of raloxifene and has been shown to
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engender positive effects on estrogen-deficient bone. For example, a number of
studies have demonstrated that LY 117018 maintains bone mineral density in
oophorectomised rats (Curiel et al. 1998, Flodsman et al. 1999) and reduces the
increased bone turnover associated with estrogen deficiency, as evidenced by the
reduced production of biochemical markers of bone turnover (Curiel et al. 1998).
However, the effects of SERMs on the osteocytic population in bone have not been
investigated so far, even though osteocytes have previously been shown to be
affected by estrogen loss in ovariectomised rats (Tomkinson et al. 1998) and in
women undergoing estrogen suppression with GnRH analogs (Tomkinson et al.
1997).
The rat model of OVX is a widely accepted and very frequently practiced in vivo
model for investigating the pathogenesis, prevention and treatment of
postmenopausal bone loss (Frost and Jee 1992), since it is characterised by changes
that mimic the response of the human skeleton to estrogen deficiency. Most studies
have demonstrated that ovariectomy results in an increased rate of bone turnover and
trabecular bone loss followed by loss in cortical bone in rats (Wronski et al. 1988).
This study has investigated whether the use of the LY 117018 SERM could mimic
the protective effects of 17(3-estradiol on the maintenance of osteocyte viability and
prevent the increase in the proportion of osteocytes undergoing apoptosis in a rat
model of ovariectomy.
In order to detect changes in osteocyte viability methods to detect both osteocyte
apoptosis and cell membrane integrity were employed. Apoptotic osteocytes were
identified by the use of the Nick Translation (NT) technique (Noble et al. 1997)
(§3.2.2), while viable osteocytes at the time of sampling were determined by using
the Lactate Dehydrogenase Assay (LDH) (Noble et al. 2003), (§3.2.3).
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3.2 Materials and Methods
3.2.1 Animals
Twenty-four, weight matched (range 250-270 g), female Sprague-Dawley rats were
purchased (Charles River, Margate, UK), a minimum of seven days before the start
of the experiment. A standard rodent diet (RM1; Special Diet Services Ltd, UK) and
tap water were available ad libitum. Rats were randomised into four treatment groups
and each treatment group was subdivided to provide two time points for analysis (7
and 14 days), such that each sub-group contained three animals. At Day 0, each of
the animals was anaesthetised. Three of the treatment groups were ovariectomised
(OVX) and an osmotic pump was implanted subcutaneously for targeted delivery to
the tissue (Alzet, USA). The pump delivered one of three treatments: 17|3-estradiol
(OVX + E2) (Calbiochem, UK) at a dose rate of 0.125 mg/kg/day; SERM LY 117018
(OVX + SERM) (Eli Lilly & Co., USA) at a dose rate of 3 mg/kg/day; or vehicle
alone (OVX+VEH) (20% (3-hydroxy-cyclodextrin). The control group was subjected
to sham ovariectomy and an osmotic pump was implanted to deliver vehicle alone
(SHAM + VEH) (20% (3-hydroxycyclodextrin).The 4th (control) group was subjected
to SHAM ovariectomy and an osmotic pump was implanted to deliver vehicle alone
(SHAM+VEH).
After either 7 or 14 days, as dictated by the experimental group, the animals were
killed. The radius and the ulna were harvested, briefly immersed in 5% polyvinyl
alcohol (Sigma, UK) and chilled to -70°C in supercooled hexane (BDH, UK), prior
to storage and analysis. Animal experimentation was conducted in compliance with
national ethical guidelines. Cryostat transverse sections of 7 pm thickness were cut
from the chilled material and transferred to Superfrost ® Plus slides (Western
Laboratory Services, UK) in order to aid adhesion of the bone section to the slide. In
this study, bone sections were taken from the metaphysis. Metaphysis has been
shown to be responsive to OVX by becoming osteopenic in comparison to the
diaphysis which is not characterised by bone loss in OVX rats (Kimmel and Wronski
1990), (Figure 3.1). Three sections were used per biopsy in order to determine each
of the measurement criteria. These sections were spaced at least three sections apart




Figure 3.1. Transverse section of the rat radius and ulna. Representative
image of a transverse section of the rat radius and ulna viewed under light
microscopy (x 4). The image demonstrates the region of secondary spongiosa with
cortical medullary distinction from which the sections used in the analysis were
obtained. Bar represents 100 pm.
3.2.2 In situ analysis of osteocyte apoptosis using Nick Translation technique
The percentage of osteocytes demonstrating significant levels of DNA fragmentation
was determined using a DNA nick translation technique, appropriately modified in
order to be of moderate sensitivity in order to increase specificity (Noble et al. 1995;
1997). The increase in specificity of this method was achieved by reducing the
polymerase concentration such that only the larger number of single DNA breaks,
associated with apoptosis, relative to necrosis, were detected. This technique allows
the determination of early DNA breaks, prior to the loss of any DNA content and
prior to plasma membrane permeabilisation (Petit et al. 1995).
7 fim transverse cryostat sections of bone were transferred to charged Superfrost
microscope slides and were fixed in 4% paraformaldehyde (Sigma, UK) for 10
minutes, washed in phosphate buffer saline (PBS) (Oxoid, UK) before
demineralisation in 0.25 mol/L ethylenediamine tetra-acetate (EDTA) (Sigma, UK)
in 50 mmol/L Tris HC1, pH 7.4, for 10 minutes. The sections were then washed
thoroughly in PBS and air dried. One group of sections were treated with
deoxyribonuclease I (DNase) (0.2mg/ml in PBS) (Sigma, UK) for 30 minutes to
induce DNA breaks in order to provide a positive control of the technique. These
sections were then washed in PBS (Figure 3.2). All sections were then treated with
the nick translation mixture which consisted of 3 mmol/L digoxigenin (DIG)-labelled
dUTP (DIG-11-dUTP); 3 mmol/L each of dGTP, dATP, and dCTP; 50 mmol/L Tris
HC1, pH 7.5; 5 mmol/L MgCf, 0.1 mmol/L dithiothreitol, 0.5 mL/100 mL DNA
polymerase I for 45 minutes at 37 °C in a humified chamber. Negative control
sections were treated as above, in the absence ofDNA polymerase I (Figure 3.3).
All sections were washed and incubated with fluorescein isothiocyanate (FITC)-
labelled anti-DIG antibody (all reagents obtained from Roche Diagnostics
Corporation, UK) and 5% normal sheep serum (Sigma) in PBS, for 1 hour in a
humified chamber at room temperature (RT). After washing in PBS, sections were
stained for nuclear DNA with propidium iodide (PI) (Sigma, UK) at 2.5 ng/ml for 3
minutes, washed thoroughly in water and mounted with fluorescent mounting
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medium (DAKO, UK). Sections were then visualised by fluorescence microscopy.
Osteocytes stained positive for both the FITC label and PI were considered as
osteocytes containing fragmented DNA.
61
Figure 3.2. In situ demonstration of a positive control for the nick
translation method. A section of cortical bone was taken from the radius of a SHAM
animal. All nuclei stained green for the FITC signal (A, C) since the section was
incubated with deoxyribonuclease I (DNase) in order to produce DNA breaks prior to
reaction with the nick translation mixture (x20). Nuclei were stained red with PI (B, C).
Bar represents 100 pm.
A. FITC B. PI C. Combined
Figure 3.3. In situ demonstration of a negative control for the nick
translation method. Sections were treated with the nick translation mixture without
the presence of DNA polymerase I. Nuclei were stained red with PI (B, C). No FITC
signal was observed indicating the inability of oligonucleotides to be incorporated into
the DNA breaks in the absence of DNA polymerase I and be recognised by the anti-DIC-
FITC labelled antibody (A, C) (x 20). Bar represents 100 pm.
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3.2.3 Cell viability assessment in situ
One parameter used as a basis for cell viability is the metabolic activity of the viable
cells. Viable cells at the time of sampling were identified in cryostat sections by
means of their lactate dehydrogenase (LDH) activity. Lactate dehydrogenase is a
cytoplasmic enzyme which catalyzes the oxidation of L-lactate to pyruvate by
reducing nicotinamide adenine dinucleotide (NAD+)to NADH (Stryer L. 1995).
LDH
L-lactate + NAD+ ^ * Pyruvate + NADH+ H+
Histochemical staining was undertaken using the method of Noble and Stevens
(Noble and Stevens 2003). 7pm unfixed tissue sections were incubated in 1.75
mg/ml disodium salt (a-nicotinamide adenine dinucleotide, NAD) (Roche
Diagnostics Corporation, UK), 60 mmol/L lactic acid, 3 mg/ml nitroblue tetrazolium
(NBT) (Sigma, UK) and 40% Polypep (Sigma, UK), pH 8.0, for 3h at 37 °C in a
humidified chamber. Finally, sections were rinsed in warm water to remove the
reaction mixture, fixed in 4% paraformaldehyde for 10 minutes, washed in PBS and
then mounted in DPX mounting medium (Fisher Scientific Ltd, UK). Sections were
examined under transmitted light and the number of dark blue stained LDH positive
osteocytes, considered to be viable per bone area (mm2), was quantified using the
NIH Image Analysis Software.
The metabolic activity of the cells was assessed by their capacity to convert NBT to a
coloured product since the colour is the outcome of metabolic activity (Widholm,
1972). The proton atom (H+) released during the reduction of NAD+ to NADH
reduces NBT to give a dark blue coloured product only in the metabolically active
cells with intact cell membranes. This suggests that the LDH assay is an appropriate
method for determining cell viability.
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3.2.4 Quantification of osteocyte viability and apoptotic criteria
Transverse cryostat sections of 7 pm in thickness were obtained from the region of
the secondary spongiosa with cortical medullary distinction moving in the direction
of the diaphysis for 2.5mm, approximately 0.6 mm from the base of the growth plate.
(Figure 3.1). Three non-consecutive sections from each bone were used to calculate
the percentage of apoptotic osteocytes by estimating the number of apoptotic
osteocytes using the nick translation technique relative to the total number of cells
which were stained positive with propidium iodide (PI). Adjacent sections from the
same area were used to determine the density of viable osteocytes (the number of
LDH positive osteocytes per mm2) using the in situ LDH viability assay. All analyses
in this study were blinded. A minimum of nine non-overlapping fields of view were
randomly selected from each section so that generally more than 70 % of the total
bone area in each section was analysed using NIH image analysis software. In all
cases, a total of at least 1000 osteocytes were assessed per bone.
The following criteria were used in order to calculate the percentage of apoptotic
osteocytes and the density of viable osteocytes following individual treatments:
Percentage of apoptotic osteocytes (%) =
Average number of FITC positive osteocytes
X 100
Average number of PI stained osteocytes
Density of viable osteocytes (mm"2) =
The number of LDH positive osteocytes
The area of bone in the field of measurement per mm2
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In this study, sections were analysed as 2D structures and therefore the density
measurement represents an "areal density" (mm"2), (Parfitt et al. 1987) rather than
volume based density (mm" ) of osteocytes. However, due to the fact that sections
have a specific thickness only the osteocytes on a particular plane of focus were
counted in each field of view.
It should be noted that the percentage of viable osteocytes in each section (the
number of LDH positive osteocytes divided by the total number of osteocytes stained
with PI) was not quantified in this study since, in some cases, the number of LDH
positive osteocytes exceeded the total number of osteocytes (PI stained) assessed in
the bone section. Taking into account that that the section thickness was 7pm while
the dimension of an osteocyte is about 10-20 pm (Cooper et al. 1966, McCreadie et
al. 2004), this finding might be explained by the fact that osteocytes could have been
cut through their cytoplasm (LDH positive osteocytes) without reaching their nuclear
DNA required in order for them to be quantified as PI positive osteocytes.
3.2.5 Statistical analysis
All statistical analyses were performed using quantitative data analysis with SPSS
release 11.5 for Windows. Data was checked for normal distribution by applying the
Kolmogorov-Smirnov test. In cases where the randomly selected sample data were
shown to have a normal (Gaussian) distribution (95% of data would fall within plus
or minus 1.96 standard deviations from the mean value) parametric statistical tests
such as two-tailed Analysis of Variance (ANOVA) and the post-hoc Tukey-Kramer
test and Dunnett test were performed directly to determine statistical significance
between the treatment groups. For comparison between percentages of osteocyte
apoptosis used in this study, the square root of each percentage was transformed into
its arcsine, which enabled the distribution of the data to be nearly normal allowing
therefore the use of parametric tests. Normal distribution of the data allowed the use
of parametric tests such as Analysis of Variance (ANOVA) followed by Dunnett's
post hoc test (when the p value of the ANOVA was p<0.05) in order to allow
comparison of all treatment groups against the control group (SHAM) (Zar 1984,
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treatment groups as it allows for comparison of more than two means without
introducing the type I error associated with multiple t-tests (Zar 1984, Fielding and
Gilbert 2000). Results are expressed as means ± S.E. p<0.05 was considered to be
statistically significant.
3.3 Results
3.3.1 Ovariectomy induces osteocyte apoptosis in both the radius and
ulna
Seven days after surgery, OVX led to a significant 2.5-fold increase in the
percentage of apoptotic osteocytes compared to SHAM operated rats in both the
radius (1.27% vs. 0.45%, respectively; p= 0.02) (Figure 3.4A, Figure 3.6) and the
ulna (1.05% vs. 0.40%, respectively; p=0.015) (Figure 3.4B), as estimated using the
nick translation technique. 14 days after OVX, osteocyte apoptosis was increased to
6-fold compared to SHAM treated rats in both the radius (1.78% vs. 0.27%,
respectively; p= 0.01) (Figure 3.5A) and the ulna (1.4% vs. 025%, respectively; p <
0.001) (Figure 3.5B).
3.3.2 17P-estradiol prevents ovariectomy-induced osteocyte apoptosis
in both the radius and ulna
Slow release of 17p-estradiol (OVX+E2) at a dose rate of 0.125 mg/kg/day for 7 days
following OVX reduced the percentage of OVX-induced apoptotic osteocytes
compared to OVX treatment, in both the radius (0.41% vs 1.27% respectively,
p=0.014) (Figure 3.4A) and the ulna (0.36% vs 1.05% respectively, p=0.01) (Figure
3.4B) to levels similar to SHAM for both the radius and the ulna (p>0.05), (Figures
3.4A and 3.4B).
In addition, application of 17P-estradiol (E2) for 14 days following OVX also
prevented the increase in apoptotic osteocytes due to OVX treatment in both the
radius (0.38% vs 1.78% respectively, p=0.02) (Figure 3.5A) and the ulna (0.68% vs
1.4% respectively, p=0.013) (Figure 3.5B).
3.3.3 LY 117018 SERM protects osteocytes from ovariectomy-induced
apoptosis
Slow release of the LY 117018 SERM at a rate of 3 mg/kg/day for 7 days was
effective in protecting the osteocytes from OVX-induced apoptosis in both the radius
(0.63% vs 1.27% respectively) (Figure 3.4A) and the ulna (0.53% vs 1.05%
respectively, p<0.05) (Figure 3.4B). The proportion of apoptotic osteocytes due to
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OVX was also decreased following treatment with the LY 117018 SERM both in the
radius (0.23% vs 1.78% respectively, p=0.009) (Figure 3.5A) and the ulna (0.16%
vsl.4% respectively, p<0.001), (Figure 3.5B). Interestingly, suppression of OVX-
engendered increase in osteocyte apoptosis by the LY 117018 SERM was
significantly greater than that of 17P-estradiol in the ulna (0.16% vs 0.68%,
respectively, p=0.004) 14 days following ovariectomy (Figure 3.5B).
3.3.5 Osteocyte viability
As also noted in previous studies (Tomkinson et al., 1998), ovariectomy in this study
did not affect the proportion of viable osteocytes either in the radius or the ulna after
7 or 14 days relative to SHAM (p>0.05 in all cases), (Figures 3.7 and 3.8), (Figure
3.10). Treatment with 17(3-estradiol or LY 117018 had no effect on the number of
viable osteocytes at 7 or 14 days post-operation, in either of the two bones compared
to SHAM animals (Figure 3.7 and 3.8).
3.3.6 % Change in body weight.
Animals were weighed prior to treatment and regularly thereafter. As shown in
Table 3.1, no statistically significant difference was observed in the percentage
change in body weight at 7 days following ovariectomy. However, by day 14 post-
surgery, comparison of the body weights prior to and following treatment revealed
significant differences between the experimental groups (p<0.05). Therefore, the
percentage change in body weight following different treatments was identified.
After 14 days of surgery, OVX rats were shown to have an increase in the percentage
rate of body weight gain compared to SHAM (17.21% ± 1.89.vs 5.74% ± 0.63,
p=0.003). Treatment with either 17P-estradiol or LY 117018 for 14 days
significantly reduced the percentage increase in body weight in OVX rats to SHAM




























Figure 3.4. The percentage of osteocytes displaying evidence of DNA
fragmentation in situ after 7 days. 17(3-estradiol and LY 117018 SERM
prevented OVX-induced osteocyte apoptosis in situ after 7 days of treatment in both
the A. radius and B. ulna. Sections obtained from all the treatment groups were
studied for the presence of fragmented DNA material using an in situ nick translation
technique. Results are expressed as the mean percentage of total osteocytes












































Figure 3.5. The percentage of osteocytes displaying evidence of DNA
fragmentation in situ after 14 days. 17(3-estradiol and LY 117018 SERM
prevented OVX-induced osteocyte apoptosis in situ after 14 days of treatment.
Sections were obtained from the A. radius and B. ulna and studied for the presence
of fragmented DNA material using an in situ nick translation technique. Results are
expressed as the mean percentage of total osteocytes displaying positive staining for









Figure 3.6. In situ demonstration of osteocytes containing fragmented
nuclear DNA in response to OVX. Sections obtained from A. SHAM and B. OVX
animals were reacted with the NT mixture and counterstained with PI (red) to identify
nuclear DNA. White arrows (B) illustrate osteocytes staining positive for DNA
fragmentation (FITC-green), identified as an orange signal where FITC-green signal was































Figure 3.7. The density of LDH positive osteocytes 7 days post-
operation. The number of viable osteocytes (LDH positive cells) per bone area
(mm ) 7 days post-operation in both the A. radius and B. ulna was not altered by the
treatments. Sections were studied for the presence of cellular LDH activity and
results are expressed as the mean ratio of the number of LDH positive osteocytes per































Figure 3.8. The density of LDH positive osteocytes 14 days post-
operation. The number of viable osteocytes (LDH positive osteocytes) per bone
2 • • • •
area (mm ) 14 days post-operation in both the A. radius and B. ulna is not altered by
the treatments. Sections were studied for the presence of cellular LDH activity and
results are expressed as the mean ratio of the number of LDH positive osteocytes per
area (mm ) for every treatment.
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Treatments
(n=3) Percentage change in body weight
DAY 7 DAY 14
SHAM/VEH 3.40 ±0.63 5.74 ±0.63
OVX/VEH 7.61 ±0.59 17.21 ± 1.89 *
OVX/E2
(0.125mg/kg/day) -4.48 ± 1.13 -0.34 ± 1.45*
OVX/SERM
(3mg/kg/day) 2.83 ±2.08 1.75 ± 0.74*
Table 3.1. Effects of 17p-estradiol and LY 117018 on body weight in the
OVX rat following 7 and 14 days of treatment. Results are expressed as group











Figure 3.9. Basic chemical structures of LY 117018 and Raloxifene.
LY 117018 is characterised by the presence of a non-steroidal core and a basic side
chain of an aryl moiety and an amine ring. The side chain of the LY 117018 SERM
is similar to that of raloxifene, lacking however one carbon atom at the amine ring.
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Figure 3.10. Histochemical reaction of the LDH enzyme in rat sections in
situ. Representative image of a section obtained from an OVX animal and stained for
LDH activity. Viable osteocytes were distinguished by the presence of LDH activity in
cells. Blue arrow identifies a viable LDH-positive osteocyte. White arrow points to
lacunae which were excluded from measurement (x20). Bar represents 100pm.
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3.4 Discussion
The study presented in this chapter has provided evidence that, in a rat model of
estrogen loss, administration of the LY 117018 SERM mimicked the protective
effects of 17|3-estradiol against osteocyte apoptosis associated with ovariectomy.
Although the beneficial effects of SERMs on bone have been well characterised on
the tissue level and have been long used in bone as a part of HRT, little is known so
far regarding the effects of SERMs on bone cells and especially on the osteocytic
population. According to the concept of osteocytes being the mechanosensors and
mechanotransducers in bone (Pead et al. 1988, Skerry et al. 1989, El Haj et al. 1990,
Lanyon 1993; Burger et al. 1995), osteocytes sense changes in the amount and
direction of mechanical loading and signal the need for removal of microdamage
(Burr et al. 1985, Parfitt. 2001, Noble et al. 2003). Based on these findings
suggesting that the presence of osteocytes within bone is crucial for the maintenance
of mechanically optimal bone microarchitecture, impaired osteocyte viability could
potentially result in lack of bone mass and poor bone quality. Studies have shown
that osteocyte cell death in response to ageing, osteoporosis (Mullender et al. 2005)
and osteoarthritis lead to increased bone fragility (Frost 1960, Dunstan et al. 1990,
1993; Qiu et al. 2003) possibly due to loss of the ability of bone to sense or repair
microdamage (Parfitt 1993).
Osteocytes have previously been shown to be negatively affected by estrogen loss in
human, rat (Tomkinson et al. 1997, 1998) and mouse tissue (Kousteni et al. 2001).
Removal of estrogen by GnRH treatment in humans or by OVX in rats resulted in a
substantial increase in the number of osteocytes undergoing apoptosis (400% and
375%, respectively), as evidenced by the in situ nick translation technique at 24 and
3 weeks, respectively (Tomkinson et al. 1997, 1998). In this study the time points of
7 and 14 days were selected based on previous experience on osteocyte apoptosis in
these bones (Noble et al. 2003). Although the detailed time course of the estrogen
loss-engendered osteocyte apoptosis in vivo is unknown, in this study apoptotic
osteocytes in both the radius and the ulna were identified as early as 7 days following
ovariectomy and were increased by 182% and 162% respectively, based on
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identification of DNA fragmentation using an in situ nick translation technique
(Noble et al. 1997).
In this study, administration of LY 117018, a structural analogue of raloxifene, at the
known bone sparing dose of 3mg/kg/day (Bowman et al. 1996, Hodsman et al. 1999)
resulted in the protection of osteocytes from OVX-induced apoptosis in both the
radius and ulna 7 and 14 days following surgery. Administration of 17|3-estradiol
(0.125 mg/kg/day) was shown to inhibit the osteocyte apoptosis induced by 21 days
of OVX (Tomkinson et al. 1998). In this study, the same dose of 17|3-estradiol was
employed, based on the study by Tomkinson et al., and was shown to prevent
osteocyte apoptosis at the earlier time points of 7 and 14 days post-surgery. These
findings confirm the importance of estrogen in the maintenance of the osteocytic
population in bone. However, investigation ofmore time points-including the 21 day
time point-would have allowed the direct comparison regarding the anti-apoptotic
effects of 17p-estradiol between these studies.
In agreement with previous studies (Tomkinson et al. 1998), the increase in osteocyte
apoptosis observed in this study due to ovariectomy in the rat was not associated
with gross changes in the number of viable osteocytes compared to control that was
estimated to be in the range of 800-1000 osteocytes per mm2 and was found to be
similar to the mean value of ~ 800 osteocytes/mm2 reported by Tomkinson et al.
(Tomkinson et al. 1998). This finding could be explained by the fact that apoptotic
cells remain viable and maintain membrane integrity until the early stages of
apoptosis (Wyllie et al. 1980) providing further evidence supporting the apoptotic
nature of osteocyte death in this model. An alternative explanation might take into
account the rapid rate of remodelling thought to occur in rats (Tomkinson et al. 1998)
which might have contributed to the efficient renewal of dead or dying cells.
However, in contrast to rodent bone, the more slowly turning over human bone has
been characterised by a cumulative loss of osteocytes as a result of increased
osteocyte apoptosis associated with estrogen loss (Tomkinson et al. 1997) indicating
that the rate of bone remodelling plays an important role in osteocyte viability.
However, the effects of ovariectomy on osteocyte apoptosis in this study are small
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(<2%) based on the low incidence of apoptosis observed in these samples. The small
percentage of apoptotic osteocytes might also explain the lack of change in the
density of viable osteocytes.
As expected, there was a significant increase in body weight following ovariectomy
that manifest at 14 days of treatment (Wronski et al. 1987). Previous studies have
indicated that estrogen loss in both women (Gambacciani et al. 1997) and rats
(Wronski et al. 1987) is associated with a significant gain in body weight. An
increase in fat mass has two obvious confounding influences on bone metabolism;
firstly the estrogenic nature of fat and secondly the conferring increased mechanical
load on some components of the skeleton. Both of these influences would be
predicted to decrease osteocyte apoptosis based on our current understanding (Noble
et al. 2003). The fact that osteocyte apoptosis is influenced upon OVX is likely to be
the consequence of the overpowering influence of estrogen loss compared to the
very small weight gains observed in these studies. The fact that administration of
estrogen reduced body weight to below the SHAM levels could suggest that the dose
of estrogen employed in this study was possibly high. Possible over-dosage could
have been investigated by measuring the weights of the uteri. In agreement with
previous studies showing that the LY 117018 compound is capable of inhibiting
weight gain (Bowman et al. 1996, Li et al. 1998, Curiel et al. 1998), administration
of LY 117018 to OVX-treated animals reduced the OVX-induced increase in the
body weight to levels lower than that in SHAM animals.
The precise anti-apoptotic mechanism of action employed by these compounds was
not addressed in this study. In vitro studies by Kousteni et al have suggested that sex
steroids exert non-genotrophic receptor-dependent anti-apoptotic effects on
osteoblasts and osteocytes involving the activation of a mitogen-activated protein
signalling pathway (Kousteni et al. 2001, 2003). Alternatively, data in Chapters 4
and 5 have demonstrated that both 17p-estradiol and LY 117018 are capable of
preventing osteocyte apoptosis possibly in a non-genomic, receptor-independent
manner by exerting antioxidant activities on osteocytes.
79
In conclusion, treatment with the SERM LY 117018 inhibited the increase in
osteocyte apoptosis associated with estrogen loss mimicking the bone-sparing effects
of 17p-estradiol in a rodent model of ovariectomy. The present study is the first to
elucidate that current therapies for the treatment of osteoporosis, such as SERMs,
exert positive estrogen-like effects on bone viability at the cellular level by
maintaining the osteocytic population following ovariectomy.
In addition, there is growing interest in the current hypothesis that osteocytes are
important in maintaining bone quality and modulating bone formation (possibly
through sclerostin secretion) (Poole et al. 2005) and resorption (Noble et al. 2003).
This study highlights an important bioactivity that may explain part of the action of
SERMs in vivo. While the effect of LY 117018 on bone quality has not been directly
addressed in this study, a number of other studies have demonstrated that
administration of LY 117018 to OVX rats exert clear bone-sparing effects, as
evidenced by a reduction in the increase in bone turnover due to OVX and
improvement of BMD (Bowman et al. 1996, Li et al. 1998, Curiel et al. 1998,
Hodsman et al. 1999). It is possible that the effects of SERMs on preventing
osteocyte apoptosis will in the future be harnessed to increase their effectiveness in
the treatment of a number of clinical conditions including those of old age.
SECTION 2
Inhibition of osteocyte apoptosis
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CHAPTER 4
The anti-oxidant effect of 17p-estradiol in the inhibition
of osteocyte apoptosis in vitro.
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Abstract
This work is the subject of a published manuscript. Estrogen withdrawal promotes
postmenopausal bone loss and is associated with the apoptotic death of osteocytes in
vivo (Tomkinson et al. 1997, Tomkinson et al. 1998). Although administration of HRT
in the form of 17p-estradiol has demonstrated clear estrogen receptor-mediated benefits
to bone mass, the molecular mechanism by which estrogen maintains bone cells has not
been fully elucidated. A large number of studies have documented protective effects of
estrogen against oxidative stress in neuronal and endothelial cells. However, no studies
have investigated the effects of estrogen against oxidative stress induced in bone cells.
The purpose of this study was to examine whether 17P-estradiol could benefit the
osteocytic population by exerting antioxidant properties against oxidative stress-
engendered apoptotic cell death in the osteocyte-like MLO-Y4 cell line.
MLO-Y4 osteocytes were treated with estrogen and estrogen derivatives alone or in
combination with the specific estrogen receptor antagonist ICI 182,780 prior to the
induction of oxidative stress with H2O2. The effects of estrogenic compounds on
oxidative stress induced by H2O2 were studied by quantification of apoptosis and ROS
generation in osteocytic cultures.
H2O2 was shown to induce osteocyte apoptosis, which was significantly inhibited in the
presence of 17P-estradiol. Similar protective effects of 17P-estradiol were also observed
in ex vivo calvarial osteocytes. However, the receptor antagonist ICI 182,780 did not
abrogate the effect of 17p-estradiol possibly implying an estrogen receptor-independent
action. In addition, ICI 182,780 also demonstrated protective effects on its own against
H2C>2-induced apoptotic death stimuli. Use of the stereoisomer 17a-estradiol that binds
weakly to the estrogen receptor also prevented H2C>2-induced apoptosis in MLO-Y4
osteocytes. Furthermore, pre-treatment of the ER-negative HeLa and HEK 293 cell lines
with 17P-estradiol in the presence of H2O2 prevented oxidative stress-induced death,
further supporting a possible estrogen receptor-independent effect of 17p-estradiol.
Common to all of the five compounds with anti-apoptotic effects tested in this study was
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the presence of the putative free radical scavenger C3-OH moiety on the steroid A-ring.
The two compounds mestranol and quinestrol, which lack the C3-OH group, did not
prevent oxidant induced apoptosis. In addition, all C3-OH containing compounds, but
not mestranol nor quinestrol, significantly reduced intracellular ROS generation in the
presence of H2O2, in MLO-Y4, HeLa and HEK 293 cell lines, as measured by the use of
the H2DCF-DA dye.
These data have suggested that the anti-apoptotic effects of 17P-estradiol on MLO-Y4
osteocytes, HeLa and HEK 293 cells might operate through a possible antioxidant
mechanism of action and could aid the understanding of the potential use of 17p-
estradiol and estrogen-related compounds in the improvement of both the quantity and
quality of bone through osteocyte saving.
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4.1 Introduction
The presence of viable osteocytes within bone has been associated with the bones'
ability to remodel efficiently (Kamijou et al. 1994, Power et al. 2001, Qiu et al. 2002,
Marotti et al. 1998, Hernandez et al. 2004) and to repair the accumulated microdamage
(Frost et al. 1998, Burr et al. 1993). The number of viable osteocytes has been shown to
decrease during the process of ageing (Frost 1960, Dunstan et al. 1993), while increased
osteocyte apoptosis has been associated with chronic administration of glucocorticoids
(Weinstein et al. 1998, 2000), estrogen loss (Tomkinson et al. 1997, 1998), fatigue
microdamage (Verborgt et al. 2000, Noble et al. 2003) and disuse (Bakker et al. 2004,
Basso et al. 2006, Aguirre et al. 2006); indicating that the maintenance of a viable
osteocytic population in bone is an important parameter of bone quality. Estrogen loss
has been shown to increase osteocyte apoptosis in human and rat bone (Tomkinson et al.
1997; 1998), while the ovariectomy-induced stimulation of osteocyte apoptosis in rats
was shown to be reversed following estrogen administration (Tomkinson et al. 1998).
The mechanisms by which estrogen exerts its effects are broadly categorized as genomic
when they involve gene transcription mediated through the binding of estrogen to the
intracellular estrogen receptors (Razandi et al. 1999, Tsai et al. 1998) or as non-genomic
(Pietras & Szego 1975; 1977, Wehling et al. 1997, Collins & Webb 1999, Levin et al.
1999, Falkenstein et al. 2000) when estrogen binds to estrogen receptors located in the
plasma membrane activating intracellular signaling pathways such as the MAPK
pathway (Kousteni et al. 2001) and the PI3K (Levin et al. 2002). For example, estrogen
was shown to exert non-genomic anti-apoptotic effects against death stimuli induced by
dexamethasone, TNF-a (Kousteni et al. 2001, 2003) and etoposide administration
through the activation of the ERK1/2 pathway in osteocyte cultures in vitro (Kousteni et
al. 2001,2003).
In addition, there is evidence accumulating that estrogen could also act as a free radical
scavenger through the presence of the hydroxyl group (-C30H group) at the C3 position
of the phenolic A ring (-OH group) of the hormone, as has been for example
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demonstrated in neuronal cell cultures where estrogen has been shown to prevent
oxidative stress-induced cell death (Behl et al. 1995, 1997). Several in vivo studies have
also suggested a beneficial role of estrogen administration in the development of
Alzheimer's disease (AD) in postmenopausal women (Tang et al. 1996), a disease that
has been strongly associated with oxidative stress (Behl et al. 1992, 1994; Yan et al.
1996), further supporting the possible action of estrogen as an antioxidant molecule.
Previous studies have shown that administration of the antioxidant enzyme catalase,
which prevents the accumulation of H2O2, to ovariectomised mice reversed bone loss
induced by ovariectomy in mice (Lean et al. 2005) while treatment with H2O2 has been
shown to induce apoptosis in MLO-Y4 osteocytes in vitro (Kikuyama et al. 2002).
However, no evidence is available so far to demonstrate possible antioxidant effects of
estrogen on osteocytes against oxidant attack.
The purpose of this study was to investigate whether estrogen could act as an antioxidant
molecule against oxidant-induced death of MLO-Y4 osteocytes in culture. The ER
antagonist ICI 182, 780 and the ERK inhibitor UO 126 were used to demonstrate
possible involvement of the estrogen receptors and the ERK V2 pathway, respectively. In
addition, various estrogen derivatives that contain the C3-OH moiety in their structure
were used to indicate free radical scavenging activity in the protective effects of estrogen
against oxidant-induced apoptotic cell death.
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4.2 Materials and Methods
All chemicals were purchased from Sigma-Aldrich, UK, unless otherwise stated. All
tissue culture reagents were purchased from Invitrogen, UK and tissue culture well
plates were purchased from Corning, UK. Tissue culture procedures were perfonned in a
laminar flow hood (class 2) receiving HEPA-filtered air, using sterile equipment.
4.2.1 Cell culture and maintenance
The murine long-bone derived MLO-Y4 osteocyte-like cell line (obtained from Prof.
Lynda Bonewald, School of Dentistry, University of Missouri-Kansas City) was
cultured in Modified Eagles Medium Alpha (a-MEM) supplemented with 5% fetal
bovine serum (FBS), 5% newborn calf serum (NCS), 1% penicillin/streptomycin (P/S)
and 1% L-glutamine (Kato et al. 1997). The HeLa human cervical epithelial cell line
(obtained from the European Collection of Cell Cultures) was cultured in a-MEM
supplemented with 5% FBS, 5% NCS, 1% P/S, and 1% L-glutamine (Kousteni et al.
2001). The HEK 293 human embryonic kidney epithelial cell line (obtained from Prof
Philippa Saunders, MRC Reproduction Unit, University of Edinburgh) was cultured in
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10 % FBS, 1% P/S,
and 1% L-glutamine (Evdokiou et al. 1999).
Growth media were stored at 4HC and warmed to 37°C prior to use. Cells were
maintained in an incubator at 37°C in a 95% humidified atmosphere of CbiCCb in the
ratio of 95%: 5%. Sub culturing was performed once weekly upon reaching 90% of
confluency, maintaining the cells in the log phase of proliferation. The monolayer of
cells was detached following the addition of 1 ml of trypsin solution at 2.5 gm/1 for 5-10
minutes, followed by addition of 10 ml of growth medium. The MLO-Y4 cell
suspension was diluted 1:10 in fresh growth media in 75cm2 tissue culture flasks while
the HeLa and the HEK 293 cell suspensions were diluted 1:10 in fresh growth media in
25 cm2 sterile tissue culture flasks. Tissue culture plastics, either in the form of flasks or
well plates, used to maintain the MLO-Y4 cell line were coated with 0.1M collagen type
I from rat tail prior to use.
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4.2.2 Cell treatment
MLO-Y4 osteocytes and HeLa cells were plated at a density of 2.4 x 104 cells per ml
and HEK 293 cells were plated at a density of 5 x 104 cells per ml in 24 multi-well
plates, 24 hours prior to experimentation. Following appropriate treatment, cells were
returned to the incubator at 37 °C for 2 hours. Experiments were carried out a minimum
of three times, and each treatment group was represented by 3 wells in each experiment.
Cells were observed in 3 fields per well resulting in 9 fields per treatment group using a
x 20 magnification lens for all estimates allowing similar numbers of cells to be counted
per field (approximately 40-100 cells per field) in all individual experiments using an
inverted microscope fitted with DXM 1200 camera (Nikon UK Limited). All estrogenic
compounds were diluted in 70 % ethanol while H2O2 was directly diluted in growth
medium. Control treatments represent untreated cultures. Where indicated in the figure
legends, vehicle represents treatment with 70 % ethanol subjected to dilutions identical
to the highest concentration under study in the absence of the compound.
4.2.3 Induction of oxidative stress
MLO-Y4 osteocytes and HeLa cells were incubated in growth medium supplemented
with H2O2 within a concentration range of 0.08mM-0.6mM for 2 hours in order to
induce oxidative stress. HEK 293 cells were treated with H2O2 at the concentration of
0.3 mM previously shown to induce oxidative stress in this cell line (Nomura et al.
2006). The induction of apoptotic cell death was monitored microscopically using
nuclear morphological criteria.
4.2.4 Prevention of cell death and oxidative stress
All agents that were used to prevent cell death remained in culture during H2O2 induced
oxidative stress.
4.2.4.1 Estrogens
MLO-Y4 osteocytes and HeLa cells
MLOY-4 osteocytes and HeLa cells were pre-treated for 1 hour with 17p-estradiol
(Calbiochem, UK) and the biologically inactive stereoisomer 17a-estradiol (Sigma)
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(Figure 4.12) diluted in 70% ethanol at concentrations of 10~6M tolO~8M (Kousteni et
al. 2002), followed by H2O2 treatment used at 0.3mM for 2 hours.
HEK 293
HEK 293 cells were pre-treated for 1 hour with 17|3-estradiol (Calbiochem, UK) diluted
in 70% ethanol at concentrations of 10~6M tolO~8M (Kousteni et al. 2002), followed by
H2O2 treatment used at 0.3mM for 2 hours.
4.2.4.2 Estrogen-related compounds
MLO-Y4 osteocytes
MLOY-4 osteocytes were pre-treated for 1 hour with the estrogen receptor antagonist
ICI 182, 780 (Wilson et al. 2000, Gu et al. 2005, Kousteni et al. 2001), (Tocris Cookson
Ltd), (Figure 4.12) at a concentration range of 10"6M-10"8M, diluted in 70% ethanol,
followed by H2O2 treatment used at 0.3mM for 2 hours.
MLO-Y4 osteocytes and HeLa cells
MLO-Y4 osteocytes and HeLa cells were pre-treated for 1 hour the estrogen derivatives
ethinylestradiol 3-methyl ether (Mestranol), 17a-ethinylestradiol and ethinyl estradiol 3-
cyclopentyl ether (Quinestrol) (Figure 4.12), diluted in 70% ethanol, at a concentration
range of 10"5 M-10"10 M (Behl et al. 1997) followed by H2O2 treatment used at 0.3mM
for 2 hours.
4.2.4.3 Vitamin E
The anti-oxidant Vitamin E was used to investigate the potential cell saving activity of a
potent antioxidant compound in this model system. MLO-Y4 osteocytes were pre-
treated for 1 hour with a-tocopherol (vitamin E), (Figure 4.12), at concentrations of 10"4
M, 10"6 M and 10"8 M (Behl et al. 2000), diluted in 70% ethanol, followed by H202
treatment used at 0.3mM for 2 hours.
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M, 10"6 M and 10"8 M (Behl et al. 2000), diluted in 70% ethanol, followed by H2O2
treatment used at 0.3mM for 2 hours.
4.2.5 Inhibitors of intracellular signaling proteins
4.2.5.1 Inhibition of caspase 3/7 activity
Caspases are involved in various stages in apoptotic cascades, mediating either initial
stages in death receptor pathways or events further down in apoptotic pathways that
involve the disassembly of the cell's structure (Thornberry et al. 1998). To determine
whether osteocyte apoptosis in response to H2O2 was a caspase-dependent process
osteocytes were pre-incubated with the selective caspase 3/7 inhibitor
(GlaxoSmithKline, USA), a non-peptide selective inhibitor of caspases 3 and 7 based on
sulphanilamide derivatives (Lee et al. 2000) mainly mediating end-stage cytoskeletal
and nuclear changes in the apoptotic cell at a concentration of 1 pM for 1 hour prior to
0.3mM H2O2 treatment.
4.2.5.2 MAPK inhibitors
U0126 is a chemically synthesized organic compound that inhibits activation ofMAPK
(ERK 1/2) by inhibiting the kinase activity of MAP Kinase Kinase (MAPKK or MEK
1/2) (Favata et al. 1998). Cells were pre-incubated for 1 hour with U0126 (Calbiochem,
UK) at a concentration of 20pM in DMSO, a concentration previously shown to inhibit
ERK in osteocytes (Kogianni et al. 2004). UO 126 remained in the culture media prior to
the further addition of 17P-estradiol and estradiol derivatives, and then also subsequently
in the presence of H2O2.
4.2.6 Determination of apoptotic state
4.2.6.1 DAPI staining for healthy and apoptotic cell morphology
The DAPI (4', 6-Diamidino-2-phenylindole) compound stains nuclear DNA, giving a
fluorescent image of nuclear structure when subjected to UV light illumination at 344
nm. DAPI reveals chromatin condensation, nuclei shrinkage and the fragmentation of
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the nuclear material into smaller blebs indicating late stages of the apoptotic cascades
(Cowden et al. 1981). It is rapidly taken up by the cells and forms fluorescent complexes
with double-stranded DNA by forming stable hydrogen bonds with the minor groove of
the double helix. Following experimental treatments, cells were fixed in 4%
paraformaldehyde for 10 minutes, washed three times in PBS and air-dried. Cells were
then incubated with DAPI at a concentration of 2.5ng/ml for 20 minutes. Normal cells
were characterised by intact nucleus and normal cytoplasmic appearance whereas
apoptotic cells were characterised by cell shrinkage, plasma membrane blebbing
observed using transmitted light and nuclear condensation examined using fluorescence
(358nm excitation, emission 461nm). Necrotic cells were identified by cell swelling
and/or bursting and loss of membrane integrity. Cell numbers were also determined
following H2O2 treatment in order to monitor the rapid cell death characteristic of
necrosis.
Within each field the total cell number and the number of apoptotic cells was assessed;
the results were expressed as the percentage of the ratio of apoptotic to non-apoptotic
cells, as calculated using the equation:
Percentage of apoptotic osteocytes per field =
Average number of DAPI apoptotic osteocytes per field
X 100
Total number of DAPI stained osteocytes per field
4.2.6.2 DNA fragmentation using in situ Nick Translation
The percentage of target osteocytes demonstrating DNA breaks was investigated in
murine calvaria using the in situ nick translation staining (Noble et al. 1997), which
allows the determination of DNA breaks following the incorporation of DIG-labelled
dUTP, as described in § 3.2.2. The ratio of total osteocytes (DAPI stained) to apoptotic
(FITC positive) was determined using fluorescence microscopy with digital capture.
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the presence of ROS. It becomes de-esterified intracellularly and turns to a highly
fluorescent 2', 7'-dichlorodihydrofluorescein upon oxidation by intracellular H2O2 (Bass
et al. 1983, Lebel et al. 1992; Royal et al. 1993) and reactive oxygen species (Zhu et al.
1994, Gunasekar et al. 1995). H2DCF-DA was added to the culture medium of MLO-
Y4 osteocytes and HeLa cells at 10 pM (Yen. et al. 2001, Ohashi et al. 2002) for 30
minutes prior to addition of either 17P-estradiol, 17a-estradiol, ICI 182, 780, 17a-ethinyl
estradiol, vitamin E, mestranol or quinestrol for 1 hour. HEK 293 cells were incubated
with FEDCF-DA for 30 minutes and then with 17P-estradiol or vitamin E for a further
hour. All cultures received treatment with H2O2 0.3mM for a further 2 hours. The
H2DCF-DA and pre-treatment agents remained in culture during H2O2 treatment after
which the media were removed and the cells were washed twice with PBS before re-
addition of normal growth medium. Live cells were monitored using an inverted
microscope fitted with an environmental chamber to maintain temperature at 37 °C and
5% humidified CO2. ROS positive cells were detected at 490nm excitation and images
captured at 20x magnification using DXM1200 colour camera. For analysis 3 wells per
treatment and six fields per well were counted. Negative control was represented by
cultures incubated in the absence of the FLDCF-DA in order to determine the absence of
auto-fluorescence in MLO-Y4 cultures.
4.2.8 Isolation of murine calvariae for ex vivo experimental conditions
Mouse calvariae were aseptically isolated from 12 Balb/c mice. Calvariae were carefully
broken across the suture line in order to provide controls from each animal (for each of
the treatments) and were kept in individual wells in a 24-well plate in a-MEM medium
supplemented with 5% FBS, 5% NCS, 1% P/S and 1% L-glutamine. The calvariae were
then randomly divided into 4 treatment groups (n=3 for each group). The treatment
groups are comprised of control, H2O2 and 17P-estradiol in the presence or absence of
H2O2. Calvariae were pre-treated for 1 hour with 17P-estradiol (10"8M) followed by
H2O2 treatment at 0.3 mM for 24 hours at 37 °C. Following the experimental period, the
bones were submerged immediately in 5% polyvinyl alcohol and snap frozen in a
hexane-chilling bath before being stored at -70 °C prior to cryostat sectioning. Cryostat
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groups are comprised of control, H2O2 and 17|3-estradiol in the presence or absence of
H2O2. Calvariae were pre-treated for 1 hour with 17P-estradiol (10"8M) followed by
H2O2 treatment at 0.3 mM for 24 hours at 37 °C. Following the experimental period, the
bones were submerged immediately in 5% polyvinyl alcohol and snap frozen in a
hexane-chilling bath before being stored at -70 °C prior to cryostat sectioning. Cryostat
sections of 7pm thickness were cut from the chilled material and transferred to 3-
aminopropylnethoxy-silane (TESPA) coated slides, which aid adhesion of the bone
section to the slide by creating a highly charged surface. Nine sections (three sections
per each calvaria) were used per treatment group, scored for the total number of
osteocytes inside the lacunae using nuclear counterstain (DAPI) while the percentage of
apoptotic osteocytes for each treatment was estimated using the nick translation
technique.
4.2.9 Statistical analysis
All statistical analyses were performed using quantitative data analysis with SPSS 11.5
for Windows. Data was checked for normal distribution by applying the Kolmogorov-
Smirnov test. When the p value of the ANOVA was p<0.05, the use of the Tukey-
Kramer post-hoc test allowed comparison of more than two means at once without
introducing the type I error associated with multiple t-tests (Zar 1984, Fielding and
Gilbert, 2000). Results are expressed as means ± S.E. The probability score p<0.05 was
considered to be statistically significant. Results were considered significant when
p<0.05 denoted by *; p<0.01 denoted by ** and p<0.001 denoted by *** when
experimental treatment was compared to H2O2 treatment, and p<0.05 denoted by ;
p<0.01 denoted by t+ and p<0.001 denoted by t++ when experimental treatment was
compared to the non treated control.
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4.3 Results
4.3.1 H202 induces ML0-Y4 cell apoptosis in a dose dependent-manner
MLO-Y4 osteocytes were cultured with H2C>2 at a range of concentrations between
0.08mM and 0.6mM for 2 hours (Figure 4.1A). Healthy and degenerating (apoptotic
and necrotic) cell morphology was investigated with DAPI nuclear staining, as described
in the methods section. H202 induced apoptosis in osteocytes in a dose dependent
manner over a 2 hour incubation period (Figure 4.1A). An increased proportion of
apoptotic cells compared to control cultures was observed at H202 concentrations as low
as 0.08mM and and reached maximal levels at H202 concentrations above 0.4mM
(Figure 4.1A). However, apart from apoptosis, concentrations higher than 0.4mM also
induced necrotic cell death of osteocytes as confirmed by the presence of cells that had
expanded and burst, characteristics of necrosis, and by the rapid reduction in cell
numbers within 2 hours of addition to cultures (Figure 4.1B). In contrast, H202
concentrations below 0.4mM induced the morphological characteristics of apoptosis and
did not alter cell numbers within 2 hours (Figure 4.IB, Figure 4.2). Based on the
apoptotic criteria and the loss of cells in culture in response to the different
concentrations investigated, the dose of 0.3mM, which did not induce necrosis and
induced a moderate reduction in cell number at 2 hours, was selected for future
experiments.
4.3.2 Caspase 3/7 selective inhibitor reduces H202- induced apoptosis
In order to further demonstrate the apoptotic nature of the oxidant engendered response a
specific caspase 3/7 inhibitor (GlaxoSmithKline, USA), which is based on Isatin
Sulphonamides (Lee et al. 2001), was used to inhibit terminal effector caspases 3 and 7.
Pre-incubation of the cells for 1 hour with the specific caspase 3/7 inhibitor prior to
H202 treatment at 0.3mM significantly reduced the percentage of apoptotic cells induced
by H202 to near control levels confirming caspase dependency of osteocyte death under
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Figure 4.1. H202 induces apoptosis in MLO-Y4 osteocytes in a
concentration-dependent manner. MLO-Y4 osteocytes were incubated with H202
at 0.08-0.6 mM for 2 hours. Cell were stained for apoptosis determination with DAPI
and examined by fluorescent microscopy. Graphs represent A. mean percentages of
apoptotic osteocytes ± SE. and B. mean number of osteocytes in culture ± SE. Control
cultures represent untreated cultures, (fff = p< 0.0001, ff = p< 0.0001 relative to the
untreated control, *** =p<0.0001, ** = p< 0.001, * = p< 0.05).
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Figure 4.2. H202 induces cytoplasmic and nuclear condensation, DNA
fragmentation and formation of osteocyte apoptotic bodies. Representative
images of H202-treated MLO-Y4 osteocytes at H2O2 0.3 mM for 2 hours and stained with
DAPI. Arrows indicate nuclear condensation and fragmentation (DAPI stain) and







Control Caspase 3/7 inhibitor
Figure 4.3. Inhibitor of caspase 3/7 reduces pro-apoptotic stimuli induced
by H2O2. MLO-Y4 osteocytes were incubated with the selective inhibitor of caspase
3/7 for 1 hour, prior to H2O2 treatment at 0.3 mM for 2 hours. Cells were stained with
DAPI and examined by fluorescence microscopy. Graphs represent mean percentages of
apoptotic osteocytes ± SE. (*** =p<0.0001 compared to H2O2 treatment, tft ~
p<0.0001 compared to control).® = control cultures, a = H2O2 treated cultures in the
absence or presence of caspase 3/7 inhibitor. Control cultures represent untreated
cultures.
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4.3.3 17p-estradiol prevents H202-induced apoptosis in MLO-Y4 osteocytes
Dose response studies were used to identify concentrations of 17P-estradiol that did not
increase apoptosis above the control levels. Mean percentages of osteocytes displaying
apoptotic morphology were significantly increased compared to the control following
treatment with 17P-estradiol at 10"6M (p<0.0001), whereas concentrations of 10"7M and
o
10" M did not increase the levels of apoptosis above control levels (p>0.05) (Figure
4.4). 17P-estradiol was then used to treat osteocytes prior to addition of H2O2 to cultures.
The percentage of H2O2 induced apoptotic osteocytes was significantly reduced after
pre-treatment of cells for 1 hour with 17P-estradiol at doses of 10"6 M (p<0.01), 10"7 M
(p<0.007) and 10"8 M (p<0.001) (Figure 4.4). The dose of 10"8 M, which is near the
physiological concentration of 17P-estradiol (Ganong 1999, Dotsch et al. 2001), was
used in subsequent treatments since it significantly reduced H2O2 induced apoptosis
without itself demonstrating a pro-apoptotic effect on osteocytes (Figure 4.5).
4.3.4 17a-estradiol prevents H202-induced apoptosis in MLO-Y4 osteocytes
The pro-apoptotic stimuli by H2O2 in osteocytes were further investigated in the
presence of 17a-estradiol, a stereoisomer of 17P-estradiol that is characterised by a
lower binding affinity to estrogen receptor than 17P-estradiol and has been reported by
many studies to be biologically inactive (Gorski et al. 1994). Dose response studies were
used to identify concentrations of 17a-estradiol that did not increase apoptosis above the
control levels. Mean percentages of osteocytes displaying apoptotic morphology were
increased compared to control following treatment with 17a-estradiol at 10"6M, whereas
concentrations of 10"7M and 10"8M did not increase the levels of apoptosis above control
levels (p>0.05) (Figure 4.6). Pre-treatment of cells for one hour with 17a-estradiol at
concentrations of 10"6 M to 10"8 M resulted in a significant reduction in the percentage of
apoptotic osteocytes induced by H2O2 treatment at all the concentrations used (Figure
4.6). The dose of 10"8M was chosen for subsequent experiments using 17a-estradiol,
since it reduced H2O2 induced osteocyte apoptosis without itself exerting toxic effects to






























Figure 4.4. 17p-estradiol prevents MLO-Y4 osteocyte apoptosis induced by
H2O2. Osteocytes were incubated with 17P-estradiol at 10"6 M, 10"7 M and 10"8 M for 1
hour prior to H2O2 treatment for a further 2 hours. Mean percentages of apoptotic
osteocytes were statistically different compared to control following treatment with 17(3-
estradiol at 10"6M. All concentrations of 17P-estradiol significantly reduced the
percentages of apoptotic osteocytes induced by H2O2 treatment to levels similar to
control. Cells were stained with DAPI and examined with fluorescence microscopy
Graphs represent mean percentages of apoptotic osteocytes ± SE. (*** =p<0.0001, ** =
p< 0.001, compared to H2O2 treatment, ftf = p<0.0001 compared to control). Control
cultures represent untreated cultures. Vehicle cultures for 17P-estradiol at 10"6M were
similar to control in percentages of apoptotic osteocytes (8.3 ± 1.35 % S.E., p>0.05).
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Figure 4.5. 17p-estradiol prevents H202-induced apoptosis in MLO-Y4
osteocyte cultures. Representative images of osteocytes in culture treated with 17(3-
estradiol for 1 hour followed by H2O2 treatment for a further two hours and stained with
DAPI. H2O2 induced osteocyte apoptosis (middle panel) which was reversed following
administration of 17|3-estradiol (bottom panel). White arrow shows an apoptotic
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Figure 4.6. 17a-estradiol prevents MLO-Y4 osteocyte apoptosis induced by
H2O2. Osteocytes were incubated with 17a-estradiol at 10"6 M, 10"7 M and 10"8 M for 1
hour prior to H2O2 treatment for a further 2 hours. All concentrations of 17a-estradiol
significantly reduced the percentages of apoptotic osteocytes induced by H2O2 treatment
to levels similar to control. Cells were stained with DAPI and examined with
fluorescence microscopy. Graphs represent mean percentages of apoptotic osteocytes ±
SE. (** = p< 0.001, * = p< 0.05 compared to H2O2 treatment, fff= p<0.0001 compared
to control). Control cultures represent untreated cultures. Vehicle cultures for 17a-
estradiol at 10"6M were similar to control in percentages of apoptotic osteocytes (5.3 ±
0.81 % S.E., p>0.05).
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4.3.5 The estrogen receptor antagonist ICI 182 780 does not prevent the
anti-apoptotic effects of 17p-estradiol
In order to determine whether the anti-apoptotic effects of 17p-estradiol were mediated
via the nuclear estrogen receptor, the pure estrogen receptor antagonist ICI 182,780 was
used. Dose response studies showed that ICI 182 780 did not prevent the anti-apoptotic
effects of 17p-estradiol at any of the concentrations used in this study (p=0.0005 at 10"
8M) (Figure 4.7A). The lowest dose of 10"8 M of ICI 182 780, which is similar to the
dose used for 17P-estradiol, was employed in subsequent treatments. (Figure 4.7A).
ICI 182 780 prevents H202-induced osteocyte apoptosis
Estimation of the apoptotic osteocyte levels induced by H2O2 in the presence of ICI 182
780 indicated that pre-treatment of osteocytes with the ICI 182 780 compound in the
absence of 17P-estradiol was sufficient to reduce H2O2 pro-apoptotic stimuli (p= 0.001,
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Figure 4.7. ICI 182 780 does not prevent the protective effects of 17(3-
estradiol on MLO-Y4 osteocyte apoptosis induced by H202. A. Osteocytes
were pre-incubated with ICI 182 780 at 10 6 to 10"8 M for 1 hour prior to addition of
17(3-estradiol for 1 hour and H2O2 treatment for a further 2 hours. ICI 182 780 did not
prevent the anti-apoptotic effects exerted by 17(3-estradiol. B. Pre-treatment of cells with
ICI 182 780 alone prior to the addition of H202 prevented H202-induced osteocyte
apoptosis. Cells were stained with DAPI and examined with fluorescence microscopy.
Graphs represent mean percentages of apoptotic osteocytes ± SE. (** = p< 0.001,
compared to H2O2 treatment, f= p<0.01 compared to control). Control cultures represent
untreated cultures. Vehicle cultures for ICI 182 780 at 10"6M were similar to control in
percentages of apoptotic osteocytes (5.23 ± 0.2 % S.E., p>0.05).
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4.3.6 17P-estradiol and 17a-estradiol prevent H202-induced apoptosis in
the ER-negative HeLa cells
To further investigate the potential contribution of the estrogen receptor in the anti-
apoptotic effects of 17P-estradiol against H202 induced death, the ER-negative HeLa
cervical epithelial cell line was employed (Rago et al. 2004; Carpino et al. 2004).
Administration of H202 induced apoptosis in HeLa cells in a dose dependent manner
between 0.08mM and 0.6mM over a 2 hour incubation period (Figure 4.8) while the
dose of 0.3mM H202j that was used to characterise oxidative stress in MLO-Y4
osteocytes, induced comparable levels of apoptosis in HeLa cells and was therefore used
in subsequent experiments. Mean percentages of HeLa cells displaying apoptotic
morphology were significantly increased compared to the control following treatment
with 17P-estradiol at 1CT6M (p<0.0001), whereas concentrations of 10"7M and 10"8M did
not increase the levels of apoptosis above control levels (p>0.05) (Figure 4.9A). Pre-
treatment of HeLa cells with 17p-estradiol for 1 hour at doses of 10"6M, 10"7M and 10"
8M all significantly reduced the percentage ofH202 induced apoptosis (p<0.05 for 10"6M
and 10"7M and p< 0.001 for 10"8M), (Figure 4.9A). In addition, administration of 17a-
/TO
estradiol to HeLa cells for 1 hour at concentrations of 10" M to 10" M resulted in a
significant reduction in the percentage of osteocytes undergoing apoptosis, when
compared to H202 treatment, at all doses used (Figure 4.9B). The dose of 10"8 M for
both 17P-estradiol and 17a-estradiol was used in subsequent treatments since it
significantly reduced H202-induced apoptosis without demonstrating a pro-apoptotic





Figure 4.8. H202 induces apoptosis in HeLa cells in a concentration-
dependent manner. HeLa cells were incubated with H2O2 at 0.08-0.6 mM for 2
hours. Cell were stained for apoptosis determination with DAPI and examined by
fluorescent microscopy. Graphs represent mean percentages of apoptotic HeLa cells ±
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Figure 4.9. 17(3-estradiol and 17a-estradiol prevent HeLa cell apoptosis
induced by H2O2. HeLa cells were incubated with A. 17|3-estradiol and B. 17a-
estradiol at 10"6 M, 10"7 M and 10"8 M for 1 hour prior to H2O2 treatment for a further 2
hours. Cells were stained with DAPI and examined with fluorescence microscopy
Graphs represent mean percentages of apoptotic HeLa cells ± SE. (* = p< 0.05
compared to H202 treatment, tt= p<0.001, compared to control). Control cultures
represent untreated cultures. Vehicle cultures for 17(3-estradiol, 17a-estradiol at 10"6M
were similar to control in percentages of apoptotic cells (7.85 ± 0.917 % S.E., p>0.05;
4.74 ± 0.322 % S.E., p>0.05).
4.3.7 17/?-estradiol prevents H202-induced apoptosis of the ER-negative
HEK 293 cells
To further investigate the potential contribution of the estrogen receptor in the anti-
apoptotic effects of 17/3-estradiol against H2O2 induced death, the HEK 293 cell line that
lacks the ER was employed (Kahlert et al. 2000, Thomas et al. 2005). The dose of
0.3mM H2O2, which was previously chosen in order to characterise oxidative stress in
MLO-Y4 osteocytes and HeLa cells, was also employed in the HEK 293 cell line and
was found to be within the dose range previously shown to induce oxidative stress-
induced apoptosis in HEK 293 cells (Nomura et al. 2006). Pre-treatment of HeLa cells
with 17P-estradiol for 1 hour at doses of 10"6M, 10"7M and 10~8M all significantly
reduced the percentage of H2O2 induced apoptosis (p<0.05 for 10"6M and 10"7M and p<
0.001 for 10"8M), (Figure 4.10).
4.3.8 Inhibition of MAP kinase signalling does not block the protective
effect of 17/?-estradiol on MLO-Y4 osteocytes.
Previous studies have implicated the ERK V2 pathway in the protective effects of 17p-
estradiol against dexamethasone, TNF-a, etoposide in osteocytes (Kousteni et al. 2001,
2003). In order to determine whether the saving effect of 17/3-estradiol against H2O2 on
MLO-Y4 osteocytes was mediated via activation of MAP kinase signalling pathways,
the MEK1/2 inhibitor U0126 was used. Pre-treatment of MLO-Y4 with U0126 at the
concentration of 20pM previously shown to inhibit ERK phosphorylation (Favata et al.
1998, Kogianni et al. 2004) prior to the addition of 17P-estradiol did not inhibit the anti-




























Figure 4.10. 17(3-estradiol prevents HEK 293 cell apoptosis induced by
H2O2. HEK 293 cells were incubated with 17P-estradiol at 10"6 M, 10"7 M and 10"8 M
for 1 hour prior to H2O2 treatment for a further 2 hours. Cells were stained with DAPI
and examined with fluorescence microscopy Graphs represent mean percentages of
apoptotic HEK 293 cells ± SE. (* = p< 0.05 compared to H2O2 treatment, ftt =
p<0.0001, compared to control). Control cultures represent untreated cultures. Vehicle
cultures for 17p-estradiol at 10"6M were similar to control in percentages of apoptotic
HEK 293 cells (4.4 ± 0.6 % S.E., p>0.05).
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Figure 4.11. The MEK V2 inhibitor U0126 does not inhibit the anti-apoptotic
effects of 17p-estradiol. MLO-Y4 osteocytes were incubated with U0126 for 30
minutes at 20 |iM prior to the addition of 17P-estradiol for 1 hour in the presence and
absence of H2C>2 at 0.3mM for a further 2 hours. U0126 did not prevent MLO-Y4
osteocyte apoptosis induced by H2O2 treatment and did not block the protective effect of
17P-estradiol on MLO-Y4 osteocytes. Cells were stained with DAPI and examined by
fluorescence microscopy. Graphs represent mean percentages of apoptotic osteocytes ±
SE. (** = p< 0.001, * = p< 0.05, compared to H202 treatment, ttt= p<0.0001, tt
=p<0.001 compared to control). Control cultures represent untreated cultures and are
similar to vehicle (DMSO) cultures in percentages of apoptotic osteocytes.
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4.3.9 Prevention of H202-induced apoptosis in MLO-Y4 osteocytes is
associated with the presence of the C3-OH group in the structures of the
estrogenic compounds
Comparison of the structures of all the estrogenic compounds that exerted protective
effects against H202-induced apoptosis pointed out that 17/3-estradiol, 17a-estradiol and
IC1 182 780 all had in common a hydroxyl group (-OH) at the C3 position of their
phenolic A ring (Figure 4.12). Based on these observations, compounds that did not
contain this moiety in their structure, such as mestranol (CHjO-methyl group instead of
the C3-OH group) and quinestrol (cyclopentyl group instead of the C3-OH group) were
further utilised against H202-induced apoptotic cell death.
Dose response studies were used to identify the concentrations of mestranol and
quinestrol that did not induce osteocyte apoptotic death when administered alone in
culture. Estimation of mean percentages of osteocytes displaying apoptotic morphology
showed that mestranol and quinestrol at 10 5M induced significant apoptosis compared
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to control (p=0.008, p=0.05, respectively) whereas lower doses such as 10" M and 10"
M were not different compared to the control levels (p>0.05) (Figure 4.13A, 4.13B).
Mestranol and quinestrol were then used to treat osteocytes prior to addition of H202 to
cultures. Pre-incubation of osteocytes with mestranol or quinestrol, which do not contain
the -OH group in their structure, for 1 hour failed to inhibit H202-induced apoptosis
(p>0.05), (Figure 4.13A, 4.13B, 4.14).
To further determine the dependency of the saving effects of estrogenic compounds
against oxidant attack on the presence of the -OH group, 17a-ethinylestradiol was used
against H202-induced apoptosis in MLO-Y4 osteocytes. 17a-ethinylestradiol is
structurally similar to mestranol and quinestrol, but with the -methyl and -pentyl groups
substituted by C3-OH, respectively (Figure 4.12). Estimation of mean percentages of
osteocytes displaying apoptotic morphology showed that 17a-ethinylestradiol used at 10"
5M induced significant apoptosis compared to control (p=0.01) whereas lower doses
such as 10"8 M and 10"'° M were not different compared to the control levels (p>0.05)
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(Figure 4.13C). In contrast to the effects observed with mestranol and quinestrol
(Figure 4.13A, 4.13B), pre-treatment of osteocytes for 1 hour with 17o;-ethinylestradiol
prevented pro-apoptotic stimuli induced by H2O2 at all concentrations used (Figure
4.13C, 4.14).
4.3.10 Prevention of H202-induced apoptosis in HeLa cells is associated
with the presence of the C3-OH group in the structures of the estrogenic
compounds
To characterise the contribution of the hydroxyl group present in the estrogenic
compounds in the prevention of the oxidative stress in HeLa cells, cultures were pre-
treated with 17o;-ethinylestradiol, mestranol and quinestrol at doses 10"5, 10~8 and 10"'°M
for 1 hour in the presence or absence of H2O2. Estimation ofmean percentages of HeLa
cells displaying apoptotic morphology showed that 17a-ethinylestradiol prevented H202
-induced apoptosis (Figure 4.15A), whereas neither mestranol nor quinestrol


















Figure 4.12. Chemical structures of 17(3-estradiol and estrogen-related
compounds. 17(3-estradiol and all related compounds employed in this study, apart
from mestranol and quinestrol, are characterized by the presence of a hydroxyl group (-
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Figure 4.13. Protection against oxidant attack in osteocytes by estrogenic
compounds was dependent on the presence of the -OH group. Osteocytes
were pre-incubated with A. mestranol, B. quinestrol and C. 17a ethinylestradiol at 10 3
to 10"10 M for 1 hour followed by addition of H2O2 for a further 2 hours. Apoptosis of
osteocytes induced by H2O2 was not reduced in the presence of A. mestranol or B.
quinestrol. C. 17a ethinylestradiol prevented osteocyte apoptosis induced by H2O2
treatment at all concentrations used. Cells were stained with DAPI and examined with
fluorescence microscopy. Graphs represent mean percentages of apoptotic osteocytes ±
SE. (** = p< 0.001, * = p< 0.05 compared to H2O2 treatment, t= p<0.05 compared to
control). Control cultures represent untreated cultures. Vehicle cultures for mestranol,
quinestrol and 17a ethinylestradiol at 10 3M were similar to control in percentages of
apoptotic osteocytes (6.9 ± 1.42 % S.E., p>0.05; 10.54 ± 1.63 % S.E., p>0.05, 7.11 ±
0.22 % S.E., p>0.05 respectively).
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Figure 4.14. The presence of the -OH group determines the prevention of
H202-induced apoptosis in MLO-Y4 osteocytes. Representative images of MLO-
Y4 osteocytes treated with either mestranol, quinestrol or 17a ethinyl estradiol for 1 hour
followed by H2O2 treatment for a further two hours and stained with DAPI stain. In
contrast to mestranol (C) or quinestrol (D), 17a ethinylestradiol (E) reduced H2O2-
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Figure 4.15. Protection against oxidant attack by estrogenic compounds in
HeLa cells was associated with the presence of the -OH group. HeLa cells
were pre-incubated with A. 17a-ethinylestradiol, B. Mestranol and C. Quinestrol at 10°
M, 10"8 M and 10"10 M for 1 hour followed by addition of H202 treatment for 2 hours.
A. 17a-ethinylestradiol but not B. mestranol or C. quinestrol prevented H202 induced
apoptosis of HeLa cells at all concentrations used. Cells were stained with DAPI and
examined with fluorescence microscopy. Graphs represent mean percentages of
apoptotic HeLa cells ± SE. (* =p<0.05 compared to H202 treatment; tt= p<0.001
compared to control). Control cultures represent untreated cultures. Vehicle cultures for
17a-ethinylestradiol, mestranol and quinestrol at 10"5M were similar to control in
percentages of apoptotic HeLa cells (5.86 ± 0.72 % S.E., p>0.05; 4.69 ± 0.6 % S.E.,
p>0.05; 8.48 ± 0.69 % S.E., p>0.05, respectively).
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4.3.11 Vitamin E prevents H202-induced apoptosis in MLO-Y4 osteocytes in
a dose dependent manner
The anti-oxidant Vitamin E was used to investigate the potential cell protective activity
of a known antioxidant compound in this model system. Mean percentages of osteocytes
displaying apoptotic morphology were not statistically different to the control following
treatment with vitamin E alone at concentrations of 10~4M, 10"6M and 10"8M (p<0.05)
(Figure 4.16). Vitamin E was then used to treat osteocytes prior to addition of H2O2 to
cultures. Estimation of apoptotic osteocytes showed that pre-incubation of cells for 1
hour with vitamin E at all concentrations used significantly decreased the pro-apoptotic
effect of H2O2, following 2 hours incubation in osteocyte cultures (Figure 4.16). Since
the dose used for 17P-estradiol and all the above estrogen-related molecules employed in
this study was the lowest effective concentration of 10"8 M, the same dose for vitamin E
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Figure 4.16. Vitamin E prevents MLO-Y4 osteocyte apoptosis induced by
H202 in a concentration dependent manner. Osteocytes were incubated with
vitamin E at 10~4 M, 10~6 M and 10"8 M for 1 hour prior to H2O2 treatment for a further 2
hours. Vitamin E reduced the mean percentages of apoptotic osteocytes to levels similar
to control without itself causing any apoptosis. Cells were stained with DAPI and
examined with fluorescence microscopy. Graphs represent mean percentages of
apoptotic osteocytes ± SE. (** = p< 0.001, compared to H2O2 treatment, ft = p<0.001
compared to control). Control cultures represent untreated cultures.
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4.3.12 17p-estradiol and estrogenic compounds that contain the -OH
group reduced the H202-induced ROS production in MLO-Y4 osteocytes
The ability of H2O2 to generate reactive oxygen species in MLO-Y4 was investigated
using 2', 7'- dichlorodihydrofluorescein-diacetate (H2DCF-DA), as described in § 4.2.7.
The proportion of ROS positive osteocytes was significantly increased within 2 hours of
treatment of osteocytes with H2O2 (p<0.0001) (Figure 4.17A, 4.17B, 4.18). Pre-
treatment of osteocytes with compounds that contain the -OH group at C3 position of
their phenol A ring such as 17[3-estradiol, 17a-estradiol, ICI 182 780, and 17a
ethinylestradiol, used at a concentration of 10"8M, significantly reduced the proportion of
ROS positive cells following treatment with H2O2 to levels similar to those seen in
control cultures, as did the potent anti-oxidant Vitamin E (10"8M) (Figure 4.17A). In
contrast to this observation, pre-incubation of osteocytes with mestranol and quinestrol
o
at 10" M concentration, failed to reduce the number of ROS positive cells (Figure
4.17B).
4.3.13 17(3-estradiol and estrogenic compounds that contain the -OH
group reduced the H202-induced ROS production in HeLa cells
The proportion of ROS positive cells was significantly increased within 2 hours of
treatment of HeLa cells with H2O2 (p=0.0001), (Figure 4.19A and 4.19B). Pre-
treatment of HeLa cells with 17P-estradiol, 17a-estradiol, ICI 182 780 and 17a
ethinylestradiol at a concentration of 10"8M, significantly reduced the proportion of ROS
positive HeLa cells induced by H2O2 treatment (p=0.004 for 17P-estradiol and p<0.05
for 17a-estradiol, ICI 182 780,17a ethinyl estradiol) (Figure 4.19A). In contrast to this
observation, pre-incubation of HeLa cells with either mestranol or quinestrol, at a
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Figure 4.17. Compounds which display the C3-OH moiety in their structure
prevent H202-induced ROS production in osteocytes. MLO-Y4 osteocytes
were incubated with HoDCF-DA for 30 min and then pre-treated with A. 17P-estradiol
or 17a-estradiol or ICI 182,780 or 17a-ethinylestradiol or Vitamin E for 1 hour prior to
addition of EhO? for a further 2 hours. The percentage of ROS positive cells induced by
H2O2 treatment was reduced in the presence of any of these compounds to levels similar
to control. B. Pre-treatment of osteocytes with mestranol or quinestrol, which lack the
C3-OH group in their structure did not reduce the percentage of ROS positive cells
induced by H202. Cells were examined with fluorescence microscopy. Graphs represent
mean percentages of ROS positive osteocytes ± SE. (*** = p<0.0001, ** = p< 0.001, * =
p<0.05 compared to H2O2 treatment, ftt = p<0.001 compared to the untreated control).









Figure 4.18. Estrogenic compounds that contain the C3-OH moiety in their
chemical structures reduced the H2C>2-induced ROS production in MLO-Y4
osteocytes. MLO-Y4 osteocytes were incubated with H2DCF-DA for 30 min and then
pre-treated with 17|3-estradiol and estrogenic compounds for 1 hour prior to H2O2
treatment for a further two hours. A. control cultures, B. H202-treated cultures, C.
cultures treated with 17|3-estradiol in the presence of H2O2, D. cultures treated with
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Figure 4.19. Compounds containing the C3-OH moiety in their structure
prevent H202-induced generation of ROS in HeLa cells. HeLa cells were
incubated with H2DCFH-DA for 30 min and then pre-treated with A. 17p-estradiol or
17a-estradiol or ICI 182 780 or 17a ethinylestradiol or vitamin E. The percentage of
ROS positive cells induced by H2O2 treatment was reduced in the presence of any of
these compounds to levels similar to control. B. Pre-treatment of osteocytes with
mestranol or quinestrol, which lack the C3-OH group in their structure did not reduce
the percentage of ROS positive cells induced by H2O2. Cells were examined with
fluorescence microscopy. Graphs represent mean percentages of ROS positive HeLa
cells ± SE. (** = p< 0.001, * = p<0.05, compared to H2O2 treatment, |t = p<0.001
compared to control). Control cultures represent untreated cultures.
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4.3.14 17p-estradiol that contains the -OH group reduced the H202-induced
ROS production in HEK 293 cells
The proportion of ROS positive cells was significantly increased within 2 hours of
treatment of HEK 293 cells with H2O2 (p=0.04), (Figure 4.20). Pre-treatment of HEK
293 cells with 17P-estradiol or vitamin E at a concentration of 10~8M, significantly
reduced the proportion of ROS positive HEK 293 cells induced by H202 treatment
(p=0.04 and p=0.01, respectively) (Figure 4.20).
4.3.15 17p-estradiol prevents H202-induced osteocyte apoptosis in murine
calvariae ex vivo.
In order to demonstrate protection of osteocytes with 17p-estradiol against H202-induced
oxidative stress ex vivo, calvariae derived from 12 Balb/c mice were incubated with
17P-estradiol at 1(T8M for 1 hour in the presence or absence of H202 for 24 hours.
Estimation of osteocyte apoptosis indicated that H202 induced bone resident osteocytes
to undergo apoptosis (p=0.02) (Figures 4.21, 4.22). Estimation of mean percentages of
osteocytes undergoing apoptosis indicated that 17P-estradiol significantly reduced in
H2C>2-induced osteocyte apoptosis compared to mean percentages of osteocyte apoptosis
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Figure 4.20. 17|B-estradiol that displays the C3-OH moiety in its structure
prevents H202-induced generation of ROS in HEK 293 cells. HEK 293 cells
were incubated with HoDCFH-DA for 30 min and then pre-treated with 17p-estradiol,
vitamin E for 1 hour prior to addition of H2O2 for a further 2 hours. Pre-treatment with
17p-estradiol or vitamin E reduced the percentage of ROS positive cells induced by
H2O2 treatment to levels similar control. Cells were examined with fluorescence
microscopy. Graphs represent mean percentages of ROS positive HEK 293 cells ± SE.
(* = p< 0.05, compared to H202 treatment, t = p<0.05 compared to control). Control



















Figure 4.21. 17p-estradiol prevents osteocyte apoptosis induced by H202
in murine calvariae ex vivo. Murine calvaria were incubated with 17P-estradiol at
10"8M for 1 hour in the presence or absence of H2O2 for a further 24 hours. Mean
percentages of osteocytes undergoing apoptosis in response to H2O2 were increased
compared to control, while pretreatment of calvariae with 17p-estradiol reduced H202-
induced osteocyte apoptosis to levels similar to control. Osteocytes were stained with
DAPI and examined with fluorescence microscopy. Graphs represent mean percentages




Figure 4.22.17p-estradiol prevents osteocyte apoptosis induced by H2O2 in
murine calvaria ex vivo. Representative images of murine calvarial osteocytes ex
vivo treated with 17|3-estradiol for 1 hour followed by H2O2 treatment for a further 24
hours and reacted with the nick translation mixture in order to identify apoptotic
osteocytes (FITC-green). H2O2 increased osteocyte apoptosis (B) which was reversed by
the presence of 17p-estradiol (C). White arrows illustrate osteocytes staining positive for
DNA fragmentation (FITC-green). (x20). Bar = 100 jim.
124
4.4 Discussion
This study has shown that exposure of MLO-Y4 osteocytes to H2O2, one of the major
reactive oxygen species, resulted in oxidative stress-induced apoptotic cell death
characterised by membrane blebbing and condensed chromatin at concentrations
between 0.08mM and 0.3mM (Figure 4.1). These data are in agreement with the work
of Kikuyama et al in which similar concentrations of H2O2 were used to induce
apoptosis in chick-derived primary osteocytes (Kikuyama et al. 2002). At higher
concentrations of H2O2, above 0.4mM and up to 0.6mM, osteocytes were shown to die
via necrosis, as has previously been noted (Kogianni et al. 2004), and therefore were not
employed in these experiments.
Several studies have reported that increased intracellular ROS production might play a
role in apoptotic cell death possibly by activating certain caspase cascades. For example,
H2O2 has been shown to trigger apoptosis in primary osteocytes (Kikuyama et al 2002)
and T cells (Dumont et al. 1999) possibly by disrupting the mitochondrial membrane
potential resulting in cytochrome c release, activation of caspase 9 and subsequent
activation of caspase 3 (Dumont et al. 1999). In order to demonstrate the apoptotic
nature of the cell death observed in response to H2O2, a selective inhibitor of caspase 3/7
based on isatin sulfonamide was employed at concentrations previously shown to inhibit
caspases 3 and 7 in osteocytes (Kogianni et al. 2004). Inhibition of caspase 3/7 activity
was shown to prevent the FFCh-triggered death of MLO-Y4 osteocytes (Figure 4.3)
indicating that this cell death was caspase- dependent and therefore apoptotic.
Pre-treatment of MLO-Y4 osteocytes with 17P-estradiol at 10"8M in the presence of
H2O2 resulted in an approximate 60% reduction in H202-induced apoptosis to levels
similar to those observed in control cultures (Figures 4.4, 4.5). The concentration of 10"
8M employed in this study is close to the physiological serum concentration of 17P-
estradiol during a typical menstrual cycle in humans (Ganong 1999, Dotsch et al. 2001),
and was shown to be non-toxic to osteocyte cultures, in accordance to other studies
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(Kousteni et al. 2001, 2003; Gu et al. 2005). Similar protective effects of 17|3-estradiol
were also demonstrated in murine calvariae exposed to H2O2 indicating the ability of
17[3-estradiol not only to protect MLO-Y4 osteocytes in culture but also to protect the
osteocytic population against oxidant attack in ex vivo cultures (Figure 4.21, 4.22).
The concentration of 10~8M employed in this study was shown to be non-toxic to
osteocyte cultures, in accordance to other studies (Kousteni et al. 2001, 2003; Gu et al.
2005). These studies have also shown that the use of 17p-estradiol at concentrations
lower than the 10~8 M, such as 10"9M -10"I2M, protected the osteocytes from etoposide
(Kousteni et al 2001, Kousteni et al 2003) and dexamethasone-induced apoptosis (Gu et
al 2005). However, lower concentrations of 17P-estradiol were not included in this
study since it was influenced by the large body of literature describing the concentration
of 10~8M as being close to the normal physiological range. In addition, investigation of
the effects of lower estrogen doses, closer to the physiological range, against osteocyte
apoptosis would have required modifications of the culture conditions such the use of
phenol red-free medium or use of charcoal-stripped serum.
In contrast to the effects observed with 17|3-estradiol at 10~8M, pre-treatment of MLO-
Y4 osteocytes with 17(3-estradiol at 10~6M, a concentration that is closer to the
pharmacological concentration, appeared to be toxic in culture as it induced osteocyte
apoptosis (Figure 4.4). Although 17|3-estradiol used at 10"6M reduced pro-apoptotic
stimuli induced by H2O2 in this study (Figure 4.4) and by etoposide in other studies
(Kousteni et al. 2001), its ability to induce apoptosis when administered alone in
osteocytic cultures has not, to the author's knowledge, been demonstrated before. In
general, consideration of the effects of the different doses of 17P-estradiol against
oxidant-induced osteocyte apoptosis employed in this study might give important insight
into the pharmacological properties of 17|3-estradiol.
17P-estradiol has previously been reported in the literature to protect osteocytes against
apoptosis induced in response to dexamethasone (Kousteni et al. 2001, Gu et al. 2005),
etoposide and TNF-a (Kousteni et al. 2001) possibly through a non-genotropic estrogen-
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presence of U0126 at concentrations known to block ERK phosphorylation in the
MLO-Y4 cell type (Kogianni et al. 2004), (Figure 4.11). The failure of U0126 to
abolish 17p-estradiol-induced survival of osteocytes might be related to the nature of the
death stimulus per se. Studies that have pointed to the involvement of ERK 1/2 pathway
in the anti-apoptotic effects of 17p-estradiol have utilised dexamethasone, etoposide or
TNF-a as pro-apoptotic stimuli (Kousteni et al. 2001, 2003), whereas in this study death
was induced in response to a direct oxidant molecule (H2O2).
MLO-Y4 osteocytes have been demonstrated to express both estrogen receptors (ERa
and ERP) (Matikainen and Vaananen 1999). In order to provide evidence for the
possible implication of the estrogen receptor in the protective effect of 17P-estradiol
against H202-induced death of MLO-Y4 osteocytes, the widely used pure estrogen
receptor antagonist ICI 182 780 was employed. ICI 182 780 is thought to compete with
estrogen for binding to the estrogen receptor on which it binds with similar affinity to
17P-estradiol (Wakeling et al. 1991) and disrupts the receptor shuttling process by
inhibiting nuclear uptake of the receptor (Dauvois et al. 1993). ICI 182 780 has been
successfully shown in other studies to block the protective effects of 17p-estradiol
against cell death indicating the possible dependency of these effects on the activation of
the classical estrogen receptor (Wilson et al. 2000, Callier et al. 2001, Gu et al. 2005,
Kousteni et al. 2001, 2003). In this study, the protection conferred by 17p-estradiol to
osteocytes was not reversed by the presence of ICI 182 780 (Figure 4.7A) suggesting, at
first inspection, lack of the classical estrogen receptor mediation in the protection against
oxidative stress. This finding was in accordance with other studies which have also
suggested the inability of ICI 182 780 to block the anti-apoptotic effects of 17P-estradiol
pointing to the possible employment of the estrogen receptor-independent mechanisms
(Behl et al. 1999; Biewenga et al. 2005, Wang et al. 2006).
Interestingly, incubation of osteocytes with ICI 182 780 alone also appeared to prevent
osteocyte apoptosis induced by exposure to H2O2 and, therefore, the use of ICI 182 780
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compound was not sufficient to elucidate lack of estrogen receptor involvement in the
anti-apoptotic effect of 17[3-estradiol. For this reason, 17a-estradiol and the ER-negative
HeLa and HEK 293 cell lines were also employed in this study. 17a-estradiol, which is a
stereoisomer of 17p-estradiol (Figure 4.12) that acts as a weak estrogen receptor agonist
(Huggins et al. 1954, Koremnan et al. 1969, Clark et al. 1982, Kneifel et al. 1982, Clark
and Markaverich 1983, Lubahn et al. 1985), is thought to be unable to activate the
classical ER-mediated transcription (Gorski et al. 1994). Interestingly, both a and P
isomers of estradiol were equally effective in protecting osteocytes against oxidant-
induced apoptosis when used at the same concentration (Figures 4.4, 4.6) possibly
indicating that the positive effect of 17P-estradiol on osteocyte survival could be
mediated via a mechanism that may not require the classical ER-mediated transcription.
These findings are in agreement with other studies which have also shown that 17a-
estradiol was equally effective as 17P-estradiol in protecting mouse HT22, rat primary
neurons and human SK-N-SH neuronal cell lines from the cytotoxic effects of amyloid P
protein (Behl et al. 1997) and serum deprivation, respectively (Green et al. 1997). In
addition, the ability of 17P-estradiol to inhibit H202-induced apoptosis in the HeLa cell
line, which is believed to lack estrogen receptors (Rago et al. 2004; Carpino et al. 2004)
(Figure 4.9A), further supported the possible lack of involvement of the estrogen
receptor in the blockade of apoptosis in osteocytes under oxidant attack. However,
although HeLa cells were initially thought not to express the ER, it is now believed that
some subtypes of the cell line might actually be expressing small amounts of the
receptor (Monje and Boland 2002). Based on these controversial reports, another cell
line the HEK 293, which has been shown to be ERa and ERP negative (Kahlert et al.
2000, Thomas et al. 2005), was also employed in this study and showed the same
protective effect of 17P-estradiol against H2C>2-induced apoptosis ofHEK 293 cells.
Based on these observations and on the fact that the ER antagonist ICI 182, 780 also
prevented H202-induced apoptosis in osteocytes (Figure 4.7B), alternative mechanisms
that could explain the anti-apoptotic effects of 17|3-estradiol and estrogenic compounds
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on osteocytes were investigated in this study. Estrogen has been shown in a number of
studies to exert direct antioxidant activity mainly in the neuronal system (Behl et al.
1995, 1997, 2003; Green et al. 1997, Miranda et al. 2000). The prevention of oxidative
stress-induced cell death in neurons by estrogen is believed to occur through its direct
anti-oxidant activity that is associated with the presence of the hydroxyl (-OH) group at
C3 position of the phenolic A ring (Behl et al. 1997, 1999, Green et al. 1997). The
presence of the C3-0H group is a common characteristic (a fundamental component of
antioxidant activities) of all antioxidant molecules including that of the well known
antioxidants such as vitamin E (Behl et al. 1992, Sano et al. 1997). This moiety
augments the antioxidant molecule to neutralize (detoxify) the accumulated ROS by
donating the proton atom of the phenol group to the unstable radicals in order to
terminate the propagation oxidative chain within the mitochondria (Behl et al. 2002).
Previous studies have demonstrated that estrogens as well as estrogenic derivatives that
contain this C3-OH group in their phenolic A ring protect neurons from oxidant attack
in a receptor-independent manner suggesting that the neuro-protective effects of 170-
estradiol are possibly related to free radical scavenging properties (Behl et al. 1995,
1997, Green et al. 1997, Sawada et al. 1998, Mossmann and Behl 1999).
In this regard, consideration of the structure of the molecules employed in this study
(Figure 4.12) provided possible insight into the anti-apoptotic nature of these
compounds in MLO-Y4 osteocytes. 170-estradiol and 17a-estradiol contain the C3-OH
group in their structures and so does the pure estrogen receptor antagonist ICI 182 780.
The presence of the C3-OH group in the structure of ICI 182 780 might account for the
potential ability of ICI 182 780 to engender anti-oxidant activity, a characteristic that
would explain its ability to save osteocytes against oxidant attack in the absence of 170-
estradiol.
To determine the involvement of the C3-OH group in the protection of MLO-Y4
osteocytes from H2O2 attack, an estrogen related compound mestranol was utilised
against oxidative stress in osteocytes. Mestranol which contains a methyl group (-
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CH3O) in the C3 position of the steroid A ring (Figure 4.12), was unable to protect
osteocytes from f^Ch-induced apoptosis (Figures 4.13A, 4.14C) while the mestranol's
active metabolite 17a-ethinylestradiol, which retains the C3-OH group but is in all other
aspects identical to mestranol in structure, was capable of preventing t^Ch-induced
osteocyte apoptosis (Figures 4.13C, 4.14E). These findings concur with those in
neuronal cell types; in which mestranol was employed in a similar context (Behl et al.
1997) indicating that upon introduction of a methyl group in the phenolic A ring of
mestranol the antioxidant activity was lost. The inability of mestranol to protect the
osteocytic population was further supported by the use of quinestrol (Figures 4.13B,
4.14D), another estrogen derivative which contains a cyclopentyl group in the C3
position of the steroid A ring (Figure 4.12), further pointing to the importance of the
C3-0H group in the saving mechanism of 17P-estradiol against oxidative stress-induced
apoptosis in osteocytes. Similar observations were made using the HeLa and the
HEK293 cells, further supporting the finding that protective effects against oxidative
stress were conferred only by the compounds that contained the OH group in their
structures.
Furthermore, the ability of these estrogen related compounds to reduce ROS generation
was tested by the use of dichlorofluorescein-diacetate (H2DCF-DA), one of the most
widespread methods used in order to detect ROS. All of the compounds tested in this
study that contained the C3-OH group, apart from mestranol and quinestrol, appeared to
reduce ROS generation in osteocytes (Figure 4.17A, 4.17B, 4.18), HeLa (Figure 4.19A,
4.19B) and HEK 293 cells that lack the ERs (Figure 4.20). These findings possibly
support the hypothesis that the anti-apoptotic effects of 17p-estradiol against oxidative
stress could be associated with a possible direct free radical scavenging activity of 17p-
estradiol and estrogenic compounds that contained the C3-OH group (Figure 4.12).
Although this method was simple and relatively easy to perform there have been reports
questioning the sensitivity of this assay since the use of this probe maybe an indicator of
the cellular redox status rather than an estimation of intracellular ROS production.
However, the use of the dye combined with fluorescence microscopy allowed the
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quantification of the exact number of the cells that produced ROS in culture at the time
of investigation rather than an estimation of the total amount of fluorescence produced in
each culture as permitted for example by the use of the fluorimeter (Bejma et al. 2000).
Oxidative stress that results from an imbalance between the pro- and anti-oxidant status
in a cell leads to increased accumulation of ROS in the aged and has been suggested to
contribute to the degeneration of biological functions and the pathogenesis of age-related
diseases (Finkel and Holbrook 2000). Production of ROS in bone has been shown to
participate in the process of bone resorption (Garrett et al. 1990) and to be involved in
osteoclastogenesis both in vitro and in vivo (Lean et al. 2003). Previous evidence has
suggested that increased oxidative stress has been associated with reduced BMD
possibly playing a role in the etiology of osteoporosis (Basu et al. 2001). Furthermore, in
vivo studies have demonstrated that estrogen deficiency due to ovariectomy (OVX)
results in increased accumulation of oxidants by down regulating the level and the
activity of antioxidant enzymes such as glutathione peroxidase 1 in osteoclasts (Lean et
al. 2003, 2005). Preliminary data in this group have provided evidence on the presence
of antioxidant enzymes such as glutathione peroxidase 1 and catalase in MLO-Y4
osteocytes. However, further experiments are required to determine any possible
involvement of these enzymes in the protection of osteocytes against oxidative
conditions.
Since results presented in this thesis demonstrate that osteocytes are sensitive to the
levels of ROS, it might be important to consider situations under which osteocytes
would be exposed to ROS in vivo. Cellular ROS generation in response to hypoxia is
known to be part of the signaling response of the contractile process in cardiomyocytes
(Duranteau et al. 1998). In bone, osteocyte hypoxia has been shown to occur under
disuse conditions suggesting that this forms part of a novel mechanotransduction
pathway (Gross et al. 2001). Osteocyte apoptosis is closely associated with regions of
osteoclastic resorption leading to the suggestion that signals derived as a result of
osteocyte apoptosis may act as a specific target for bone resorption (Noble et al. 2003).
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Maintenance of ROS homeostasis might be very important since estrogen depletion
represents a double jeopardy to bone. Not only does estrogen loss increase osteocyte
apoptosis (Tomkinson et al. 1997, 1998) which in turn may act to target osteoclastic
resorption but estrogen depletion causes increased ROS generation through negative
feedback on glutathione peroxidase 1 (Lean et al. 2005) resulting in further increased
osteoclast activity. Therefore, osteocytes could be exposed to sustained production of
ROS as a result of local generation as a result of active resorption, conditions of disuse-
induced hypoxia, mechanical load engendered cell signaling, estrogen deficiency
conditions or following local inflammatory responses.
It has been shown that estrogen plays an important role in the maintenance of osteocyte
viability (in the control of osteocyte apoptosis) but the mechanism of estrogen action on
osteocyte apoptosis is still unknown. In conclusion, this study introduces a novel
mechanism of estrogen action in the maintenance of the osteocytic population in culture
against oxidant-induced apoptosis of osteocytes and points to the importance of
understanding all aspects of estrogens activity in bone.
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CHAPTER 5
The antioxidant effect of raloxifene and LY 117018 in
the inhibition of osteocyte apoptosis in vitro.
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Abstract
This work is the subject of a published manuscript. Data in chapter 4 have suggested that
17p-estradiol and estrogen-like compounds prevented osteocyte apoptosis induced by
H2O2 possibly by exerting antioxidant properties in vitro. In addition, data in chapter 3
have demonstrated that the LY 117018 SERM is capable of mimicking the protective
effects of 17p-estradiol against OVX-induced osteocyte apoptosis in a rat model in vivo.
Based on these findings, the hypothesis investigated in this study was that raloxifene and
the LY 117018 SERM would protect MLO-Y4 osteocytes from h^C^-induced apoptosis
by exerting antioxidant properties, as effectively as previously demonstrated for 170-
estradiol and related compounds.
MLO-Y4 osteocyte cultures were incubated with H2O2 in the absence or presence of
raloxifene and LY 117018. Estimation of apoptotic osteocytes showed that both SERMs
were equally effective as 17P-estradiol in preventing H^C^-induced osteocyte apoptosis.
Importantly, the receptor antagonist ICI 182, 780 did not prevent the anti-apoptotic
effects of both SERMs against H^Cb-induced apoptosis in MLO-Y4 osteocytes. Pre-
treatment of the ER-negative HeLa and HEK 293 cells with raloxifene or LY117018
significantly inhibited H202-induced apoptosis in both these cell types possibly
indicating the induction of an estrogen receptor-independent mechanism of action
employed by these compounds for the prevention of oxidative stress. The protective
effect exerted by raloxifene or LY 117018 on osteocytes appeared to be independent of
the ERK1/2 pathway since UO 126 failed to prevent the anti-apoptotic effects of
raloxifene or LY 117018 in the presence of H2O2. Furthermore, both SERMs
significantly reduced the generation of ROS in MLO-Y4 osteocytes, HeLa and HEK 293
cells in a similar manner to 170-estradiol, suggesting that both raloxifene and LY
117018 possess anti-oxidant activity.
Evidence presented in this chapter has suggested that both raloxifene and LY 117018 are
capable of mimicking the protective effects of 170-estradiol against oxidant-induced
apoptotic death of osteocytes by acting as antioxidant molecules.
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5.1 Introduction
Selective Estrogen Receptor Modulators (SERMs) are non-steroidal molecules with
tissue specific receptor-mediated effects on the various estrogen target tissues
(McDonnell et al. 2000, Sandberg et al. 2002). In bone, SERMs are thought to retain the
positive effects of estrogen without exerting the adverse effects of estrogen on breast and
uterine tissue (Kauffman et al. 1995, Dodge et al. 1997). Furthermore, SERMs have
been shown to be effective anti-resorptive agents in vivo and, in particular, raloxifene
has been extensively used for the prevention and treatment of postmenopausal
osteoporosis (Delmas et al. 1997).
Raloxifene and the raloxifene analogue LY 117018 employed in this study have similar
chemical structures and belong to the benzothiophene group characterised by the
presence of the benzothiophene ring (Figure 5.1). However, raloxifene and LY 117018
differ in the composition and conformation of their side chains (Figure 5.1) which might
account for differences in their relative level of estrogen antagonism (Grese et al. 1997).
In addition, while structurally different to 17|3-estradiol, both raloxifene and LY117018
retain phenolic hydroxyl groups (Figure 5.1) that mimic the action of the C3-OH group
of the phenolic A ring present in the steroid structure of 17p-estradiol (Grese et al. 1997)
and could facilitate potential antioxidant activity.
Although the beneficial effects of SERMs, as part of hormone replacement therapy
(HRT), in bone are well characterised on the tissue level and demonstrate clear estrogen
receptor-mediated benefits to bone mass, less is known regarding the mechanism of
action of these compounds in the maintenance of bone cell populations. As demonstrated
in Chapter 3, the Raloxifene analogue LY117018 was shown to protect osteocytes from
ovariectomy-induced apoptosis in vivo in a rat model of ovariectomy. However, further
studies are required in order to determine the molecular mechanism of this protective
effect.
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The purpose of this study was to investigate the possibility that raloxifene or LY 117018
could mimic the anti-apoptotic effects of 17(3-estradiol, presented in the previous
chapter, by acting as anti-oxidants during oxidative stress-engendered induction of























Figure 5.1. Basic chemical structure of the SERMs LY 117018 and
Raloxifene, which belong to the benzothiophene group. Raloxifene and LY
117018 are characterized by the presence of a non-steroidal core and a basic side chain
of an aryl moiety and an amine ring. The amine ring contains a basic nitrogen atom
required for antagonising the in vivo effects of estrogen in certain tissues. The nature of
this amine ring in the two SERMs is different. The amine ring of LY 117018 is known
as the pyrrolidine ring and is very similar to the amine ring of raloxifene, known as
piperidine, lacking however one carbon atom. The topology of the side chain determines
the action of SERMs (agonist /antagonist) in different tissues. The core of these non¬
steroidal compounds is characterised by the presence of the benzothiophene group and
the phenolic hydroxyls and is the same for both LY 117018 and raloxifene.
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5.2 Materials and Methods
All chemicals were purchased from Sigma-Aldrich, UK, unless otherwise stated, all
tissue culture reagents were purchased from Invitrogen, UK and tissue culture well
plates were purchased from Coming, UK unless otherwise stated. Tissue culture
procedures were performed in a laminar flow hood (class 2) receiving HEPA-filtered air,
using sterile equipment.
5.2.1 Cell culture and maintenance
The MLO-Y4 osteocyte-like cell line, the HeLa human cervical epithelial cell line and
the HEK 293 human embryonic kidney epithelial cell line were cultured as described in
§ 4.2.1. Briefly, osteocytes were maintained in Modified Eagles Medium Alpha (a-
MEM) supplemented with 5% FBS, 5% NCS, 1% P/S and 1% L-glutamine (Kato et al.
1997). The HeLa cells were cultured in a-MEM supplemented with 5% FBS, 5% NCS,
1% P/S, and 1% L-glutamine (Kousteni et al. 2001). The HEK 293 were cultured in
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10 % FBS, 1% P/S,
and 1% L-glutamine (Evdokiou et al. 1999). Subculturing was performed twice weekly
upon reaching 90% of confluency, maintaining the cells in the log phase of proliferation.
5.2.2 Cell treatment
MLO-Y4 osteocytes and HeLa cells were plated in growth medium at a density of 2.4 x
104 cells per ml on 24 multi-well plates for 24 hours prior to experimentation, as
described in § 4.2.2. HEK 293 cells were plated at a density of 5 x 104 cells per ml in 24
multi-well plates 24 hours prior to experimentation.
Experiments were carried out a minimum of three times, and each treatment group was
represented by 3 wells in each independent experiment. Cells were observed in 3 fields
per well resulting in 9 fields per treatment group, as described in § 4.2.2. SERMs were
diluted in 70% ethanol while H202 was directly diluted in growth medium. Control
treatments represent untreated cultures. Where indicated in the figure legends, vehicle
represents treatment with 70% ethanol subjected to dilutions identical to the highest
concentration under study in the absence of the compound. Tissue culture plastics, either
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in the form of flasks or well plates, used to maintain the MLO-Y4 cell line were coated
with 0.1M collagen type I from rat tail prior to use.
5.2.3 Induction of oxidative stress
MLO-Y4 osteocytes, HeLa cells and HEK 293 cells were incubated in growth medium
supplemented with H2O2 (30% v/v) at a concentration of 0.3mM for 2 hours in order to
induce oxidative stress, as described in § 4.2.3. Apoptotic cells were monitored
microscopically using nuclear morphological criteria.
5.2.4 Prevention of cell death
5.2.4.1 Selective Estrogen Receptor Modulators (SERMs)
MLO-Y4 osteocytes, HeLa cells and HEK 293 cells were pre-treated for 1 hour with the
SERMs raloxifene or LY 117018 (a kid gift from Eli Lilly) at concentrations of 10"6M,
10"7M and 10"8 M diluted in 70 % ethanol, followed by H202 treatment at 0.3mM for a
further 2 hours. The pre-treatment agents remained in culture during H2O2 induced
oxidative stress.
5.2.4.2 17p-estradiol
MLO-Y4 osteocytes, HeLa cells and HEK 293 cells were pre-treated for 1 hour with
o
17P-estradiol (Calbiochem, UK) diluted in 70% ethanol at a concentration of 10" M, as
described in § 4.2.4.1 followed by H2O2 treatment at 0.3mM for further 2 hours. The
pre-treatment agents remained in culture during H2O2 induced oxidative stress.
5.2.4.3 Pure estrogen receptor antagonist ICI 182, 780
MLO-Y4 osteocytes were pre-treated for 1 hour with the pure estrogen receptor
antagonist ICI 182, 780 (Tocris Cookson Ltd, UK) at a concentration of 10"8M, as
described in § 4.2.4.2, in the presence or absence of raloxifene or LY 117018 followed
by H2O2 treatment used at 0.3mM for a further 2 hours. The pre-treatment agents
remained in culture during H2O2 induced oxidative stress.
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5.2.5 Inhibition of intracellular signaling proteins
5.2.5.1 MAPK inhibitors
ML0-Y4 osteocytes were pre-incubated for 1 hour with U0126 (Promega, UK) at a
concentration of 20pM, as described in § 4.2.5.2 and remained in culture prior to the
further addition of SERMs and also in the presence of H2O2.
5.2.6 Determination of apoptotic state
5.2.6.1 DAPI staining for healthy and apoptotic cell morphology
Following experimental treatments, cells were fixed in 4 % paraformaldehyde and
incubated with DAPI used at 2.5 ng/ml for 20 minutes, as described in § 4.2.6.1.
5.2.7 Detection of intracellular reactive oxygen species (ROS)
The presence of intracellular reactive oxygen species (ROS) was detected as described
in § 4.2.7. Briefly, H2DCF-DA (10 pM) (Yen et al. 2001) was added to the culture
medium 30 minutes prior to incubation of MLO-Y4 osteocytes, HeLa cells and HEK
293 cells with either raloxifene, LY 117018, 17|3-estradiol or vitamin E. MLO-Y4
osteocytes, HeLa and HEK 293 cells were then incubated with each of these agents, all
employed at 10"8M, for 1 hour prior to treatment with H2O2 at 0.3mM for a further 2
hours. H2DCF-DA and all pre-treatment agents in MLO-Y4 osteocytes, HeLa cells and
HEK 293 cells, remained in culture during H2O2 treatment after which the media was
removed and the cells were washed twice with PBS before re-addition of a-MEM
growth medium. Live cells were monitored for 2 hours using an inverted microscope
fitted with an environmental chamber to maintain temperature and 5% humidified CO2.
For analysis 3 wells per treatment and six fields per well were counted. Negative control
was represented by cultures incubated in the absence of the H2DCF-DA in order to




Statistical analysis were performed using quantitative data analysis with SPSS release
10.1 for Windows, as described in § 4.2.9 using Analysis of Variance (ANOVA),
followed by the Tukey-Kramer and Dunnett post-hoc tests for comparison between the
treatment groups and comparison between each treatment group with the experimental
control, respectively (only when the significance of the ANOVA was p<0.05). Results
were expressed as means ± S.E. Results are considered to be statistically significant
when p<0.05 denoted by *; p<0.01 denoted by ** and p<0.001 denoted by *** when
experimental treatment was compared to H2O2 treatment, and p<0.05 denoted by +,
p<0.01 denoted by +t and p<0.001 denoted by t+t when experimental treatment was
compared to the non-treated control.
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5.3 Results
5.3.1 Raloxifene and LY 117018 prevent H202-induced apoptosis in MLO-Y4
osteocytes.
Dose response studies were used to identify concentrations of raloxifene and LY 117018
that did not increase apoptosis above the control levels. Mean percentages of apoptotic
osteocytes following treatment of osteocytes with raloxifene and LY 117018 used at
concentrations of 10~6M , 10~7M and 10"8M were not statistically different to the control
cultures (p>0.05) (Figure 5.2A and 5.2B). Estimation of apoptotic osteocytes based on
morphological criteria showed that raloxifene or LY117018, at all concentrations used,
significantly reduced the pro-apoptotic effect of H2O2 at 0.3mM following two hours of
incubation in culture (Figure 5.2A, 5.2B, 5.3). The lowest concentration of 10"8M for
both raloxifene and LY 117018, which was comparable to the optimal anti-apoptotic
concentration of 17P-estradiol (Figure 5.2C), was chosen to pre-treat osteocytes prior to
addition of 0.3mM H2O2 in subsequent experiments.
5.3.2 The estrogen receptor antagonist ICI 182 780 does not prevent the
anti-apoptotic effects of raloxifene or LY 117018.
As described in chapter 1, estrogen receptor antagonist ICI 182, 780 was employed in
order to determine whether the observed anti-apoptotic effects of the above mentioned
SERMs on MLO-Y4 osteocytes was mediated via the nuclear estrogen receptor. In a
similar way to 17P-estradiol (as described in § 4.3.5), the anti-apoptotic effect of both
raloxifene and LY117078 was not blocked by pre-incubation of osteocyte cultures with
ICI 182,780 at 10"8M for 1 hour prior to the addition of the SERMs (Figure 5.4).
Furthermore, pre-treatment of osteocytes with ICI 182 780 in the absence of the SERMs
significantly reduced H202. induced apoptosis indicating that the ICI 182 780 compound
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Figure 5.2. Raloxifene and LY 117018 prevent osteocyte apoptosis induced
by H202 in a concentration-dependent manner. Osteocytes were incubated with
A. raloxifene and B. LY 117018 at 10~6M-10~8M for 1 hour prior to H2O2 treatment for a
further 2 hours. Mean percentages of apoptotic osteocytes were not significantly
different compared to control cultures following treatment with A. raloxifene and B. LY
117018 at all concentrations used. All concentrations of A. raloxifene and B. LY
117018 reduced the percentages of apoptotic osteocytes induced by H2O2 treatment to
levels similar to control. C. Pre-incubation of osteocytes with raloxifene and LY 117018
o
at 10" M for 1 hour in the presence of H2O2 prevented ELCL-induced osteocyte apoptosis
to a similar extent as 17[3-estradiol. Graphs represent mean percentages of apoptotic
osteocytes ± SE., estimated by DAPI nuclear staining and fluorescent microscopy. (***
= p< 0.0001, * = p< 0.05 compared to H202 treatment, t =p<0.05 compared to control).
Control cultures represent untreated cultures. Vehicle cultures for raloxifene and LY
117018 at 10"6M were similar to control in percentages of apoptotic HeLa cells (4.61 ±
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Figure 5.3. Raloxifene and LY 117018 prevent H2C>2-induced apoptosis in
MLO-Y4 osteocyte cultures. Representative images of osteocytes in culture treated
with either raloxifene or LY 117018 for 1 hour followed by H2O2 treatment for a further
two hours and stained with DAPI. H202 induced osteocyte apoptosis (B), which was
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Figure 5.4. ICI 182 780 does not prevent the protective effects of raloxifene
and LY 117018 on MLO-Y4 osteocyte apoptosis induced by H202. In order to
determine whether the anti-apoptotic effects exerted by SERMs were mediated via the
nuclear estrogen receptor osteocytes were pre-treated with the pure estrogen receptor
antagonist ICI 182 780 at 10~8 M for 1 hour prior to the addition of A. raloxifene and B.
LY 117018 for 1 hour in the presence or absence of H2O2 at 0.3mM for a further 2
hours. Pre-treatment of cells with ICI 182,780 did not inhibit the anti-apoptotic effects of
A. raloxifene and B. LY 117018. Cells were stained with DAPI and examined by
fluorescence microscopy. Graphs represent mean percentages of apoptotic osteocytes ±
SE. (*** =p<0.0001, ** = p< 0.001, compared to H2O2 treatment, ttt =p<0.001
compared to control).
145
5.3.3 Raloxifene and LY 117018 prevent H202-induced apoptosis in ER-
negative HeLa cells
Administration of H2O2 at the dose of 0.3mM induced apoptosis in HeLa cells over a 2
hour incubation period, as described in § 4.3.6. Administration of raloxifene or LY
117018 for 1 hour at concentrations of 10"6M, 10"7M and 10"8M did not increase the
levels of apoptosis above control levels (p>0.05), (Figure 5.5A and 5.5B). Pre-
treatment of HeLa cells with raloxifene and LY 117018 for 1 hour at all concentrations
used significantly reduced the percentage of H2O2 induced apoptosis following two
hours of incubation in culture (p<0.001, p= 0.001, p=0.02, respectively for raloxifene),
(p=0.02, p= 0.008, p=0.0015, respectively for LY 117018), (Figure 5.5A and 5.5B).
The dose of 10"8 M for both raloxifene and LY 117018, comparable to the optimal anti-
apoptotic concentration of 17P-estradiol (Figure 5.5C), was employed in subsequent
treatments.
5.3.4 Raloxifene and LY 117018 prevent H202-induced apoptosis of the ER-
negative HEK 293 cells
To further investigate the potential contribution of the estrogen receptor in the anti-
apoptotic effects of raloxifene or LY 117018 against H2O2 induced death, the HEK 293
cell line that lacks the ER was employed (Kahlert et al. 2000, Thomas et al. 2005). The
dose of 0.3mM H2O2, which was used to characterise oxidative stress in MLO-Y4
osteocytes and HeLa cells, was also employed in the HEK 293 cell line as mentioned in
§ 4.3.7. Pre-treatment of HEK 293 cells with raloxifene (Figure 5.6A) or LY 117018
(Figure 5.6B) for 1 hour at doses of 10"6M, 10"7M and 10"8M all significantly reduced
the percentage of H202 induced apoptosis (p<0.05 for 10"6M and 10"7M and p<0.001 for
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Figure 5.5. Raloxifene and LY 117018 prevent HeLa cell apoptosis induced
by H2O2. HeLa cells were incubated with A. raloxifene and B. LY 117018 at 10"6 M,
10~7 M and 10~8 M for 1 hour prior to H2O2 treatment for a further 2 hours. C. Pre¬
incubation of HeLa cells with raloxifene and LY 117018 at 10~8M for 1 hour in the
presence of H202 prevented H202-induced apoptosis in HeLa cells to a similar extent as
17|3-estradiol Cells were stained with DAPI and examined with fluorescence microscopy
Graphs represent mean percentages of apoptotic HeLa cells ± SE. (** = p< 0.001, * = p<
0.05 compared to H2O2 treatment, ttt = p<0.0001, compared to control). Control
cultures represent untreated cultures. Vehicle cultures for raloxifene and LY 117018 at
10"6M were similar to control in percentages of apoptotic HeLa cells (4.07 ±0.91 %
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Figure 5.6. Raloxifene and LY 117018 prevent HEK 293 cell apoptosis
induced by H2O2. HEK 293 cells were incubated with A. raloxifene and B. LY
117018 at 10~6 M, 10"7 M and 10"8 M for 1 hour prior to H2O2 treatment for a further 2
hours. Cells were stained with DAPI and examined with fluorescence microscopy
Graphs represent mean percentages of apoptotic HEK 293 cells ± SE. (*** = p< 0.0001,
* = p< 0.05 compared to H2O2 treatment, ttt = p<0.0001, t= p<0.01, compared to
control). Control cultures represent untreated cultures. Vehicle cultures for raloxifene at
10~6M were similar to control in percentages of apoptotic HEK 293 cells.
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5.3.5 ERK 1/2 inhibition does not block the protective effects of SERMs on
MLO-Y4 osteocytes.
As described in chapter 4 (§ 4.2.5.2), the MEK 1/2 inhibitor U0126 was used in order to
determine whether the saving effect of raloxifene or LY 117018 was mediated via
receptor activation of MAP Kinase signalling pathways. Pre-treatment of osteocytes
with U0126 at 20pM prior to the addition of raloxifene or LY117018 for 1 hour did not
inhibit the anti-apoptotic effects of the raloxifene and LY 117018 against the H2O2
treatment (Figure 5.7).
5.3.6 Raloxifene or LY 117018, compounds that contain the -OH group,
reduced the H202-induced ROS production in MLO-Y4 osteocytes
As described in § 4.3.12, treatment of osteocytes with H2O2 for 2 hours resulted in a
significant increase in the proportion of ROS positive cells compared to the control
(p=0.002). Pre-treatment of osteocytes with raloxifene or LY 117018 for 1 hour, at a
concentration of 10~8M, significantly reduced the percentage of H202-induced ROS
positive cells to levels similar to those seen in control cultures, as did the potent anti¬
oxidant Vitamin E at 10~8M (Figure 5.8). In contrast, pre-incubation of osteocytes with
o
mestranol at 10" M concentration failed to reduce the number of ROS positive cells, as
described in § 4.3.12, (Figure 5.8).
5.3.7 Raloxifene or LY 117018 reduced the H202-induced ROS production
in HeLa cells
As described in chapter § 4.3.13, treatment of HeLa cells with H2O2 for 2 hours resulted
in a significant increase in the proportion of ROS positive cells compared to the control
(p=0.01). Pre-treatment ofHeLa cells with raloxifene or LY 117018 for 1 hour used at a
concentration of 10"8M significantly reduced the percentage of H202-induced ROS
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Figure 5.7. The MEK Vi inhibitor U0126 does not inhibit the anti-apoptotic
effects of raloxifene or LY 117018. MLO-Y4 osteocytes were incubated with
U0126 for 30 minutes at 20 pM prior to the addition of raloxifene and LY 117018 for 1
hour in the presence or absence of H2O2 at 0.3mM for a further 2 hours. U0126 did not
prevent MLO-Y4 osteocyte apoptosis induced by H2O2 treatment and did not block the
protective effect of raloxifene and LY 117018 on MLO-Y4 osteocytes. Cells were
stained with DAPI and examined by fluorescence microscopy. Graphs represent mean
percentages of apoptotic osteocytes ± SE. (*** =p<0.0001, ** = p< 0.001, compared to
H2O2, ttt=p<0.0001, tf=P<0.001, compared to control). Control cultures represent
untreated cultures and are similar to vehicle (DMSO) cultures in percentages of
apoptotic osteocytes.
150




*1 -r^ ^0 cfb r
Control Raloxifene LY 117018 17p-estradiol VitaminE
Treatments (10"8M)
Figure 5.8. Raloxifene or LY 117018, which display the C3-OH moiety in
their structure, prevent H202-induced generation of ROS in MLO-Y4
osteocytes. MLO-Y4 osteocytes were incubated with H2DCF-DA for 30 min at lOpM
and then pre-treated with raloxifene, LY 117018, 17P-estradiol and vitamin E at 10"8M
for 1 hour in the presence or absence of H2O2 at 0.3mM, for a further 2 hours. The
percentage of ROS positive osteocytes was significantly increased compared to control
following treatment with H202. Pre-treatment of MLO-Y4 osteocytes with raloxifene,
LY 117018, 17p-estradiol and vitamin E significantly reduced the percentage of ROS
positive osteocytes following treatment with H2O2. Cells were examined by fluorescence
microscopy. Graphs represent mean percentages of ROS positive osteocytes ± SE. (***
= p< 0.0001, compared to H202, ttt =p<0.0001 compared to the control). Control
cultures represent untreated cultures.
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Figure 5.9. Raloxifene and LY 117018 reduced the H202-induced ROS
production in MLO-Y4 osteocytes. MLO-Y4 osteocytes were incubated with
H2DCF-DA for 30 min and then pre-treated with raloxifene and LY 117018 for 1 hour
prior to H2O2 treatment for a further two hours. A. control cultures, B. F^CL-treated
cultures, C. cultures treated with raloxifene in the presence of H2O2, D. cultures treated
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Figure 5.10. Raloxifene or LY 117018 prevent H202-induced production of
ROS in HeLa cells. HeLa cells were incubated with H2DCF-DA for 30 min at lOpM
prior to the addition of raloxifene, LY 117018 and 17[3-estradiol for 1 hour in the
presence or absence of H2O2 at 0.3mM, for a further 2 hours. The percentage of ROS
positive HeLa cells was significantly increased compared to control following treatment
with H202. Pre-treatment of HeLa cells with raloxifene, LY 117018 and 17(3-estradiol
used at a concentration of 10~8M, significantly reduced the percentage of ROS positive
HeLa cells following treatment with H202. Cells were examined by fluorescence
microscopy. Graphs represent mean percentages of ROS positive HeLa cells ± SE. (* =
p< 0.05, compared to H2O2, t =p<0.05 compared to control). Control cultures represent
untreated cultures.
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5.3.8 Raloxifene or LY 117018 that contain the -OH group reduced the
H202-induced production of ROS in HEK 293 cells
The proportion of ROS positive cells was significantly increased within 2 hours of
treatment of HEK 293 cells with H2O2 (p=0.04), (Figure 5.11). Pre-treatment of HEK
293 cells with raloxifene or LY 117018, at a concentration of 10"8M, significantly
reduced the proportion of ROS positive HEK 293 cells induced by H2O2 treatment

































HH T I m
Control Raloxifene LY 117018 17p-estradiol Vitamin E
Figure 5.11. Raloxifene or LY 117018 that display the C3-OH moiety in their
structure prevent H202-induced generation of ROS in HEK 293 cells. HEK
293 cells were incubated with H2DCFH-DA for 30 min and then pre-treated with
raloxifene, LY 117018, 17p-estradiol or vitamin E for 1 hour prior to addition of H2O2
for a further 2 hours. Pre-treatment with raloxifene, LY 117018, 17|3-estradiol or vitamin
E reduced the percentage of ROS positive cells induced by H202 treatment to levels
similar control. Cells were examined with fluorescence microscopy. Graphs represent
mean percentages of ROS positive HEK 293 cells ± SE. (* = p< 0.05, compared to
H202, t =p<0.05 compared to control). Control cultures represent untreated cultures.
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5.4 Discussion
Data presented in chapter 4 have demonstrated that 17p-estradiol was capable of
preventing osteocyte apoptosis in response to oxidant attack in vitro. Data provided in
this study demonstrate that both raloxifene and LY 117018 are equally effective as 170-
estradiol in reducing the pro-apoptotic signals induced by H2O2 administration on the
MLO-Y4 osteocytic population in vitro.
Pre-treatment of osteocyte cultures with raloxifene and LY 117018 reduced the
proportion of osteocytes displaying membrane blebbing and cytoplasmic and chromatin
condensation induced by H2O2 treatment (Figures 5.2 and 5.3). Previous studies have
demonstrated that, in response to alternative forms of death such as etoposide, raloxifene
was not capable of protecting MLO-Y4 osteocytic cells from apoptosis (Kousteni et al.
2003) indicating that the protective effects exerted by raloxifene could be related to
specific death-inducing stimuli.
Investigation of the ERK 1/2 pathway revealed that pre-incubation of MLO-Y4
osteocytes with the ERK1/2 inhibitor UO 126 did not abrogate the anti-apoptotic effects
of neither raloxifene nor LY 117018 on osteocytes (Figure 5.7). Furthermore, Kousteni
et al have demonstrated the inability of raloxifene to activate the ERK1/2 pathway in
MLO-Y4 osteocytes (Kousteni et al. 2003) suggesting that the ERK1/2 pathway might
not be implicated in the prevention of oxidative stress by the SERMs raloxifene and LY
117018 in osteocytes, as also indicated in this chapter. These findings are also in
agreement with results from chapter 4, which demonstrated that 170-estradiol did not
utilise the ERK1/2 pathway in order to prevent FLCh-induced osteocyte apoptosis under
identical culture conditions.
At the molecular level raloxifene has been shown to exert its effects both through
classical estrogen receptor mechanisms (Taranta et al. 2002) as well as non classical
estrogen receptor mechanisms (Yang et al. 1996, Balfour et al. 1998). In order to
elucidate the importance of the estrogen receptor in the SERM mediated response, the
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pure estrogen receptor antagonist ICI 182 780 and the ER-negative HeLa (Rago et al.
2004, Carpino et al. 2004) and HEK 293 cell lines (Kahlert et al. 2000, Thomas et al.
2005) were employed. Both raloxifene and LY 117018 were capable of inhibiting
oxidant-induced apoptosis in the MLO-Y4 osteocytes even in the presence of the ICI
182 780 (Figures 5.4A and 5.4B). In addition, exertion of anti-apoptotic effects by
raloxifene or LY 117018 in the ER negative HeLa (Figures 5.5) and HEK 293 cells
(Figures 5.6) in response to H202 attack further supported the activation of an ER-
independent mechanism of apoptosis blockade, as previously suggested for 17P-estradiol
in chapter 4.
Studies outlined in the previous chapter have demonstrated that the ability of the
estrogenic compounds to exert protective effects against oxidant attack in MLO-Y4
osteocytes might be associated with the presence of the C3-OH group in their phenolic
A ring. Examination of the structures of raloxifene and LY 117018 revealed that both
compounds also contained a hydroxyl group associated with their phenolic moiety
(Figure 5.1) in principle capable of mimicking the steroid A-ring phenolic hydroxyl
group of 17(3-estradiol. In a similar manner to 17P-estradiol, both SERMs were capable
of reducing the generation of ROS induced in response to H202 in osteocytic cultures, as
detected by the use of the H2DCF-DA dye (described in Chapter 4), (Figures 5.8 and
5.9). This finding indicates a possible antioxidant mechanism of action exerted by
raloxifene or LY 117018 in osteocytes which might be associated with the presence of
the hydroxyl moiety in their structures.
Several lines of evidence exist in the literature to support an antioxidant function of
SERMs, as reviewed in Chapter 2. For example, raloxifene has been shown to prevent
apoptosis induced by H202 in neurons (Biewenga et al. 2005) while it was also involved
in the reduction of atherosclerotic lesions by reducing the release of ROS from vascular
cells and increasing the bioavailability of nitric oxide (NO) (Wassmann et al. 2002). In
addition, raloxifene treatment on plasma collected from postmenopausal women that had
been pre-exposed to CUSO4 in vitro was shown to prevent oxidation of low density
157
lipoproteins (LDLs) more effectively than estrogen or tamoxifen used in the same study
(Arteaga et al. 2003). However, in this study reduction in the levels of ROS in the
presence of either LY 117018 or raloxifene was comparable to that induced by 170-
estradiol pointing to similar free radical scavenging properties between SERMs and 170-
estradiol in osteocytes.
Data provided in this thesis have shown that LY 117018 exerted protective effects on
osteocytes against OVX-induced apoptosis in vivo while in this chapter both raloxifene
and LY 117018 were shown to prevent osteocyte apoptosis induced by H2O2 in vitro.
Furthermore, this study has identified a novel action of SERMs as free radical
scavengers which might account for their anti-apoptotic effects in osteocytes.
The presence of the C3-OH group identified in this chapter to be responsible for the
novel function of SERMs as antioxidants in osteocytes, could contribute further to our
understanding of the molecular design criteria required for the production of new
SERMs that would maintain bone quality and prevent bone diseases.
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CHAPTER 6
The influence of 17p-estradiol and mechanical




Data presented in previous chapters have demonstrated the beneficial effects of 170-
estradiol administration on the viability and apoptotic death of murine osteocytes in vitro
and rat osteocytes in vivo. This pilot study attempted to investigate the effect of 170-
estradiol on the viability of osteocytes in human cancellous bone explants ex vivo in the
presence or absence of mechanical loading using a 3D bioreactor system (ZetosrM).
Bone cores obtained from the human femoral head were incubated in the bioreactor
system for 27 days and subjected either to disuse conditions (Unloaded), physiological
loading regime on a daily basis (Loaded), disuse conditions in the presence of 170-
estradiol (Unloaded+E2) and mechanical loading in the presence of 170-estradiol
(Loaded+Ei). Outcome measures following 27 days in culture included osteocyte
viability based on LDH activity, osteocyte apoptosis based on situ nick translation
technique and histomorphometric indices based on the use of the BIOQUANT OSTEO
histomorphometry software.
Results suggested that application of either mechanical stimulation or 170-estradiol alone
increased the Bone Formation Rate (BFR/BS), the mineral apposition rate (MAR) and the
proportion of pseudo double-labelled surfaces compared to the unloading conditions.
Furthermore, application of mechanical loading at physiological levels improved
osteocyte viability and significantly reduced osteocyte apoptosis relative to that seen
under disuse conditions. In contrast, administration of mechanical stimulation and 170-
estradiol or 170-estradiol alone to the unloaded samples did not reduce osteocyte
apoptosis compared to the disuse conditions.
These data have indicated that application of physiological loading or administration of




It is well documented in the literature that osteocytes sense the mechanical strains
produced in their local environment and produce a number of molecules such as nitric
oxide (NO) (Pitsillides et al. 1995, Klein Nulend et al. 1995), prostaglandin (PGE2)
(Ajubi et al. 1999) and collagen type I gene expression (Sun et al. 1995). Production of
these molecules by osteocytes leads to subsequent changes in the function of the bone
effector cells, regulating therefore the bone remodelling process in order to allow the
tissue to adapt efficiently to the mechanical requirements (Burger et al. 1995, Lanyon
1993, Mullender and Huiskes 1997).
Studies have reported an age-related decline in osteocyte viability (Frost 1960, Dunstan
et al. 1993, Qiu et al. 2005) which may result in impaired detection of mechanical strain
and microdamage, leading to inappropriate bone remodelling, accumulation of
microdamage (Mori et al. 1997), loss of micro-architecture and increased fracture risk
(Burr et al. 1985, Parfitt 1993). However, the mechanism by which osteocytes might be
regulating the remodelling process is not understood yet. A line of evidence is available
to suggest that the death of osteocytes through apoptosis might be providing such signals
(Noble et al. 1997, Verborgt et al. 2000, Noble et al. 2003, Aguirre et al. 2006) since
osteocyte death has been associated with increased resorptive activity in response to
estrogen deficiency (Tomkinson et al. 1997, 1998) and chronic use of glucocorticoids
(Weinstein et al. 1998). In addition, it has been hypothesised that a U-shaped relationship
exists between the survival of osteocytes and the strains produced in their local
enviromnent such that low or excessive strains lead to osteocyte apoptosis following
microdamage (Noble et al. 2003). This hypothesis might provide evidence for a possible
causal mechanism by which signals derived from apoptotic osteocytes can regulate bone
architecture (Noble et al. 2003).
Studies have shown that the application of mechanical loading that produced strains
within the physiological range appeared to preserve osteocyte viability compared to the
unloaded conditions in vivo (Noble et al. 2003) and ex vivo (Lozupone et al. 1996) as
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well as to provide an osteogenic stimulus required by the bone tissue in order to maintain
its structure and function (Frost 1988, Lanyon 1996, Robling 2000).
Evidence has suggested that the adaptive response of bone to mechanical stimulation is
negatively affected by conditions such as estrogen loss and ageing, in particular, studies
have shown that the presence of estrogen enhanced the osteogenic response of rat ulna to
mechanical stimulation (Cheng et al. 1994, 1996, 1997) while reduced expression and
activity of the ERa has been shown to limit the anabolic effects of mechanical
stimulation on murine bone (Lee et al. 2003). Further studies are required in order to
characterise the physiological significance of the relationship between 17p-estradiol and
mechanical stimulation in the human bone that may lead to the development of
therapeutic regimes against post-menopausal osteoporosis. However, this task has proved
difficult to undertake due to the inability to obtain human bone explants before and after
exercise and the difficulty in maintaining viable cultures of bone explants ex vivo (Jones
et al. 2003).
In this study, a novel 3D bioreactor system (Zetos 1M) that enables the long term ex vivo
culture of human cancellous bone explants in a well-controlled mechanical environment
(Jones et al. 2003, Davies et al. 2006) was employed. This culture system is designed to
provide a better understanding of the skeletal physiology as it maintains the tissue in its
3D structure in a near to physiological environment through the constant perfusion of
nutrients and oxygen throughout the tissue (Jones et al. 2003). Furthermore, this system
allows the bone cells to interact with each other as well as with the extracellular matrix
while the controlled application of mechanical loading or the administration of hormones
and growth factors might enable the study of bone remodelling in normal and
pathological bone in a near to natural environment.
This pilot study has investigated the effects of "physiological" levels of mechanical
loading on the maintenance of the osteocytic population in human bone in the presence or
absence of 17(3-estradiol following 27 days in culture in the Zetos™ bioreactor.
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6.2 Materials and Methods
Unless indicated otherwise, all reagents were purchased from Sigma, UK. Preparation
and culture of bone tissue was performed in a sterilised environment using sterile
equipment.
6.2.1 Zetos™ description
The Zetos™ bioreactor consists of two parts; a set of diffusion chambers in which
cancellous bone cores are placed and supplied with media by the use of a perfusion
system, and a computer-controlled loading device used to apply daily physiological
mechanical stimulation to individual cores (Figure 6.1), (Mann et al. 2006).
Bone cores are housed within the diffusion chambers where they are immersed in growth
media and subjected to mechanical loading. Chambers contain a loading piston at the top
plate which transmits the loading force to the bone core while the bottom plate is open in
order to measure bone deformation at the bottom of the plate. The media is pumped
continuously around the system by the use of a perfusion pump which supplies media to
multiple chambers simultaneously. The loading device is controlled by a computer
programme and applies a defined load to the bone cores (Jones et al. 2003).
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Loading device Perfusion pump
Media reservoirs1 /
Figure 6.1. The Zetos™ system. The Zetos™ bioreactor consists of a loading device
controlled by a computer and diffusion chambers perfused with media through individual
reservoirs with the aid of a peristaltic pump.
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6.2.2 Culture of bone tissue in the Zetos™ system
6.2.2.1 Preparation of human biopsies for culture
Human femoral head tissue was obtained from a 65 year-old male undergoing total hip
arthroplasty with written informed consent and with the approval of the local ethical
committee. The samples were processed within 2 hours following the surgery and were
cut into 8 mm slices (Figure 6.2) in thickness using an Exackt 310 diamond-coated band
saw. During the cutting process, the femoral head was continuously rinsed with sterile
PBS at 4 °C in order to minimise heat-induced damage to the tissue and to prevent the
bone from drying out (Mann et al. 2006). Cylindrical bone cores at 10mm in diameter
were drilled from each of these 8 mm-thick slices (Figure 6.2) using a diamond-coated
hollow drill (made in house), while their height was adjusted to 5mm (± 2pm) with the
Exackt 310 diamond coated band saw. The bone cores were then thoroughly washed
three times for 10 min in Hank's Balanced Salt Solution (HBSS) at 37°C, and
subsequently washed for 20 min in HBSS supplemented with the antibiotics
Penicillin/Streptomycin (50IU/ml) (Invitrogen, UK), gentamycin (lOmg/ml) and the
antimycotic amphotericin B (4pg/ml) in order to minimise the risk of contamination
during the harvesting procedure. Cores were randomly assigned into four groups;
explants that were subjected daily to mechanical stimulation (n=3) (Loaded), explants
that were subjected to mechanical stimulation and received treatment with 17p-estradiol
(Calbiochem, UK) at the same time (n=2) (Loaded+E2), explants that were not subjected
to mechanical loading but received 17(3-estradiol treatment (n=3) (Unloaded+E2) and
explants that were not subjected to mechanical loading nor received 17p-estradiol
treatment (n=2) and provided the untreated control of the study (Unloaded) (Table 6.1).
6.2.2.2 Controls samples
As described in § 6.2.2.1, core samples that were not subjected to mechanical loading nor
received 17p~estradiol treatment (Unloaded) were included in the Zetos IM chambers in
order to provide negative controls for mechanical stimulation or treatment with 17P-
estradiol. Besides the untreated controls that were incubated in the ZetosIM bioreactor for
27 days, additional control samples that were not included in the ZetosIM chamber were
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also provided in the study. Two bone cores (TO) were frozen immediately in super cooled
hexane after the harvesting procedure in order to provide an indication of the state of the
tissue at the beginning of the experiment and to act as positive controls for cell viability
assays. In addition, three cores were submerged in sterile H2O overnight following their
extraction from the femoral head and then frozen immediately, in order to induce necrosis
as an alternative form of death to apoptosis. This technique is known to induce the
bursting of the cells (cytolysis) due to the excessive movement ofH20 molecules through
the plasma membrane towards the inside of the cells causing them to explode (Niquet et
al. 2004). Bone cores samples subjected to this treatment are termed "dead bone samples"
throughout this thesis in order to account for the presence of necrotic osteocytes.
6.2.2.3 Maintenance of bone cores in the Zetos ™ system
Individual cores were inserted into specific diffusion chambers and each diffusion
chamber was connected to individual media reservoir via a peristaltic pump system
allowing continual perfusion (7ml/hour) of the bone tissue with culture media (Figure
6.1). Cores were perfused with Dulbecco's Modified Eagle medium (DMEM) (Gibco,
UK) containing 10% FCS, lOmM HEPES, 2mM L-glutamine (Gibco, UK), (lOpg/ml) L-
ascorbic acid-2-phosphate, 5mM P-glycerophosphate disodium hydrate, 0.14mM
NAHCO3 and Penicillin (50 IU/ml) Streptomycin (50pg/ml) (Gibco, UK). Cores were
maintained within the 37°C environmental chamber for a period of 27 days (Figure 6.2)
with media being replaced every third day in order to provide adequate supply of
nutrients and remove waste products. Throughout the experimental period, the pH of the
media in each diffusion chamber was closely monitored (~ pH 7.25) in order to ensure a
physiological pH value during the maintenance of the cores in the Zetos™ bioreactor.
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6.2.3 Treatments
6.2.3.1 Loading of the samples
In this chapter, mechanical compressive loading was applied to the bone cores for 5
minutes on a daily basis. The applied forces resulted in strains of 3000 pstrain at a
frequency of 1 Hz, in a waveform that corresponded to physiological jumping movement,
based on preliminary studies in bovine bone (Mann et al. 2004).
6.2.3.2 Treatment with 17(3-estradiol
17P-estradiol was prepared from an initial stock of lOmM in 100% ethanol vehicle and
was further diluted to 1 OpM in normal growth medium. Samples then received treatment
with 17P-estradiol at 1 pl/ml in nonnal growth medium to give a final concentration of
lOnM. Treatment was administered at the beginning of the experiment (day 1) and was
supplied fresh every 3 days into the appropriate chambers throughout the experimental
period of 27 days.
6.2.3.3 Fluorescent labelling of bone explants
Calcein label is a fluorochrome that chemically binds to calcified tissues and specifically
to the calcium ions present on bone-forming surfaces (Frost 1969, Lee et al. 2003).
During the experimental period of 27 days, one calcein label (at a concentration of 2
mg/ml) was added to the culture media on day 6 and was re-circulated in the system for
approximately 16 hours in order to allow the fluorochrome to fully bind to the matrix. In
order to remove the excess staining, all explants were washed with fresh media for 4
hours which was then removed and replaced as normal.
Since in this study only one label was administered on day 6 of the experiment, any bone
material present above the label at the end of the experiment was therefore synthesized









Figure 6.2. Schematic overview of the experimental setup using the 3D
bioreactor system (Zetos™). Human trabecular bone cores were drilled from 8 mm-
thick bone slices obtained from the human femoral head and housed within the diffusion
chambers. Cores were randomly assigned into four different treatment groups (§6.2.2.1)
and maintained in the Zetos™ bioreactor for a period of 27 days. Following that period,
cores were frozen and sections were collected from each core (see §6.2.4) for subsequent
analysis for osteocyte viability, apoptosis and histomorphometric indices.
168
6.2.4 Sample processing
After 27 days in the bioreactor, bone cores were immersed in 5 % polyvinyl alcohol and
snap frozen in hexane prior to storage at -70 °C. Transverse cryostat sections of 7pm in
thickness were cut from the chilled material using an ultra pure tape for sections (Taab
Laboratories, UK) and transferred to Superfrost slides (Western Laboratory Services,
UK) for further analysis. The use of the ultra pure tape allowed better adhesion of the
bone sections including the bone marrow onto the slides. In order to broadly identify
appropriate regions for subsequent analysis of osteocyte viability, apoptosis and
osteogenic activity, sections were collected from distances 0-0.5mm (Zone 1) and 1-
2.5mm (Zone 2) from the upper surface of the bone cores as outlined in Table 6.1, and
Figure 6.3.
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No of No of Total no of No of fields/ Total no of
Treatments cores sections sections/ section fields
/treatment /Zone Zone/ /Zone
treatment /treatment
TO 2 6 12 6 72
Unloaded 2 6 12 6 72
Unloaded +E2 3 6 18 6 108
Loaded 3 6 18 6 108
Loaded +E2 2 6 12 6 72
Dead bone 3 6 18 6 108
Table 6.1. Outline of sections collected and fields analysed from each Zone.
Six sections were collected from each Zone per core and six fields of view were analysed









Figure 6.3. A schematic representation of a bone core. Bone cores are
cylindrical in shape, 5 mm in height and 10 mm in diameter. The arrows point to the
distances between which cryostat sections were collected in order to carry out subsequent
analysis. Sections obtained from distances 0-0.5mm were grouped into the Zone 1
sections, while sections between distances 1- 2.5mm comprised the Zone 2 sections.
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6.2.5 Cell viability assessment in situ
Osteocytes that were viable at the time of sampling were identified in cryostat sections by
means of their lactate dehydrogenase (LDH) activity as described in §3.2.3. The number
of LDH positive osteocytes, representing the viable osteocytes, was expressed over the
bone area (mm2) which was measured using the bone histomorphometry software
BIOQUANT OSTEO (Bioquant Image Analysis Corporation, USA). LDH staining was
performed on three consecutive sections taken at each specified distance through each of
the bone cores and six image fields were analysed per section.
6.2.6 In situ analysis of osteocyte apoptosis using Nick Translation
The percentage of osteocytes demonstrating fragmented DNA and therefore considered to
be apoptotic, was investigated using in situ DNA nick translation technique (Noble et al.
1997), as previously described in § 3.2.2. Counterstaining was performed using DAPI, at
2.5ng/ml in order to enable visualisation of the osteocyte number in each section.
Sections were then visualised by fluorescence microscopy in order to determine the ratio
of the apoptotic osteocytes (FITC positive) over the total number of osteocytes (DAPI
stained osteocytes). NT technique was employed on three consecutive sections per biopsy
and a minimum of eight fields of view were analysed per section taken at each specified
distance through the bone cores covering in principle more than 70% of the total bone
area at 20x magnification.
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6.2.7 Histomorphometry
Bone histomorphometry provides detailed information on bone structure and remodelling
at a specific location within the biopsy, whereas other approaches, such as the use of
biochemical markers of bone turnover, allow the measurement of histomorphometric
indices at the whole skeleton (Chavassieux and Delmas 2006). Histomorphometric
indices are categorised into the primary measurements such as measurements of bone
volume (BV), surface (BS), distance between points or lines and number (Parfitt 1987)
and the derived (from the primary) measurements some ofwhich include the mineralising
surface (MS), mineral apposition rate (MAR) and Bone Formation Rate (BFR/BS).
Using fluorescent microscopy, the fluorescent label and the bone surfaces were traced on
the sections from the samples maintained in the Zetos™ system and qualitative analysis
of the histomorphometric parameters within the tissue sections from all explants was
carried out using the specific bone histomorphometry software BIOQUANT OSTEO
(Bioquant Image Analysis Corporation, USA). All histomorphometric measurements,
analysed in this chapter, are described according to the standard nomenclature system
established by the American Society of Bone and Mineral Research (ASBMR)
nomenclature committee (Parfitt 1987).
The sections used for histomorphometric analysis were collected from Zones 1 and 2 of
each of the bone cores. Three consecutive un-decalcified 7pm thick sections were fixed
in 4 % paraformaldehyde (PFA) for 10 minutes, washed in PBS three times and mounted
in fluorescent mounting medium (DAKO). Eight random fields from each section
obtained from each distance (24 fields in total obtained for each treatment group) were




Primary measurement of bone surface (BS) was performed on decalcified sections on a
minimum of eight fields obtained from three sections obtained at each of the distances
using the formula:
BS (mm) = Total Bone Surface - Artificial edges
6.2.7.2 Derived measurements
Mineralising surface (MS) describes the bone surface (BS) that exhibits both single (sL)
and double-labelled (dL) surfaces. Single-labelled surfaces refer to the presence of the
calcein label localised at the bone edge while the presence of a second or third label
would be localised either on or further away form the edge of the bone. Although this
study was limited by the administration of only one label on day 6 of the experiment,
interesting results were obtained. In more detail, any bone material existing above the
label at the end of the experiment was synthesized during the 21 day period and therefore
the edge of the bone on day 27 was considered as a second pseudo label by the
histomorphometry software.
The measurement includes the pseudo double plus half of the single labels in order to
provide a more accurate explanation of the actively mineralising surface. The
Mineralising surface formula employed in this study was:
MS / BS (%) = pdLS + (0.5 x sLS) / BS
where pdLS is the pseudo double-labelled surfaces and sLS is the single-labelled surfaces
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The Mineral Apposition Rate (MAR) was estimated by the mean distance between the
two calcein labels (first label and pseudolabel) (interlabel thickness) divided by the time
period between the administration of the first label and the final day of the experiment
(interlabel time-21 days) and represents the rate of progression of the mineralization front
(Parfitt et al. 1987).
Measurements were taken at the midpoint of each label at approximately four equidistant
points along the pseudo double-labelled surface.
MAR (pm/day) = Ir.L.Th / Ir.L.t
Where Ir.L.Th is the interlabel thickness and Ir.L.t is the interlabel time.
In addition to the primary measurements described above; Trabecular Bone Formation
Rate (BFR) was also studied in relation to the bone surface (BFR/BS) obtained by
multiplying the MAR by the total mineralising surface (the sum of the pseudo double-
labelled surface and half of the single-labelled surface). It expresses the rate of bone
formation per unit of bone surface and is calculated as:
BFR/ BS (pm/day) =MAR x MS/BS
6.2.8 Statistical analysis
All data analyses were performed using the statistical software package SPSS for
Windows 11.5. All data were checked for normality. In cases where the randomly
selected sample data were shown to have a nonnal (Gaussian) distribution, parametric
statistical tests such as the two-tailed Analysis of Variance (ANOVA) followed by the
Tukey-Kramer post hoc test (when the significance of the ANOVA was p<0.05) were
performed in order to determine statistical significance between the treatment groups. For
percentages or proportions which were not found to be normally distributed, the square
root of each proportion was transformed into its arcsine, which allowed the distribution of
the data to be nearly normal enabling the use of parametric tests. Results are presented as
means ± SEM. p< 0.05.
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6.3 Results
6.3.1 Bone Formation Rate (BFR)
All bone cores introduced in the Zetos™ system received calcein label at day 6. A second
label was considered to be the bone edge at day 27 of the experiment, which enabled the
measurement of bone formation indices in response to various treatments (see § 6.2.3.3, §
6.2.7.2).
As shown in Figure 6.4A, no significant differences in the BFR/BS were observed in
response to the different treatments in Zone 1 (Figure 6.4A). However, in Zone 2 of the
biopsy perimeter, application of mechanical stimulation in the absence of E2
supplementation significantly increased the BFR/BS compared to the unloaded samples
(p=0.04), (Figure 6.4B, Figure 6.5).
Administration of 17(3-estradiol alone to the unloaded samples also induced a significant
increase in the BFR/BS compared to the unloaded samples alone in Zone 2 of the cores
(p= 0.001), (Figure 6.4B, Figure 6.5). However, application of mechanical loading in the
presence of 17[3-estradiol significantly suppressed the increase in bone formation indices
induced by 17P-estradiol alone in Zone 2 (p=0.006), (Figure 6.4B). As shown in Figure
6.4C, no significant differences were identified in the BFR/BS between Zone 1 and Zone
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Figure 6.4. The effects of mechanical loading and/or 17p-estradiol
administration on the Bone Formation Rate (BFR/BS) after 27 days in the
Zetos™ system. Sections were analysed for indices of bone formation using the
specific bone histomorphometry software BIOQUANT OSTEO (USA). A. There were
no differences observed in the BFR/BS measurements between different treatments in
Zone 1. B. Application of mechanical stimulation increased the rate of bone formation in
the sections obtained from Zone 2 compared to the unloaded samples. In addition,
administration of 17p-estradiol in the absence of loading increased the BFR/BS compared
to all other treatments in Zone 2. Results are expressed as the mean rate of bone
formation per unit of bone surface. C. There are no differences in the BFR/BS between
Zone 1 and Zone 2 in response to individual treatments ± S.E. ft=p<0.001, f=p<0.01
compared to the unloaded cores in Zone 2, * = p<0.05, compared to the E2-treated bone
cores in Zone 2.
Figure 6.5 . Calcein label and Bone Formation Rate. Calcein label was
administered on day 6 of the 27 day experiment. Bone overlying the calcein label was
measured using the histomorphometry software. Representative images of A. the
unloaded sample showing no label, B. mechanically stimulated sample and C. 17|3-
estradiol- treated sample showing calcein label and newly formed bone (arrowheads).
Bar =100 pm.
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6.3.2 Mineral Apposition Rate (MAR)
Sections were also analysed for the Mineral Apposition Rate (MAR), as described in
methods. As shown in Figure 6.6A, no significant differences were observed in the MAR
between the different treatments in Zone 1 (Figure 6.6A).
However, in Zone 2, application of mechanical loading increased the MAR compared to
the unloaded samples (p=0.04) (Figure 6.6B). In addition, the MAR was also increased
in the unloaded samples that received 17P-estradiol and was significantly higher
compared both to the unloaded samples alone and to the samples that received both
mechanical loading and 17P-estradiol in Zone 2 (p=0.038, and p=0.0004, respectively),
(Figure 6.6B). As shown in Figure 6.6C, there are no significant differences in the MAR
between Zone 1 and Zone 2 in response to individual treatments (p>0.05), (Figure 6.6C).
6.3.3 Percentage of pseudo -double labelled surface (% pdL/BS)
Sections were further analysed for the percentage of pseudo double-labelled surface (%
pdL/BS). Application of mechanical stimulation for 27 days in the Zetos™ bioreactor
significantly increased the percentage of the pseudo doubled-labelled surface compared
to the unloaded samples in Zone 2 (p=0.01), (Figure 6.7B), but not in Zone 1 (Figure
6.7A). The presence of 17P-estradiol in the unloaded cores, as shown in Figure 6.7, also
induced a significant increase in the % pdL/BS compared to the unloaded samples alone
in Zone 2 (p=0.0007) sections as well as in Zone 1 sections (p=0.019) (Figure 6.7A and
Figure 6.7B), Furthermore, it was observed that the administration of 17P-estradiol to
bone cores induced a similar increase in the % pdL/BS both in the presence and the
absence of mechanical loading. However, there was no significant increase in the %
pdL/BS observed in samples that received both loading and 17p-estradiol treatment
compared to the unloaded samples alone in Zone 2 (p>0.05), (Figure 6.7B).
As shown in Figure 6.7C, there are no significant differences in the % pdL/BS between

















































Figure 6.6. The effects of mechanical loading and/or 173-estradiol
administration on the Mineral Apposition Rate (MAR) after 27 days in the
Zetos™ system. Sections were analysed for indices of mineral apposition using the
specific bone histomorphometry software BIOQUANT OSTEO (USA). A. There are no
differences in the MAR between different treatments in Zone 1. B. Administration of
17P-estradiol to the unloaded samples increased the MAR both compared to the unloaded
samples alone and to the loaded samples treated with 17P-estradiol in Zone 2. Results are
expressed as the mean mineral apposition rate. C. There are no differences in the MAR
between Zone 1 and Zone 2 in response to individual treatments. ± S.E. ff = p< 0.001, f
= p<0.05 compared to unloaded cores in Zone 2, * = p < 0.05, compared to E2-treated
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Figure 6.7. The effects of 17(3-estradiol administration and/or loading
application on the % pdL/BS after 27 days in the Zetos™ system. Surfaces
were analysed for indices of pseudo double calcein labels using the specific bone
histomorphometry software BIOQUANT OSTEO (USA). A-B. Administration of 17(3-
estradiol to the unloaded samples increased the % pdL/BS compared to the unloaded
samples both in Zone 1 and Zone 2. B. Application of mechanical loading increased the
% pdL/BS compared to the unloaded samples in Zone 2. C. There are no differences in
the % pdL/BS between Zone 1 and Zone 2 in response to individual treatments. Results
are expressed as the mean % pdL/BS. ± S.E. ft = p< 0.001, f = p<0.05 compared to the
unloaded cores in A and B.
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6.3.4 Osteocyte viability at day 0 post-harvest from the human femoral head.
In order to provide positive controls for the viability of osteocytes prior to the
introduction of the cores to the Zetos™ system, two samples were frozen immediately
following the harvesting procedure, as described in methods, and were termed time zero
(TO) controls. Cryostat sections obtained from Zone 1 and Zone 2 were analysed for LDH
activity per mm2 of bone tissue, as described in §6.2.4 and §6.2.5. Figure 6.8 shows that
osteocyte viability in Zone 2 was significantly higher compared to Zone 1 in the TO
controls (p=0.0002).
6.3.5 Osteocyte apoptosis at day 0 post-harvest from the human femoral head
TO cores were also examined for indices of osteocyte apoptotic death, which was
estimated as the proportion of osteocytes displaying DNA fragmentation in situ against
the total number of osteocytes per field of view as described in methods, at sections
obtained from either Zone 1 or Zone 2. As demonstrated in Figure 6.9, the percentages of




Zone 1 Zone 2
Figure 6.8. The density of LDH positive osteocytes at 0 days post-harvest.
TO cores were harvested and frozen prior to entry in the Zetos™ system and sections
collected from Zone 1 and Zone 2 were analysed for the presence of LDH activity in
osteocytes. In sections obtained from Zone 2 the viability of osteocytes per mm was
higher compared to sections obtained from Zone 1. Results are expressed as the average
number of the LDH positive osteocytes per area (mm2) in sections derived from Zone 1





























Zone 1 Zone 2
Figure 6.9. The percentage of osteocytes displaying evidence of DNA
fragmentation in situ in the TO controls. TO bone cores were frozen prior to the
entry in the Zetos™ system and sections obtained from both Zonel and Zone 2 were
examined for the presence of fragmented DNA material using an in situ nick translation
technique. The percentage of apoptotic osteocytes in the TO controls was similar between
Zone 1 and Zone 2. Results are expressed as the mean percentage of osteocytes
displaying positive staining for fragmented DNA over the total number of osteocytes per
field of view. ± S.E.
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6.3.6 Negative control for osteocyte viability
In order to provide controls for low LDH activity/mm2 three cores were incubated in H2O
overnight following their extraction from the femoral head in order to induce necrosis to
osteocytes as an alternative form of death to apoptosis (Niquet J et al., 2004). Bone cores
samples subjected to this treatment are termed "dead bone samples" throughout this
thesis, to account for the presence of necrotic osteocytes. Sections were analysed for
osteocyte viability using the LDH staining method (see §6.2.5). Figure 6.10 shows that
the number of viable osteocytes in the dead bone samples was significantly lower
compared to the number of viable osteocytes in the TO samples, analysed either in Zone 1
or Zone 2 sections (p<0.0001).
As shown in Figure 6.10, bone cores that were subjected to this treatment, contained
very few or no viable osteocytes and therefore the nick translation technique for detection





Figure 6.10. The density of LDH positive osteocytes in the dead bone
samples. Cryostat sections collected from Zonel and Zone 2 of the dead bone cores
were analysed for the presence of LDH activity in osteocytes. The number of viable
osteocytes in the dead bone samples was found to be lower compared to the TO samples
in both □ = Zone 1 and □= Zone 2. Results are expressed as the mean number of LDH
positive osteocytes per area (mm2) of bone ± S.E. ftt= p<0.0001, compared to the TO in
Zone 1, *** = pcO.0001 compared to the TO in Zone 2.
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6.3.6 The effect of mechanical loading on osteocyte viability
Following their extraction from the femoral head, three bone explants were introduced
into the Zetos™ bioreactor and subjected to mechanical stimulation on a daily basis for
27 days as described in §6.2.3.1. In addition, two further cores were maintained in the
Zetos1 M system in the absence of mechanical loading (disuse condition) in order to
provide appropriate negative controls for the samples that received loading. After 27 days
in culture, both treatment groups were analysed for cell viability using the LDH staining
method (see §6.2.5).
The number of viable osteocytes observed in the TO samples was significantly higher
compared to either the loaded or the unloaded samples (p<0.0001). However, the
viability of osteocytes in samples maintained in the ZetosIM bioreactor in the presence or
absence of mechanical stimulation was significantly higher when compared to the dead
bone samples (p<0.001) both in Zone 1 and Zone 2 sections (Figure 6.11A-B, Figure
6.12).
As demonstrated in Figure 6.1 IB, the number of viable osteocytes in Zone 2 was
significantly higher following the application of mechanical stimulation to bone cores
compared to the unloaded samples (p<0.009) after 27 days in the Zetos™ bioreactor. In
addition, as shown in Figure 6.11C, no significant difference was found in the number of
viable osteocytes between sections obtained from Zone 1 and Zone 2 in any of the
treatment groups (p>0.05).
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6.3.7 The effect of mechanical loading on osteocyte apoptosis
Samples that were deprived of mechanical stimulation in the Zetos™ system exhibited
increased osteocyte apoptosis after 27 days of unloading, as indicated in Figures 6.13A
and 6.13B. Application of mechanical stimulation in the Zetos™ system reduced the
proportion of osteocytes that appeared apoptotic compared to the unloaded samples both
in Zone 1 (p< 0.05), (Figure 6.13A) and Zone 2 (p <0.0001), (Figure 6.13B) after 27
days of treatment. Furthermore, it was observed that the levels of apoptosis in samples
that received mechanical stimulation were significantly lower than those observed in
samples that did not receive mechanical loading (Figure 6.13A, Figure 6.13B).
Comparison between the levels of apoptosis in Zones 1 and 2 revealed significant
differences in the unloaded samples so that Zone 2 sections contained a higher number of






























































TO Unloaded Loaded Dead bone
Figure 6.11. Osteocyte viability in the presence or absence of mechanical
loading. Bone cores were maintained for 27 days in the Zetos™ system in the presence
or absence of mechanical stimulation and examined for LDH activity in osteocytes in
both Zone 1 and Zone 2 sections. A-B. The number of viable osteocytes in either the
loaded or the unloaded samples was lower compared to the TO samples and higher
compared to the dead bone samples both in A. Zone 1 and B. Zone 2. B. Application of
mechanical stimulation increased the number of viable osteocytes compared to the
unloaded samples in Zone 2. C. Besides the TO control, the density of viable osteocytes
was found to be similar between Zones 1 and 2 in all treatments. Results are expressed as
the mean number of the LDH positive osteocytes per area (mm2) of bone ± S.E. ttt=
p<0.0001 and **=p<0.001 denote significant differences of TO and necrotic bone
respectively to the other treatments.
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Figure 612 Histochemical reaction of LDH enzyme in sections of human
bone explants cultured in the Zetos system for 27 days. Osteocyte lacunae
showed either strong reaction with LDH indicating viable osteocytes or no reaction
indicating empty lacunae or non-viable osteocytes. Representative images from the A. TO
control, B. unloaded samples, C. mechanically stimulated samples and D. dead bone
samples. Black arrows identify viable LDH-positive osteocytes. Blue arrow points to
















































JL g Zone 2
TO Unloaded Loaded
Figure 6.13. The percentage of apoptotic osteocytes displaying evidence of
DNA fragmentation in situ in the presence or absence of mechanical
loading. Sections collected from both the unloaded and the loaded cores were examined
for the presence of fragmented DNA using the in situ nick translation technique. The
percentage of apoptotic osteocytes in the unloaded samples was higher compared to
either the TO control or the loaded samples in sections obtained either from A. Zone 1 or
B. Zone 2 of the cores. C. Comparison of the levels of apoptosis between Zones 1 and 2
revealed significant differences only in the unloaded samples. Results are expressed as
the mean percentage of the osteocytes displaying positive staining for fragmented DNA
over their total number. ± S.E. * = p<0.05 and *** = p<0.0001 denote significance
compared to the unloaded samples in A and ttt = p<0.0001, denotes significance
compared to the unloaded samples in B.
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6.3.8 The effect of mechanical loading on osteocyte viability in the presence or
absence of 17p-estradiol
Three bone explants received treatment with 17(3-estradiol at a concentration of 10~8M
supplied fresh every three days for a period of 27 days in the Zetos™ bioreactor in the
absence of loading, as described in the method section. Furthermore, two bone cores were
subjected to repeated loading cycles and additionally received similar 17p-estradiol
treatment. After 27 days, both groups were analysed for cell viability using the LDH
activity (see §6.2.5) in order to determine any changes in the number of viable osteocytes
following mechanical stimulation in the presence or absence of 17P-estradiol.
The number of viable osteocytes in either the loaded or the unloaded samples in the
presence or absence of 17p-estradiol was lower compared to the TO samples (p<0.0001)
in sections obtained from both Zone 1 (Figure 6.14A) and Zone 2 (Figure 6.14B)
(pO.OOOl).
Furthermore, as demonstrated in Figure 6.14, the density of viable osteocytes observed
in the unloaded samples was not affected following the administration of 17p-estradiol
either in Zone 1 (Figure 6.14A) or Zone 2 (Figure 6.14B). In addition, mechanical
stimulation in the presence of 17P-estradiol did not significantly affect the density of
viable osteocytes present in the loaded samples both in Zone 1 (Figure 6.14A) and Zone
2 (Figure 6.14B), (p>0.05). Flowever, mechanical strain did not affect osteocyte viability










































TO Unloaded Unloaded Loaded Loaded +E2
+E2
Figure 6.14. The density of LDH positive osteocytes in the presence or
absence of mechanical loading and 17(5-estradiol. Cores were maintained in the
Zetos™ system in the presence or absence of mechanical loading and/or 17(3-estradiol for
27 days. Sections collected from Zone 1 and Zone 2 were analysed for the presence of
LDH activity in osteocytes. A-B. Mechanical stimulation in the presence of 17(3-estradiol
did not change the density of viable osteocytes induced by loading conditions alone. C.
Treatment of unloaded bone cores with 17p-estradiol significantly increased osteocyte
viability in Zone 1 compared to Zone 2. Results are expressed as the mean number of the
LDH positive osteocytes per area (mm2) ± S.E. ttt= p<0.0001 denotes significance
compared to all the different treatments in Zone 1 (A) and Zone 2 (B).
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6.3.9 The effect of mechanical loading on osteocyte apoptosis in the presence or
absence 17(B-estradiol
Bone cores treated with 170-estradiol in the presence or absence of mechanical loading
were also analysed for indices of osteocyte apoptosis in Zones 1 and 2, as described in
methods (Figure 6.16).
Application of mechanical loading in the presence of 170-estradiol significantly increased
osteocyte apoptosis compared to samples subjected to mechanical stimulation alone in
Zone 2 (Figure 6.15B), (p=0.001). Furthermore, administration of both mechanical
stimulation and 170-estradiol to bone cores reduced the apoptosis induced in response to
17|3-estradiol treatment alone in Zone 1 (Figure 6.15A), (p=0.008).
In addition, in samples that received mechanical stimulation in the presence of 170-
estradiol, the levels of osteocyte apoptosis in Zone 2 were higher than in Zone 1 (Figure
6.15C), (p<0.001). Administration of 170-estradiol to the unloaded cores did not alter the
levels of osteocyte apoptosis induced in response to the unloading conditions alone either
in Zone 1 (Figure 6.15A) or Zone 2 (Figure 6.15B).
Furthermore, the percentage of apoptotic osteocytes appeared higher compared to the TO
controls following the administration of 170-estradiol either in the presence or absence of
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TO Unloaded Unloaded Loaded Loaded +E2
+E2
Figure 6.15. In situ evidence of DNA fragmentation in osteocytes subjected
to mechanical stimulation in the presence or absence of 17p-estradiol.
Sections obtained from Zone 1 and Zone 2 were analysed for osteocyte apoptosis using
the in situ nick translation technique. A-B. Treatment of bone cores with 17(3-estradiol
either in the presence or absence of loading increased the percentage of apoptotic
osteocytes compared to the TO controls. Application of loading in the presence of 17P-
estradiol reduced osteocyte apoptosis induced in response to A. 17p-estradiol alone in
Zone 1 and B. mechanical stimulation alone in Zone 2. C. The percentage of apoptotic
osteocytes in samples that received both mechanical loading and 17p-estradiol was higher
in Zone 2 compared to Zone 1. Results are expressed as the mean percentage of the
osteocytes displaying positive staining for fragmented DNA over their total number. ±
S.E. ttt= p<0.0001 denotes significance compared to the TO control.
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FITC DAPI
Figure 6.16 In situ evidence of DNA fragmentation in osteocytes subjected
to mechanical loading in the presence or absence of 170-estradiol. The
percentage of apoptotic osteocytes was quantified in sections after NT staining (FITC).
Representative images of apoptotic osteocytes (arrows) and the corresponding total cell
DAPI stain in A. TO, B. unloaded, C. 170-estradiol-treated, D. mechanically stimulated
and E. 170-estradiol-treated samples in the presence ofmechanical loading. Bar=100 |im.
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6.4 Discussion
Data presented in the previous chapters demonstrated a protective effect exerted by 17p~
estradiol on the viability of murine osteocytes in vitro and rat osteocytes in vivo. The
study presented in this chapter attempted to investigate the potential effects of 17p-
estradiol in the presence or absence of physiological loading on the viability of human
osteocytes ex vivo after 27 days in culture using the Zetos1M bioreactor.
A great line of evidence is available to suggest that mechanical loading is able to regulate
skeletal function and architecture (Frost 1998, Lanyon 1987, Lanyon 1992). According to
the mechanostat theory (Frost 1987), as well as experimental evidence (Mosley et al
1997, Lanyon 1987, Lanyon 1992), application of mechanical loading within the
physiological range of strains has been shown to promote anabolic effects to bone, while
unloading conditions induced resorption of bone and bone loss. The study presented here
investigated possible changes induced in histomorphometric indices in response to
unloading conditions or to the application of physiological loading by the ZetosIM
bioreactor on human bone core explants.
After 27 days in culture, application of mechanical stimulation in the Zetos1M system
increased the rate of bone formation with reference to the bone surface (BFR/BS)
compared to the unloading conditions. These findings indicated that the mechanical
strains produced in the ZetosIM bioreactor induced an osteogenic response in the bone
cores even in the absence of supplementation of known osteogenic factors such as 1,25
vitamin D3. The BFR/BS induced in response to mechanical loading was estimated to be
of the order of 0.02 prn/day and found to be within the lowest range of the BFR/BS
reported in the literature for the human iliac crest (Compston et al. 2002). The low values
obtained for the BFR/BS variable could be explained by the fact that a pseudo label was
used instead of a second fluorescent label in order to calculate dynamic indices of bone
turnover. However, to our knowledge there are no histomorphometric estimates available
so far regarding the BFR/BS estimates for the human femoral head bone in order to allow
comparison with the data presented in this study. The increased BFR/BS observed in this
study is in agreement with the mechanostat theory (Frost 1987) as well as with in vivo
studies (Chow et al. 1993, Pead et al. 1988, Jagger et al. 1995, Chambers et al. 1993,
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Zetos™ ex vivo experimental system has the potential to mimic the response of
trabecular bone to physiological strains sensed in vivo.
Furthermore, application of mechanical loading increased the proportion of pseudo
double-labelled surfaces (% pdL/BS) as well as the mineral apposition rate (MAR)
compared to the unloaded samples after 27 days in culture. These findings might suggest
that application of mechanical loading might have induced the conversion of previously
quiescent surfaces into active bone forming surfaces (Chow et al. 1993) and the increase
in the mineralising activity (productivity) of osteoblasts (Parfitt et al. 1987).
Mechanical loading is known to directly influence the viability of cells that sense
mechanical forces in some tissues (Dimmeler et al 1998). Having shown that the
application of strains within the physiological range in the ZetosrM bioreactor induced an
osteogenic response to the bone explants, the response of the osteocytes was investigated
in these bone explants ex vivo.
Organ and cell culture systems have provided important insights regarding the response
of bone cells to mechanical loading or to growth factors and hormones (Rawlinson et al.
1995, Cheng et al. 1996, Zaman et al. 1997). However, it has not been possible so far to
maintain the tissue viable in culture due to their inability to mimic the in vivo bone
microenvironment (Jones et al. 2001) resulting in tissue necrosis mainly in the centre of
the organ culture (Jones et al. 2001, Davies et al. 2004). Furthermore, very little is known
regarding the viability of osteocytes, considered to be the mechanosensors (Lanyon 1993,
Zhang et al. 1997, Noble et al. 2003) and transducers in bone (Lean et al. 1996, Aarden et
al. 1996, Duncan and Turner 1995, Klein Nulend et al. 1995, Yellowley et al. 2000)
based on the ex vivo organ culture systems available to date. However, studies on bovine
bone using the Zetos™ bioreactor have previously been shown to improve osteocyte
viability by two fold in response to mechanical stimulation compared to the unloaded
conditions following 28 days in culture (Mann et al. 2004). In this study the Zetos™
bioreactor was also employed in order to investigate possible beneficial effects of
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mechanical loading on osteocytes in the presence or absence of, 17P-estradiol in human
bone following 27 days in culture.
In order to determine the viability of the bone core samples immediately following their
extraction from the patient, osteocytes were examined by means of their LDH activity in
the TO samples. In addition, osteocytes were categorised into two zones (Figure 6.3),
depending on their distance from the upper surface of the cores, in order to determine
possible effects of the cutting process on osteocyte viability. It was observed that more
viable osteocytes (per mm2) were present in Zone 2 compared to Zone 1 in the TO cores
possibly suggesting that the cutting process might have induced the loss of osteocytes
observed in the latter. However, despite this loss of osteocytes in Zone 1, the density of
osteocytes per mm2 in both zones (125-150 osteocytes per mm2 in Zone 1 and 200-250
osteocytes per mm2 in Zone 2) was found to be within the range of viable osteocytes per
mm2 reported for human trabecular bone in the literature (Mullender et al. 1996,
Tomkinson et al. 1998, Qiu et al. 2002).
Although the viability of osteocytes in the TO was found to be within the lowest range of
viable osteocytes per mm2 reported (125-250 osteocytes/mm2), the maintenance of bone
explants under unloading conditions in the Zetos™ bioreactor resulted in a dramatic
decrease in the density of viable osteocytes (30 osteocytes/mm2) after 27 days in culture.
However, application of mechanical loading improved the viability of osteocytes in the
human bone core explants compared to the unloaded samples by 1.5 fold. Studies in other
ex vivo organ cultures of bovine trabecular bone demonstrated the inability ofmechanical
stimulation to improve osteocyte viability after 22 days in culture possibly due to
insufficient nutrient perfusion to osteocytes in this ex vivo bone explant model (Takai et
al. 2004). In contrast to these findings, mechanical loading applied in the Zetos1 M
bioreactor appeared to maintain the viability of osteocytes to levels higher than those
observed in the unloaded samples both at short-term (Mann et al. 2006) and long-term
experiments as presented in this chapter.
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In this study, the viability of cells was examined by means of their metabolic activity.
More specifically, the metabolic activity of the LDH enzyme was monitored following
the addition of tetrazolium salts to cells (§3.2.3), which are reduced in viable cells to a
coloured product by the action of dehydrogenases (Tisserat and Manthey 1996, Verleysen
et al. 2004). Based on this assay, only the living osteocytes were coloured because the
colour observed is a product of metabolic activity in cells (Widholm 1972), whereas the
non-coloured osteocytes were considered dead. These findings suggested that the
measurement of viable cells per mm2 in this study included only cells that were
metabolically active. Although the estimation of LDH positive cells, as described above,
would exclude the non-viable (necrotic) cells, it might be possible that apoptotic cells
would be included in the viable pool measurements. This is based on evidence that
suggests that apoptosis is an active, ATP-dependent process (Kerr 1972) and therefore
cells at the early stages of apoptosis induction would still be metabolically active
(Gramaglia et al 2004) and would possibly demonstrate LDH activity. Therefore, the
response of osteocytes to the different treatments was further characterized by examining
indices of early apoptosis based on an in situ DNA fragmentation technique.
Estimation of osteocyte apoptosis based on DNA fragmentation in the TO samples
indicated levels of apoptosis similar to levels reported in the literature for control human
samples (Tomkinson et al. 1997). Maintenance of human bone in the Zetos1M bioreactor
in the absence of mechanical stimuli for 27 days resulted in an increase in osteocyte
apoptosis by 627% in Zone 1 and by 436% in Zone 2 compared to the levels of apoptotic
osteocytes in the TO samples. This finding is in accordance with other studies showing
that absence of mechanical loading resulted in an increase in osteocyte apoptosis (Noble
et al. 2003, Bakker et al. 2004, Aguirre et al. 2006, Basso et al. 2006).
Furthermore, application of mechanical loading, which produced strains in the Zetos1M
bioreactor within the known osteogenic range (Mann et al. 2006), reduced osteocyte
apoptosis compared to the unloading conditions in human bone. These findings are in
accordance with previous studies that suggested that the application of physiological
loading not only is beneficial for the maintenance of osteocyte viability in rat bone either
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in vivo (Noble et al. 2003) or ex vivo (Lozupone et al. 1996) but are capable of regulating
osteocyte viability and apoptosis in the human bone. In the absence of mechanical
stimulation, the percentage of apoptotic osteocytes was estimated to be higher inside the
bone cores. This finding could suggest that the perfusion of media alone without the
presence of mechanical loading might not be enough to prevent osteocyte apoptosis in the
middle of the cores and therefore mechanical stimulation is required.
A number of studies have suggested that estrogen might be affecting the response of bone
to mechanical stimuli by lowering the threshold of sensitivity to loading (Frost 1988,
Lanyon 1996). In addition, bone loss associated with estrogen deficiency might also be
related to impaired responsiveness to mechanical stimulation caused by the absence of
estrogen (Lanyon 1996). In this study, the effect of 17p~estradiol on the osteocytic
population was investigated under disuse conditions or physiological loading stimuli in
the human bone. Administration of 17|3-estradiol did not decrease the levels of osteocyte
apoptosis induced in response to the unloading conditions. Although estrogen is usually
associated with beneficial effects on osteocyte viability (Tomkinson et al. 1997, 1998,
Kousteni S et al., 2001) there are no previous reports in the literature to demonstrate the
effects of estrogen on osteocyte apoptosis when osteocytes are subjected to mechanical
stimulation. Findings reported in this thesis indicate that 17P-estradiol was unable to
prevent osteocyte apoptosis induced by disuse situations in the human bone under the
conditions investigated. In fact, it was observed that not only apoptosis was not prevented
by 17P-estradiol in response to disuse conditions, but also that the anti-apoptotic effects
exterted by mechanical stimulation were abolished in the presence of 17P estradiol in the
inner zone. These findings indicated the possibility that 17p-estradiol could exert
differential effects on the response of osteocytes to the disuse and loading conditions.
However, the difference in this response according to what zone of the bone core was
examined is very difficult to be explained and surely has to be investigated in the future
in order to exclude human error or other reasons such as intra-sample variability.
Further studies are therefore required in order to determine the significance of these pro-
apoptotic stimuli exerted by estrogen in the presence of loading on osteocytes. These
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observations should be interpreted with caution since only one concentration of 170-
estradiol was employed in this study due to the limited number of cores obtained from the
patient. For example, it might be possible that the concentration used in this study could
have exerted toxic effects to the cells or it could have sensitised the cells to undergo
apoptosis in response to the particular loading regime. A higher sample size would have
allowed the use of different concentrations of estrogen as well as loading regimen.
Therefore, further studies need to be conducted in order to determine the dose-
dependency of the effects of 170-estradiol on osteocytes in response to mechanical
stimulation.
Histomorphometric analysis following administration of 170-estradiol in the unloaded
samples demonstrated a significant increase in the BFR compared to the unloaded
samples that did not receive 170-estradiol. As previously discussed in relation to the
effects of mechanical stimulation, this finding possibly resulted from the increase in
MAR and % pdL/BS pointing to a possible direct action of estrogen on the osteoblastic
population/activity. The effects of estrogen and/or mechanical stimulation on the number
and activity of osteoblasts could have been investigated by the use of the alkaline
phosphatase staining that gives an indication of bone formation in response to mechanical
stimulation.
Furthermore, studies have shown that bone formation induced by the administration of
170-estradiol can occur independently of increased bone resorption (Lean et al. 1993).
However, it is not known whether osteoclastic activity could have preceded bone
formation by the osteoblasts since investigation of earlier time points was not included in
this study. Further studies are required to address the presence of osteoclasts on these
bone surfaces at this late time of investigation. This study did not cover the effects of
estrogen and/or loading on osteoblasts or osteoclasts, which is the subject of future
studies. Histological examination of the bone with phenotypic characterisation of the
osteoblasts and osteoclasts would provide additional evidence that the Zetos system can
maintain the viability of bone tissue during the experimental period. However, the use of
frozen sections required in this study for the Nick Translation technique do not lend
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themselves to the detailed histological analysis required for the study of bone surface-
resident cells.
Furthermore, it is interesting to note that the same samples characterised by an increase in
BFR, MAR and % pdL/BS in response to 17(3-estradiol treatment were also characterised
by high levels of apoptotic osteocytes. A number of studies are available to indicate that
apoptotic osteocytes might be producing signals that direct the remodelling process
(Verborgt et al. 2002, Noble et al. 2003) to specific areas in bone by increasing the
osteoclastic activity. The perceived increase in osteocyte apoptosis in response to 17P-
estradiol might have resulted from a reduced clearance of the apoptotic material due to a
possible direct action of 17P-estradiol on the osteoclastic population. Studies have shown
that 17P-estradiol exerts negative effects on osteoclast formation and survival (Girasole et
al. 1992, Hughes et al. 1996, Kameda et al. 1997), although such a possibility could not
have been explored in this study due to the absence of osteoclasts at the later stages of
investigation. In addition, the increase in osteocyte apoptosis due to the administration of
17[3-estradiol in the presence of mechanical loading did not seem to affect osteocyte
viability. This finding could be explained by the fact that the density of LDH-positive
(viable) osteocytes is a cumulative effect over the 27-day culture period. On the contrary,
the percentage of the apoptotic osteocytes presented in this study reflects a phenomenon
that occurs at the time of the examination.
Other studies in bone have also reported a high incidence of apoptotic osteocytes during
growth (Noble 1997), or in response to glucocorticoid (Weinstein et al. 1998) or GNRH
treatment (Tomkinson et al. 1997). These findings indicate that apoptotic osteocytes might
not be rapidly removed from a site and might persist in their lacunae for prolonged
periods of time. In fact, it has been shown in previous studies that dead osteocytes might
remain in their lacunae for 16 weeks (Kenzora et al. 1978). This phenomenon of delayed
removal of apoptotic osteocytes might be attributed either to the inaccessibility of
osteoclastic cells to the mineralized matrix or to the low rate of turnover observed in
human bone (Tomkinson et al. 1997). This might suggest that the time course of
completion of the apoptotic process in osteocytes in the mineralised bone matrix is
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the addition of 17(3-estradiol to the system resulted in the enhancement of bone formation
by the presence of 17P-estradiol compared to the loading treatment alone (Jagger et al.
1996). Therefore, although 17|3-estradiol did not suppress the ability of mechanical
stimulation to activate bone formation in this study, the fact that it did not further enhance
BFR or MAR as observed in the disuse situation might be attributed to the fact that both
17P-estradiol and mechanical loading were administered at the same time. Further studies
are required in order to address different osteogenic responses to a time delay between
17p-estradiol and loading administration. In addition, it might be possible that different
biochemical pathways are employed by 17P-estradiol in response to disuse and loading
stimuli which might also account for the significant differences between BFR and MAR
under disuse and loading conditions in the presence of 17P-estradiol.
In summary, this study has provided evidence that osteocytes undergo apoptosis in
response to disuse conditions which could be improved following the application of
physiological loading in the Zetos™ bioreactor. Application of mechanical loading or
administration of 17p-estradiol to the unloaded samples induced an osteogenic response
in this patient in terms of bone formation accompanied by increased mineral production.
The use of the Zetos™ bioreactor in this thesis has enabled the study of the response of
the osteocytic population to mechanical stimulation in the presence or absence of 170-
estradiol, since it is difficult to obtain human bone biopsies pre- and post-exercise due to
ethical issues. However, this is a pilot study and a number of limitations were identified
both in the design of the experiment as well as in the analysis of the results. The study
was based on samples obtained from a single patient and not from n=3 as indicated by the
statistical power of the experimental design. In addition, variability existed between the
number of samples analysed for each treatment group (n=3 or n=2) which might have
accounted for the high error bars (variance from the mean value) that were observed in
some of the treatment groups. The low number of samples employed in this study was
affected by the limited number of cores obtained from the patient. It would be important
to determine the effect ofmore patients and a higher sample size on the results presented
in this chapter. Furthermore, this study is limited by the administration of only one
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are required in order to address different osteogenic responses to a time delay between
17p-estradiol and loading administration. In addition, it might be possible that different
biochemical pathways are employed by 17P-estradiol in response to disuse and loading
stimuli which might also account for the significant differences between BFR and MAR
under disuse and loading conditions in the presence of 17P-estradiol.
In summary, this study has provided evidence that osteocytes undergo apoptosis in
response to disuse conditions which could be improved following the application of
physiological loading in the ZetosIM bioreactor. Application of mechanical loading or
administration of 17P-estradiol to the unloaded samples induced an osteogenic response
in this patient in terms of bone formation accompanied by increased mineral production.
The use of the Zetos™ bioreactor in this thesis has enabled the study of the response of
the osteocytic population to mechanical stimulation in the presence or absence of 17P~
estradiol, since it is difficult to obtain human bone biopsies pre- and post-exercise due to
ethical issues. However, this is a pilot study and a number of limitations were identified
both in the design of the experiment as well as in the analysis of the results. The study
was based on samples obtained from a single patient and not from n=3 as indicated by the
statistical power of the experimental design. In addition, variability existed between the
number of samples analysed for each treatment group (n=3 or n=2) which might have
accounted for the high error bars that were observed in some of the treatment groups. The
low number of samples employed in this study was affected by the limited number of
cores obtained from the patient. Due to inter-individual and inter-site variability, it would
be important to determine the effect of more patients and a higher sample size on the
results presented in this chapter. In addition, whilst some differences observed in
osteocyte viability and apoptosis between Zone 1 and Zone 2 might have occurred due to
different proximity to the loading device, they might also have occurred due to intra-
sample variability and the small sample size.
In the absence of mechanical stimulation, the percentage of apoptotic osteocytes was
higher inside the bone cores. This finding could suggest that the perfusion of media
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without mechanical loading might not be enough to prevent osteocyte apoptosis (and
therefore mechanical stimulation is required).
Furthermore, this study is limited by the administration of only one calcein label on day 6
of the experiment. All histomorphometric analyses based on the estimation of double-
labelled surfaces were performed using a pseudo label and therefore results should be
interpreted with caution. However, the histomorphometric software employed in this
study (BIOQUANT OSTEO, USA) allows for such an estimation to take place. In
addition, the Zetos system does not come close to in vivo situations due to the lack of
blood vessels. Diffusion might not be enough to ensure exchange of nutrients or waste
metabolites between the cells away from the vessels. The bone marrow is not renewed
and therefore it is difficult to investigate bone growth in this system following 27 days in
culture.
Data in this chapter have suggested that, despite the low numbers of viable osteocytes
present in the human bone explants following 27 days in culture, osteoblasts appeared to
be responsive to the administration of 17P-estradiol or application of mechanical loading.
Taking into account studies that suggest that osteocytes might be regulating the
remodelling process (Noble et al. 2003, Power et al 2002) and that necrotic bone is
poorly remodelled (Kenzora et al. 1978) these findings possibly point to a minimum
number of osteocytes required in order to obtain an osteogenic response to loading.
205
CHAPTER 7
Conclusions and future work
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Conclusions and future work
Withdrawal of estrogen either due to menopause or ovariectomy has previously been
shown to induce bone loss and to be associated with osteocyte apoptosis in vivo. Data
presented in this thesis, demonstrated a protective effect exerted by 17|3-estradiol on the
viability ofmurine osteocytes in vitro and rat osteocytes in vivo. However, administration
of 17p-estradiol to ex vivo cultures of human bone in the Zetos bioreactor resulted not
only did it not protect osteocyte viability but it resulted in the increase of osteocyte
apoptosis as well. This finding could be explained by the fact that 17P-estradiol might
employ different biochemical pathways in response to different stimuli such as for
example estrogen loss or disuse.
However, no specific effects of SERMs have been associated so far with osteocyte
viability. Data in this thesis have provided evidence that demonstrate for the first time
that besides 17P-estradiol, the SERM LY 117018 also exerted protective effects on the
osteocytic population in a rat model of ovariectomy. This finding has suggested that
SERMs may play an important role in the maintenance of osteocyte viability, which
might in the future contribute to the clinical development of estrogen replacement
compounds with activities consistent with the maintenance both of bone mass and bone
quality. Further studies are however required in order to determine a possible association
between osteocyte apoptosis and bone loss using histomorphometric analysis, as well as
the effects of SERMs on either or both of these processes.
This thesis has also provided novel evidence for the potential action of SERMs and
estrogen as direct antioxidants, as part of their preventive mechanism against H2O2-
induced osteocyte apoptosis. These findings are particularly important taking into
account evidence that suggests that the accumulation of ROS, and specifically of H2O2
observed in ovariectomised mice (Lean et al. 2003), might be responsible for mediating
the estrogen deficiency-induced bone loss (Lean et al. 2005). They also point to the need
for further investigation into the antioxidant potential of compounds administered for the
treatment of postmenopausal osteoporosis.
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Although several studies have demonstrated the antioxidant capabilities of 17p-estradiol
in various tissues in vivo, it remains to be answered whether SERMs also possess
antioxidant properties in vivo and the possible association of these properties with the
prevention of bone loss. This might be enabled for example by the measurement of
oxidative stress markers in samples of urine/plasma along with markers of bone turnover.
Further experiments are also required to determine any possible changes in the levels of
antioxidant enzymes, as part of the protective effects of 17P-estradiol or SERMs, on
osteocytes against oxidative stress.
In addition, it might be interesting to investigate any direct association between the
increase in ROS production observed during estrogen loss and osteocyte apoptosis in
vivo. Such an investigation would involve the use of ovariectomised mice, measurement
of oxidative stress markers along with histochemical examination of apoptotic osteocytes.
Futhermore, studies have shown that the inflammatory process associated with bone
fractures is characterized by increased accumulation of ROS (introduction) and osteocyte
apoptosis. Therefore, fracture repair studies on ovariectomised animals could be
important in order to investigate any positive effects of the antioxidant properties of
estrogen and SERMs on accelerating fracture healing in vivo. This approach could have a
potential application in the aged postmenopausal population and might also open up new
therapeutic possibilities for fracture repair.
Furthermore, taking into account data in both chapters 4 and 5, it might be possible to
suggest that antioxidant properties might indeed be implicated in the prevention of
osteoporosis. In addition, besides 17|3-estradiol and SERMs which were demonstrated in
this thesis to possess antioxidant properties, it remains to be determined whether pure
antioxidant molecules also have a beneficial effect on bone loss when administered alone.
In addition, this study has provided important information on the effects of 17p-estradiol
and mechanical stimulation on osteocyte viability in human bone ex vivo, and has
demonstrated that the Zetos1M bioreactor might be a valuable system for the prolonged
maintenance of bone samples in culture. Further questions regarding the time course of
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osteocyte apoptosis might be answered by the use of the Zetos™ system which allows
human trabecular bone biopsies to be examined over a time course. Future work should
also explore whether SERMs exert any beneficial effects on human osteocytes ex vivo,
similar to those observed in rat osteocytes in vivo and murine osteocytes in vitro
(chapters 3, 4 and 5). Furthermore, the application of molecular biology techniques on
samples maintained in the ZetosrM system might provide useful insight into the
mechanisms and pathways employed by mechanical stimulation and/or estrogen or
SERMs in the maintenance of osteocyte viability in human bone.
Previous studies have suggested that disuse conditions have been associated with an
increase in oxidative stress in rat bone (Smith et al., 2005). Using the Zetos™ system it
might be interesting to investigate the impact of mechanical stimulation and/or anti-
osteoporotic drugs such as estrogen or SERMs on oxidative stress in human bone in
association with osteocyte viability and bone histomorphometric indices. Possible
changes in oxidative stress levels might be detected by the measurement of oxidative
stress markers collected frequently from the medium of the samples maintained in the
Zetos™ along with immunohistochemical examination of antioxidant enzymes. This
might prove to be valuable in order to explore the potential novel action of estrogen and
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Abstract
Withdrawal of estrogen represents the primary factor determining post menopausal bone loss and has been associated with negative indicators
of bone quality including the apoptotic death of osteocytcs in vivo. While hormone replacement therapy in the form of Estrogen or Selective
Estrogen Receptor Modulators (SERMs) demonstrates clear estrogen receptor (ER)-mediated benefits to bone mass, less is known regarding the
mechanism of action of these compounds in the maintenance of bone cell popidations. We have investigated the potential antioxidant effects of
estrogen, estrogen derivatives and the SERMs Raloxifene and LY117018 in the prevention of oxidative stress induced apoptosis in the osteocyte
like cell line MLO-Y4.
Treatment ofMLO-Y4 with 0.3 mM H202 induced apoptosis that was significantly inhibited (p < 0.002) when the cells were pre-treated for 1 h
with cither 17(3-estradiol, Raloxifene or LY117018 (10 nM). The stereoisomer 17a-estradiol also prevented H202 induced apoptosis in MLO-Y'4.
Importantly, pre-trcatmcnt ofER-negative HEK293 cells with either 1 pM, 100 nM or 10 nM l7(i-estradiol, Raloxifene or LY117018 significantly
inhibited II202 induced apoptosis in these cells (/?<4.2x 10~5) indicating an estrogen receptor-independent effect of these compounds.
Comparisons of 17(3-estradiol and similar molecules containing the putative free radical scavenger C3-OH moiety on the steroid A-ring (17a-
estradiol, 17a-ethinylestradiol; 10 nM) with structurally related molecules lacking the C3-OH grouping (Mestranol and Quinestrol; 10 nM)
demonstrated that only compounds containing the C3-OI1 moiety showed anti-apoptotic behavior in these studies {p< 0.0033). Similarly the
identification of the presence of reactive oxygen species (ROS) in cells as evidenced by the free radical indicator 2'7'-dichlorodihydrofluorescein
diacetate demonstrated that 17(3-estradiol, SERMs and related molecules with C3-OH moiety were capable of blocking ROS generated in cells by
H202 (p < 0.002) while Mestranol and Quinestrol showed no such blockade. It is possible that the loss of osleocytes during estrogen insufficiency
may occur through a failure to suppress the activity of naturally occurring or disease associated oxidant molecules. These data suggest that the
osteocyte protective effects of estrogen and SERMs may operate through a common receptor-independent mechanism which may be related to the
antioxidant activity of these molecules.
© 2006 Elsevier Inc. All rights reserved.
Keywords: Osteocyte; Apoptosis; Estrogen; SERMs; Antioxidant
Introduction
Clinically, osteoporosis is defined as a Bone Mineral
Density (BMD) measurement of less than 2.5 standard
deviations below the young adult mean (7-score); however,
BMD alone cannot account for all of the variation in bone
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strength [1]. For this reason, measures of bone quality for
example, bone architecture [2,3] and micro-damage accumula¬
tion [4] are now considered possible determinants of bone
strength. Less well established is the obvious impact on bone
quality that reduced skeletal cellularity or osteocyte viability
might have. Osteocytes arc the terminally differentiated cells
of the osteoblast lineage which become entrapped within
newly fonncd osteoid tissue during bone formation. Osteo¬
cytes are characterized by having dendritc-like cell processes
within canaliculi that form a communication network between
Please cite this article as: Mann V, et al, The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in
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both neighboring osteocytcs and effector cells at the bone
surface [5]. The presence of viable osteocytes within bone has
been shown to be associated with bones' ability to remodel
efficiently [6-9], to maintain normal levels of mineralization
and to repair accumulated microdamage [10,11], For these
reasons, it is likely that osteocyte viability represents an
important and to date poorly understood determinant of bone
quality. The number of viable osteocytes in the human femur
decreases from 90% at age 1-10 years to 20% at age 90 years
[12], The reasons for the age related loss of osteocytes are
unclear but it is known that osteocyte apoptosis is engendered
by a wide variety of conditions including glucocorticoid
excess [13], microdamage [14], estrogen loss [15] and oxidant
attack [16],
The "free radical theory" of ageing is based on evidence
suggesting that Reactive Oxygen Species (ROS) production and
the response to oxidative stress contribute to a number of age
related phenomena [17], For example oxidative stress has been
linked to the incidence of Alzheimer's Disease (AD) and
Parkinson's disease [18], Importantly, both in vitro [19] and in
vivo [20] studies have reported neuroprotective effects of
estrogen under conditions associated with oxidative stress
induced neuronal cell death. These effects have been shown to
be receptor-independent and attributed to the antioxidant
properties of estrogen related to the presence of a hydroxyl
group at the C3 position on the steroid A ring of the hormone
[20], In a similar way to neuronal cell system, the ostcocyte
population in bone is also responsive to estrogen. Estrogen
deficiency has been shown to increase osteocyte death in human
and rat bone [15] and, in ovariectomized rats, the ovariectomy
induced stimulation of osteocyte apoptosis can be reversed
upon estrogen replacement [21]. To date the molecular
mechanism by which estrogen acts to maintain the osteocyte
population has not been fully elucidated. While the classical
mode of action of estrogen is through gene activation after
binding to specific nuclear receptors, it is now clear that
estrogen can elicit a variety of non-genomic biological effects.
Estrogen binding to specific receptors results in the activation of
G-proteins [22], MAP kinase signaling pathways [23] and PI3K
signaling pathways [24]. The Selective Estrogen Receptor
Modulators (SERMs) are non-steroidal molecules with tissue
specific receptor-mediated effects on various target tissues.
They retain the positive effects of estrogen on bone without its
associated adverse effects on breast and uterine tissue [25],
While the Raloxifene analogue LY117018 (Lilly) has been
shown to protect osteocytes from ovariectomy induced
apoptosis in vivo in a rat OVX model [26], the molecular
mechanism of the protection has yet to be determined. While
structurally different to estrogen, Raloxifene and the Raloxifene
analogue LY117018 do retain a cyclohexanc C3 hydroxyl
grouping which could potentially facilitate antioxidant activity.
The purpose of this study was to investigate the possibility that
estrogen and SERMs act as antioxidants during oxidative stress
engendered induction of apoptotic cell death in osteocyte like
cells, with a view to understanding the potential use of these




All chemicals were purchased from Sigma-Aldrich (Dorset, UK) unless
otherwise stated. Kstrogen-like compounds used in this study included 17(3-
estradiol (Calbiochem), the stereoisomer! 7a-estradiol, the estrogen receptor
antagonist ICI 182, 780 (Tocris Cookson, Ltd.), estrogen derivatives
ethinylestradiol 3-methyl ether (Mcstranol), ethinylestradiol 3-cyclopentyl
ether (Quinestrol), 17a-ethiny lestradiol and SERMs Raloxifene and Raloxifene
analogue LY117018 (a gift from Eli Lilly) (Fig. 1). The antioxidant Vitamin E
was used to investigate the potential cell protective activity of a potent
antioxidant compound in this model system.
Cell culture
The MLO-Y4 osteocyte like cell line [27] (a gift from Prof. Lynda
Bonewald, San Antonio) was cultured at a density of 2.4 x I04 cells per ml
on collagen (Type 1 Rat Tail) coated 24 well plates in alpha modified
essentia! medium (a-MEM, Gibco UK) supplemented with 5% FBS. 5%
NCS, penicillin (50 I.U./ml), streptomycin (50 [tg/tnl) and L-Glutaminc
(2 niM). The HEK293 human embryonic kidney epithelial cell line
(obtained from Prof. Phillipa Saunders, MRC Reproduction Unit. University
of Edinburgh) was cultured at a density of 2.4" 104 on 24 well plates in
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10%
FBS, penicillin (50 I.U./'ml), streptomycin (50 pg/ml) and t.-Glutamine
(2 mM). Pre-treatment of cells with estrogen, estrogenic derivatives,
SERMS and Vitamin E was carried out for 1 h prior to induction of
oxidative stress. The pre-trcatment agents remained in culture during H2O2
induced oxidative stress. In experiments using either the estrogen receptor
antagonist ICI 182780 or ERK1/2 inhibitor U0126 (Promcga), the cells
were pre-incubated for 1 h with 1CI 182780 (10 nM) or 30 min with
U0126 (20 pM) which remained in culture prior to the further addition of
estradiol, estradiol derivatives or SERMs and also throughout the induction
of oxidative stress. At the end of the experimental period, the cells were
washed with PBS and fixed in 4% paraformaldehyde solution.
Oxidative stress induced cell death
Oxidative stress was induced in cells by incubation with FLO, (30% v/v)
within a concentration range of 0.08 mM 0.6 mM. The induction of apoptotic
cell death was monitored microscopically using morphological criteria.
Identification ofapoptosis
Cells were stained using DAP1 (1 pg/ml) nuclear stain and apoptotic cells
were characterized by cell shrinkage, plasma membrane blebbing (transmitted
light) and nuclear condensation (fluorescent 358 nm excitation, emission
461 nm). Necrotic cells were identified by rapid (within 2 h ) cell swelling
and/or bursting and loss of membrane integrity. Cell numbers were
detennined following H:02 treatment in order to monitor the rapid cell
death characteristic of necrosis. Digital images of cells were captured at 20*
magnification using an inverted microscope fitted with DXM 1200 camera
(Nikon UK Limited). For analysis, /t=3 wells per treatment and six fields
per well were analyzed using Scion Image Software (Scion Corporation.
USA). Within each field, the total cell number and the number of apoptotic
cells were assessed and the results were expressed as the percentage
apoptosis± standard deviation (SD).
Inhibition of caspase 3/7 activity
In order to further demonstrate the apoptotic nature of the oxidant
engendered response, a specific caspase 3/7 inhibitor (GlaxoSmithKline,
USA) which is based on Isatin Sulfonamides [28] was used to inhibit
terminal effector caspases 3 and 7. Cells were pre-incubated with caspasc
3/7 specific inhibitor at a concentration of 1 M for 1 h prior to the
addition of 0.3 mM FLOi. At the end of the experimental period, the cells
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Ethinyl estradiol 3-methyl ether
(Mestranol)








Fig. I. The presence of an aromatic phenol group containing a free hydroxyl OH group facilitates the reaction with oxyradicals by H-atom transfer due to the
relatively weak O-H bond of the hydrogen group. This C3-OH grouping is common to the basic steroid hormone A-ring of vitamin E, 17|S-estradiol, stereoisomer
17a-estradiol and antiestrogen ICI 182 780. Mestranol, Quinestrol and 17ot-ethinylestradiol are steroidal derivatives of estradiol; however. Mestranol has a CH30-
methyl substitution and Quinestrol a cyclopentyl substitution on the C'3 A-ring position, while the SERMs Raloxifene and LY1170! 8 lack the steroidal structure of
estrogen they retain the phenolic C3-OH group.
Vitamin E
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were washed with PBS and fixed in 4% paraformaldehyde solution and the
percentage apoptosis was assessed microscopically as described previously.
Western blot analysis
Cell lysates were prepared from MLO-Y4 cells following treatment for 2 min
with 17p-estradiol, Raloxifene and LY117018 (10 nM) in the presence and
absence ofUOl 26(20 pM). The lysis buffer contained 20 mM Tris-HCl,pH 7.5,
0.1% (v/v) Igepal, 6 mM sodium deoxycholate, 150 mM NaCl, 2 mM EGTA.
2 mM EDTA. 0.1 mM Na3V04, 20 mM NaF and a protease inhibitor cocktail
tablet (Roche, UK). Protein concentrations were estimated using a commercially
available kit (Bio-Rad, UK) and lysates (35 ug/lano) were resolved on 12% SDS-
PAGE gels and transferred onto PVDF membranes and blocked with TBST
solution (10 mM Tris-HCl, pH 7.4, 150 m.M NaCl, 0.1% Tween 20)
supplemented with 3% BSA prior to hybridization with a rabbit polyclonal
antibody against phospho-p44/42MAPK (New England Biolabs, UK). Proteins
were detected using Enhanced Ohemiluminescence (ECL Amersham) according
to the manufacturer's instructions. The blots were stripped (100 mM a-
mercaptoethanol, 69 mM SDS and 62.5 mM Tris -HCl, pH 6.7) and rehybridized
with an antibody that recognizes total p44/42 MAPK to verify equal loading of
samples. Cell lystates were obtained from HEK293 along with MCF-7 epithelial
breast cancer cell line and ER-o transfected HEK293 cells as positive controls
(all obtained from Prof. Phillipa Saunders, MRC Reproduction Unit, University
ofEdinburgh). Western blots were prepared as described above and probed using
specific mouse monoclonal antibody against ERot (Novocastra).
Reverse transcription PCR
Total RNA was extracted from Human Ishikawa Endometrial cells (ISH)
(obtained from Prof. Phillipa Saunders, MRC Reproduction Unit, University of
Edinburgh) and HEK293 using RNAeasy kit (Qiagen) according to the
manufacturer's instructions. cDNA was synthesized with Oligo dT primers
using Bioscript reverse transcriptase (Bioline) and PCR performed using the
specific primers sequences listed below for ERot. ERp> and GAPDH at a final








Detection ofintracellular reactive oxygen species
Detection of cells containing significant levels of reactive oxygen species
(ROS) was determined after incubation of cells with 2',7'-dichlorodihydro-
fluorescein-diacetate (H2DCF-DA). H2DCF-DA is a cell permeable non-
fluorescent probe that is de-esterified intracellularly and turns to a highly
fluorescent 2',7'-dichlorodihydrofluorescein upon oxidation by intracellular
H202 and ROS. H2DCF-DA (10 uM) was added to the culture medium 30
min prior to incubation with either estrogen, estrogenic derivatives, SERMs
or Vitamin E or vehicle. The cells were then incubated with these agents for 1
h prior to treatment with H202 (0.3 mM for 2 h). The H2DCF-DA and prc-
treatment agents remained in culture during H202 treatment after which the
media were removed and the cells washed twice with PBS before re-addition
of ot-MEM supplemented with 5% FBS, 5% NCS, penicillin (50 I.U./ml),
streptomycin (50 gg/ml) and L-Glutamine (2 mM). Live cells were monitored
using an inverted microscope fitted with an environmental chamber to
maintain the temperature at 37°C and 5% humidified C02. ROS positive cells
were detected at 490 nm F1TC excitation and images captured at 20 x
magnification using DXM1200 color camera. The cells were monitored over
a period of 2.5 h based on preliminary experiments determining the time
course of ROS induction (data not shown). Digital images were analyzed
using Scion Image Software. For analysis, n= 3 wells per treatment and six
fields per well were counted.
Statistical analysis
Statistical differences between treatment groups were determined using one¬
way ANOVA followed by Tukey-Kramer test post hoc and results were
considered significant when p<0.05 denoted by * when the experimental
treatment was compared to H202 treatment, andp< 0.05 denoted by + when the
experimental treatment was compared to vehicle control. The results presented
here are representative of « > 3 experiments.
Results
Oxidative stress induced apoptosis
H202 induced apoptosis in osteocytes in a dose-dependent
manner over a 2 h incubation period. An increased proportion of
apoptotic cells compared to control were observed at H2O2
concentrations as low as 0.08 mM (% apoptosis 13.6±4.4 versus
control 2.7±2.6; p= 1.18 x 10~5) and was maximally induced at
H202 concentrations of 0.3 mM (% apoptosis 31.7±7.4;
p=6.5><10~9) (Fig. 2A). Based on cell morphology, both
apoptosis and necrosis were obtained after treatment with H202
concentrations of 0.4 mM and above. The evidence for necrosis
was confirmed by cell swelling/bursting and the rapid (within 2 h)
loss of cell number at the higher concentrations of H202 (cell
number 0.4 mM H202 14±7.5 versus control 29±6.7; p=
0.00043) (Fig. 2B). In contrast, H202 concentrations that induced
the morphological characteristics of apoptosis did not alter cell
numbers within 2 h (Fig. 2B). Apoptosis inducing concentrations
of FI202 did result in a reduction in cell numbers 24 h after
treatment as would be expected following the initiation of the
apoptotic cascade (cell number 27.03± 1.2 in control versus 9.2±
1.07 in 0.3 mM H202 treated cultures;p=0.0001). Pre-incubation
of the cells for 1 h with the specific caspase 3/7 inhibitor at 1 pM,
which we have shown previously to block osteocytc apoptosis
[ 13], prior to H202 treatment at 0.3 mM significantly reduced the
percentage of apoptotic cells from 16.5 ±2.02 to near control
levels of 4.4± 1.04 (/?=0.0017) confirming an apoptotic route to
cell death under these conditions (Fig. 2C). Based on these results,
a concentration of F1202 of 0.3 mM for 2 h was used to induce
apoptosis in the subsequent experiments.
Reduction in the percentage ofapoptotic osteocytes on
pre-treatment ofcells with 17p-estradiol, SERMS and vitamin E
The percentage of H202 induced apoptotic ostcocytcs
(17.7±2) was significantly reduced after pre-treatment of cells
for 1 h with 17p-estradioI at concentrations of 1 pM (5.8±2;
p=0.01), 100 nM (4.3± 1.7; p=0.007) and 10 nM (2.5±0.6;
p—0.002) (Fig. 3A). When added alone, the high 1 pM
concentration of 17[3-estradiol significantly induced apoptosis
in cells compared to control cultures (6.4±2.8 versus 1.5±0.5
respectively; p=0.016) (Fig. 3A). Since the lower, near
physiological concentration of 17|3-cstradiol (10 nM) reduced
FI202 induced apoptosis without demonstrating a pro-apoptotic
effect on osteocytes, this concentration was used in sub¬
sequent treatments.
At a concentration of 10 nM comparable to the optimal
anti-apoptotic estrogen concentration, both Raloxifene and
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Fig. 2. A 2 h incubation ofMLO-Y4 with varying concentrations ofH202 between 0.08 and 0.6 mM was used to induce oxidative stress cell death. (A) The percentage
of apoptotic cell death increased significantly compared to control between 0.08 mM and 0.3 mM H202. At H202 concentrations of 0.4 mM and above, the cells
showed morphology characteristic of necrosis (shaded area). (B) At H202 concentrations up to 0.3 mM, there was no change in cell numbers; however, at 0.4 mM and
above, cell numbers were significantly reduced compared to control indicative ofnecrotic rather than apoptotic form ofcell death. (C) Inhibition ofCaspase 3/7 caused
a reduction in the percentage apoptosis following H202 treatment confirming an apoptotic route to cell death. Bars indicate means±SD of triplicate wells (six fields per
well counted); +/?<0.05 versus vehicle control and *p<0.05 versus H202 treatment by ANOVA.
LYl 17018 significantly reduced H202 induced apoptosis
(p< 0.0003) (Fig. 3B). Treatment of cells with 1 pM and
100 nM concentrations of Raloxifene and LYl 17018 showed
no pro-apoptotic effect while significantly reducing
(p< 0.0003) H202 induced apoptosis (Fig. 3B). The percentage
of H202 induced apoptotic osteocytes (20±2) was significantly
reduced after pre-treatment of cells for 1 h with vitamin E at
concentrations of 100 pM (3.85±0.09; p=0.00023), 1 pM
(3.44± 1.74; p=0.0005) and 10 nM (1.53±0.06; p=0.0009)
(Fig. 3C).
ERK 1/2 inhibition
In order to determine whether the saving effects of estrogen
and SERMs were mediated via receptor activation of MAP
kinase signaling pathways, we used the MEK inhibitor U0126.
(JO 126 is a chemically synthesized organic compound that
inhibits activation ofMAPK (ERK 1/2) by inhibiting the kinase
activity of MAP kinase kinase (MAPKK or MEK 1/2) [29],
Dose dependency experiments have previously shown that
optimal inhibition of ERK in the absence of unwanted cell
viability side effects in MLO-Y4 cells is achieved using a
U0126 concentration of 20 pM [13], U0126 was shown to
inhibit ERK 1/2 activation following 2 min pre-treatment of
MLO-Y4 using either 10 nM 17p>-estradiol, Raloxifene or
LYl 17018 (Fig. 4A). ERK activation via estraodiol at this time
point has been shown previously by Koustcni et al. [30]. Pre-
treatmcnt ofMLO-Y4 with U0126 (20 pM) priorto the addition
of 17|3-estradiol did not inhibit the anti-apoptotic effects of 17(3-
estradiol (% apoptosis U0126+H202 15.7± 1.36 versus %
apoptosis U0126+nfYestradiol+FIzOj 6.15±1.69; p=0.0088)
or Raloxifene (% apoptosis U0126+Raloxifene +H202
3.42±0.66; p= 0.00120) and LYl 17018 (% apoptosis
U0126 + LY117018 + H2O2 8.4±2.57; p=0.037) (Fig. 4B).
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Fig. 3. (A) Pre-treatmcnt ofMLO-Y4 with 17|3-estradiol (17-pE2) at concentrations of I pM, 100 nM and 10 nM all significantly reduced the percentage ofapoptosis
induced by 0.3 mM tl202. The phannacological concentration of 17-pE2 (I pM) was found to induce apoptosis ofMLO-Y4 when compared to control. (B) Pre¬
incubation of cells with SERMs Raloxifene and Raloxifene analogue LYII7018 at concentrations of I pM, 100 nM and 10 nM also significantly reduced the
percentage of H202 induced apoptosis. (C) H202 induced apoptosis was significantly reduced on pre-treatment of osteocytes with potent antioxidant vitamin E at
concentrations of 0.1 mM. 1 pM and 10 nM. Bars indicate means±SD of triplicate wells (six fields per well counted); t/r<0.05 versus vehicle control and *p<0.0S
versus H202 treatment by ANOVA.
Non-receptor-mediated anti-apoptotic effects
In order to determine whether any anti-apoptotic effects of
these test compounds were mediated via the nuclear estrogen
receptor, we initially used the receptor antagonist ICI 182,780
which is an estradiol derivative containing an alkylamide
extension in the 7a position. Previous studies have shown that
ICI 182,780 acts to disrupt the receptor shuttling process by
inhibiting nuclear uptake of the receptor [3 1 ]. Pre-treatment of
cells with the receptor antagonist ICI 182,780 (10 nM) prior to
Fig. 4. (A) UOI26 at a concentration of 20 pM prevented activation of ERK.1/2 induced after treatment of MLO-Y4 with cither 10 nM 17(i-estradiol or SERMs.
(B) ERK 1/2 inhibition did not block the saving effects of 17-p Estradiol or SERMs on treatment of MLO-Y4 with H202. (C) Pre-treatment of MLO-Y4 with
estrogen receptor antagonist 1C1 182 780 did not block the saving effect of 17;v-estradioi; pre-treatment of cells with the stereoisomer 17a-estradiol also reduced
oxidative stress induced apoptosis. (D) ERct was not detected following Western blot analysis of HEK293 cells. MCF-7 and ERot transfected HEK.293 are shown
for positive controls. (E) Neither ERa nor ER(i was detected in HEK293 following RT-PCR. Ish cells are shown for positive control. (F) Pre-treatment of ER-
negative HEK293 cells with either 17|3-estradiol. Raloxifene or LY 117018 at concentrations of 1 pM. 100 nM and 10 nM all significantly reduced H202 induced
apoptosis. Bars indicate means; SI) of triplicate wells (six fields per well counted); +/t<0.05 versus vehicle control and */><0.05 versus U0126 treatment 4A and
*p<0.05 H202 treatment 4B and C by ANOVA.
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Fig. 5. Pre-treatment ofMLO-Y4 with either Mestranol or Quinestrol which lack the C3-OH did not prevent H?0, induced apoptosis while 17a-ethinylestradiol was
capable of saving cells from H2O2 induced apoptosis. Bars indicate means±SD of triplicate wells (six fields per well counted); *p<0.05 versus vehicle control and
*p<0.05 versus H202 treatment by ANOVA.
the addition of 17(J>-estradiol did not inhibit the anti-apoptotic
effects of 17(}-estradiol (% apoptosis 4.5±2.2 versus H202
treatment 22.4± 1.8; /?=0.0005) (Fig. 4C). In a similar way, the
anti-apoptotic effect of Raloxifene and LY117078 was not
blocked by pre-incubation with ICI 182 780 (Fig. 4C).
However, H202 induced apoptosis was also significantly
reduced on pre-treatment of cells with ICI 182 780 (%
apoptosis 7±2.4; /?=0.001) in the absence of 17R-cstradiol
indicating that the ICI 182 780 compound has an anti-apoptotic
activity in this model system (Fig. 4C). Pre-incubation of cells
with the stereoisomer 17a-estradiol (10 nM) which does not





























Fig. 6. The images shown are representative of phase contrast (top row) and H2DCF-DA activation detected at 490 nm (bottom row). (A — left panel) Control
MLO-Y4 (no treatment), (A — middle panel) MLO-Y4 following 2 h 0.3 mM H202 treatment and (A — right panel) MLO-Y4 following 1 h 17p-estradiol pre¬
incubation prior to the addition of 0.3 mM H202. Treatment ofMLO-Y4 with H202 induced the production of ROS as detected by H2DCF-DA (bottom row middle
panel). (B) ROS activity was reduced on pre-treatment with either 10 nM 17^-estradiol, 17oc-estradiol, SERMs, ICI 182,780. 17a-ethinylestradiol and vitamin E
which all display C3-OH moiety. Mestranol and Quiestrol had no effect on the reduction of ROS positive cells on H202 treatment. Bars indicate means±SD of
triplicate wells (six fields per well counted); fp<0.05 versus vehicle control and *p<0.05 versus H202 treatment by ANOVA.
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reduction in the percentage osteocyte apoptosis when com¬
pared to H202 treatment (% apoptosis 22.4±2.1 H202
treatment versus 5.2±0.8 17a-E2 + H202 treatment; p=
0.0017) (Fig. 4C).
In order to further elucidate the potential contribution of
estrogen receptor-mediated events in this response, we used the
HEK293 human embryonic kidney epithelial cell line which is
ER-a and ER-[3 negative (Figs. 4D and E) [32,33], Adminis¬
tration of H202 induced apoptosis in HEK293 cells in a dose-
dependent manner between 0.08 mM and 0.3 mM concentra¬
tions of H202 over a 2 h incubation period and apoptosis at
levels comparable to that induced in MLO-Y4 osteocyte cell
line was seen in EIEK293 cells using 0.3 mM H202 incubation
for 2 h (% apoptosis 0.3 mm H202 21.5 ±1.52 versus control
4.5±0.2; />=0.0012). The percentage of H202 induced
apoptotic HEK293 cells (20.3 ± 1.19) was significantly reduced
after pre-treatmcnt with 17p>-estradiol for 1 h at doses of 1 pM
(7.3± 1.41; p =5.3* 10~6), 100 nM (6.5±1.88; p=8.1 * 10~6)
and 10 nM (3.09±0.41; p=4.3* 10~8) (Fig. 4D). Prc-incuba-
tion of HEK293 cells with Raloxifene and LY117018 at
concentrations of 1 pM, 100 nM and 10 nM also significantly
reduced (p<4.2 * 10~5) the percentage of H202 induced
apoptosis (Fig. 4F).
Antioxidant structure and function relationship
Pre-incubation of cells for 1 h with either the estrogen
derivative Mestranol (10 nM) which has a CH30-methyl group
or Quinestrol (10 nM) which has a cyclopentyl group at the C3
position of the steroid A-ring (not a hydroxy! group) failed to
inhibit H202 apoptosis (% apoptosis H202 treatment 25.3 ±0.67
versus Mestranol+ H202 21.7±3.1;/; = 0.32; Quinestrol±H202
24.1 ±2.7; p=0.69). While pre-incubation of cells with 17a
cthinylestradiol, which is structurally similar to Mestranol and
Quincstrol but with the -methyl and -pentyl groups respectively
substituted by C3-OH, significantly reduced H202 induced
apoptosis (% apoptosis 11.8±2;p=0.0033) (Fig. 5). The ability
of H202 to generate reactive oxygen species in MLO-Y4 was
investigated using 2',7'-dichlorodihydrofluorescein diacetate
(H2DCF-DA). The proportion of ROS positive cells was
increased within 2 h of treatment with H202 (Fig. 6A). Pre-
trcatmcnt with either 17(3-estradiol, 17a-estradiol, ICI 182 780
and 17a-ethinylcstradiol or SERMs at a concentration of 10 nM
all significantly reduced (p < 0.003) the proportion of ROS
positive cells following treatment with H202 to levels similar to
those seen in control cultures, as did the potent antioxidant
vitamin E (10 nM) (Fig. 6B). In contrast to these data pre¬
incubation with Mestranol or Quinestrol at 10 nM concentration
failed to reduce the number of ROS positive cells (Fig. 6B).
Discussion
Our data demonstrate that the treatment of osteocyte like
cells with H202 caused oxidative stress engendered cell death
with the morphological characteristics of apoptosis at concen¬
trations between 0.08 mM and 0.3 mM. These data are in
agreement with the work of Kikuyama et al. [16] in which
similar concentrations ofH202 were used to induce cell death in
primary ostcocytes isolated from chick. Confirming the
apoptotic nature of the response to H202, we demonstrated
that the cell death was caspase-dependent since the isatin
sulfonamide based selective inhibitor of caspase 3/7 inhibited
H202 induced death.
Addition of 17(3-estradiol at near physiological concentra¬
tions, shown to be non-toxic to the osteocyte cells, resulted in a
total blockade ofH202 induced apoptosis reducing levels to that
of control cultures. Similarly both Raloxifene and LY117018
blocked H202 induced apoptosis in these cells. Interestingly
previous studies have demonstrated that estrogen is capable of
saving osteocytes and other bone cells from apoptosis induced
by other chemical agents including dexamethasone [34] and
etoposide [30]. In the case of dexamethasone induced apoptosis
estrogen was working through an ER-dependent mechanism
[34] and in the case of etoposide induced apoptosis estrogen
was also shown to be working through the estrogen receptor via
a non-genotropic signaling mechanism involving activation of
Src/Shc/ERK pathway[30]. In our model system studied here,
ERK activation does not appear to be an absolute requirement
for estrogens ability to inhibit oxidant induced apoptosis since
17f3-estradiol and SERMs retained their anti-apoptotic activity
in the presence of the ERK 1/2 inhibitor U0126 at concentra¬
tions known to block ERK phosphorylation in the MLO-Y4 cell
type [13], Interestingly, we have previously demonstrated that
ERKs may also be involved in pro-apoptotic pathways in
osteocytes since dexamethasone induced osteocyte apoptosis is
associated with a transient increase in ERK 1/2 phosphorylation
which can be blocked by the ERK inhibitor U0126 [13],
With regard to the possible estrogen receptor-mediated
nature of this response, pre-incubation ofcells with the estrogen
receptor antagonist ICI 182 780 did not inhibit the 17(i-estradiol
saving effect. The failure of ICI 182 780 to block the estrogen
saving effects might at first inspection suggest a lack of receptor
mediation in the response. However, conclusions are compli¬
cated by the fact that incubation of cells with the estrogen
antagonist ICI 182 780 alone also prevented H202 induced
apoptosis. For this reason, we also used the stereoisomer 17a-
estradiol that has specific non-genomic activity [35], and in ER
replete MLO-Y4 17a-estradiol was capable of similar levels of
apoptosis blockade as 17(3-estradiol pointing to a lack of
involvement of the classical ER genomic pathways in the
response. Furthermore the ability of estradiol and both SERMs
to inhibit oxidant induced apoptosis in HEK293 cell line which
are ER-a and ER-|3 negative [32,33] indicated an estrogen
receptor-independent mechanism of apoptosis blockade in cells
under oxidant attack. These findings concur with those in
neuronal cell types in which ER-indepcndcnt estradiol block¬
ades of oxidant induced apoptosis have been reported [36],
In the absence of any evidence that both estrogen and
SERMs arc working through the estrogen receptor, it is
important to consider alternative mechanisms of anti-
apoptotic activity capable of blocking this oxidant induced
apoptosis in osteocytes. Insight as to the anti-apoptotic nature
of estrogen in this model system may be gained through
consideration of the structure of the molecules used. The
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prevention of oxidative stress induced cell death in neurons
by estrogen is proposed to be through its direct antioxidant
activity and is related to the presence of the C3-OH grouping
on the steroid A ring [20]. Our study also suggests that this
moiety might be important in the ability of estrogen and
related compounds to block oxidant induced cell death in
osteocytes. Estrogen derivatives Mestranol and Quinestrol,
which have a -methyl group and a -pentyl group respectively
in the steroid A ring C3-OH position, did not prevent H202
induced apoptosis in osteocytes while the derivative 17a-
ethinylestradiol which has a steroid C3-OH group but in all
other aspects is structurally identical to Mestranol and
Quinestrol, was capable of preventing H202 induced
apoptosis. 1CI 182 780 is a 7 alpha-alkylamide analogue of
17[3-estradiol with the same antioxidant associated steroidal
moiety. For this reason, it is possible that ICI 182 780 is also
capable of antioxidant activity, a characteristic that would
explain its ability to save osteocytcs against oxidant attack in
the absence of estradiol.
The SERMs Raloxifene and LY117018 were also capable of
saving osteocytes from oxidant induced cell death. While these
SERMs are not closely structurally related to estrogens, the
hydroxyl group associated with the phenolic moiety of the
SERMs is in principle capable ofmimicking the steroid A-ring
phenolic hydroxyl of 17|i-estradiol. In line with the hypothesis
that the hydroxyl moiety is responsible for antioxidant activity
future work will establish more clearly the precise molecular
design of SERMs required to counter this characteristic. In
support of our hypothesis that the anti-apoptotic activity of
both estrogen and SERMs could be associated with a possible
direct free radical effect, all of the compounds tested in this
study apart from Mestranol and Quinestrol were also able to
reduce reactive oxygen species generation in osteocytes as
detected by H2DCF-DA.
While the controlled production of ROS has beneficial
effects in host defense mechanisms, the accumulation ofROS in
the aged can contribute to the pathogenesis of age associated
disease [17]. Previous evidence suggests that oxidative stress
might play a role in the etiology of osteoporosis with an
association between increased levels of oxidative stress and
reduced BMD [37]. ROS generation has also been shown to be
important in the process of bone resorption being both produced
by actively resorbing osteoclasts [38] and involved in the
recruitment and activation of osteoclasts both in vitro and in
vivo [39]. Experiments in rats in vivo have demonstrated that
estrogen loss (OVX) lead to a reduced ability in osteoclasts to
neutralize oxidants using antioxidant enzymes [40,41],
Our results demonstrate that osteocytes are sensitive to ROS
levels and this poses questions related to the conditions under
which osteocytes would be exposed to ROS in vivo. Hypoxia
generates cellular ROS in a range of cell types and leads to both
positive and negative cell behaviors. For example, hypoxia
engendered ROS production is known to be part of the signaling
response of the contractile process in cardiomyocytes [42],
Interestingly osteocyte hypoxia has been shown to occur in
bone as a result of disuse with the suggestion that this forms part
of a novel mechanotransduction pathway [43], In addition, the
ROS generator Nitric Oxide is known to be an important
mcchanotransduction related signal molecule in osteocytes [44].
Therefore the production and sustained exposure of osteocytes
to ROS could result from active local generation as a result of
active resorption, conditions of disuse induced hypoxia,
mechanical load engendered cell signaling or following local
inflammatory responses. The presence of estrogen and related
compounds might by virtue of their antioxidant activities
protect ostcocytes from attack by ROS in the pre-menopausal or
FIRT/SERM treated individual. Our results demonstrate that at
least in part the mechanism by which estrogen maintains a
viable osteocyte population is due to its antioxidant activity.
This study highlights the importance of understanding all
aspects of estrogen activity in bone. It also points to the
possibility that SERMs mimic not only the bone sparing activity
but also the antioxidant nature of estrogens and related
compounds. These data will contribute to our understanding
of the molecular design criteria required in the production of
estrogen replacement compounds with activities consistent with
the maintenance of both bone mass and bone quality.
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